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EVALUATION OF THE ROLE OF MICROVASCULAR
PATHOLOGY ON PERIPHERAL ARTERY DISEASE
Constance J. Mietus, Ph.D.
University of Nebraska, 2019
Supervisors: Iraklis Pipinos, M.D., Ph.D. and George Casale, Ph.D.
Background: Peripheral Artery Disease (PAD) begins with atherosclerotic narrowing of
arteries, including those that supply the legs. Individuals with PAD experience pain during
walking, which becomes increasingly limiting. Studies from our group and others have
shown that a myopathy is present in the skeletal muscle of PAD patients, and is
characterized by myofiber degeneration, fibrosis, and remodeling of vessels ranging from
50 – 150 m in diameter. However, microvascular pathology, particularly of the smallest
microvessels (5 – 15 m in diameter) remains poorly characterized. Furthermore, little is
known about the relationships between microvascular architecture, microperfusion, and
patient walking performance. We hypothesize that microvascular pathology is present in
the terminal microvasculature of PAD muscle compared to control and worsens with PAD
severity. Additionally, we hypothesize that microvascular architecture is associated with
deficits in micro- and macro- perfusion and walking performance in PAD patients with
intermittent claudication (IC).
Methods: Gastrocnemius biopsy specimens were collected from control, PAD patients
with IC, and PAD patients with critical limb ischemia.

Microvascular architecture,

microvascular fibrosis, total collagen, and the abundance and phenotype of pericytes were
quantified.

Microvascular

perfusion

was

assessed

by

Contrast

Enhanced

Ultrasonography (CEU). Gardner walking protocols were used to assess claudication

onset time (COT) and peak walking time (PWT). Patients also completed the Walking
Impairment Questionnaire (WIQ).
Results: Microvascular pathology increased with advancing PAD severity and included
progressive increases in basement membrane thickening, abundance of SMA+
pericytes, and microvessel density. In advanced PAD muscle, increases were observed
in total fibrotic burden and peri-microvascular Collagen I and IV deposition. SMA+
pericytes expressed TGF-1.

Relationships were observed between microvascular

architecture and microperfusion both at rest and after ischemic stress. Microvascular
architecture was associated with macrovascular hemodynamic restrictions. Microvascular
architecture was associated with COT, PWT, and patient self-reports of walking speed,
walking distance, and stair climbing ability.
Conclusions: Microvascular pathology worsens with PAD severity in association with
fibrosis. Alteration of microvascular architecture contributes to microperfusion deficits and
walking limitations in PAD.
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Chapter I: Introduction and Background
Atherosclerosis
Atherosclerosis, a leading cause of morbidity and mortality worldwide,1,2 is a
systemic disease that affects susceptible sites in large and medium sized arteries. During
atherogenesis, the arterial endothelial layer becomes perturbed, generating a transient
inflammatory response. Several events may lead to this endothelial damage. Physical
damage can be induced by direct trauma, stress, or hypertension. Circulating factors can
aggravate damage, notably the reactive oxygen species (free radicals) that are present in
air pollution and cigarette smoke.

Additionally, it is believed that hyperlipidemia,

chronically elevated blood glucose, and elevated levels of homocysteine exacerbate
arterial endothelial damage. Early atherosclerotic lesions appear as fatty streaks and are
observed in post mortem aortas of individuals as young as 10 years of age. It is believed
that with chronic damage and inflammation these fatty streaks evolve into atherosclerotic
plaques that are composed of accumulated lipid and fibrous material between the intimal
and medial layers of vessels. As atherosclerotic plaques grow in size, the lumen of the
affected artery stiffens and narrows, often with deleterious consequences to the
downstream tissues. Slowly growing plaques tend to be more stable due to compensatory
remodeling of the artery through migration and proliferation of vascular smooth muscle
cells (VSMC). Rapidly growing plaques are thought to contain the inflammatory and lipid
aggregations within the vessel by coverage with a fibrous cap. These unstable plaques
are more prone to rupture which results in rapid blood clot occlusion (full or partial), which
may abruptly occlude the artery, subsequently inducing tissue ischemia. Fragments of
these blood clots can dissociate from the lesion and travel to distal vasculature, where
smaller caliber vessels may also become occluded. Several organs are susceptible to the
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consequences of atherosclerotic disease, including the heart (coronary artery disease &
myocardial infarction), brain (transient ischemic attack & stroke), and kidney (renal artery
stenosis & kidney failure). Peripheral vasculature is often involved and may lead to
Peripheral Artery Disease (PAD). Plaques in PAD are most commonly found in the
aortoilliac and femoropopliteal regions of the vasculature that supplies the lower limbs.3

Peripheral Artery Disease

PAD is a progressive disease that begins with the atherosclerotic narrowing of
arteries leading to a partial or complete failure of the arterial system to deliver oxygenated
blood to peripheral tissues including the legs.4 PAD is estimated to affect approximately
202 million individuals globally, including 8.5 million Americans, 5,6 and the prevalence of
PAD is anticipated to rise as populations age.3 It is estimated that 12-20% of all individuals
above the age of 60 have PAD 7. Additionally, the total cost of PAD in the United States
exceeds $21 billion dollars annually.8,9 PAD impairs quality of life10-12 and increases the
patient’s 5-year mortality rate by up to 30%,13-18 however the pathophysiologic
mechanisms are not known.
The Fontaine scheme clinically classifies PAD into four stages. In the early stages
of PAD, a reduction in blood flow is present but the individual is asymptomatic (Fontaine
Stage I).4,19 Claudication is the most common symptomatic manifestation of PAD,
presenting as ischemic leg muscle pain and gait dysfunction (Fontaine Stage II). 19,20 In
later stages, PAD patients experience pain at rest (Fontaine Stage III) 19,21,22 and many
patients progress to developing ulcerations that range from trophic lesions to gangrene
which may require limb amputation (Fontaine Stage IV).19,21
The development of intermittent claudication (IC) is insidious, and in very mild
PAD, IC symptoms only develop during intervals of high physical activity.23 Intensity of
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physical activity fluctuates very little throughout the day of an average claudicating patient.
Additionally, a recent study from our laboratory demonstrated that PAD patient activity
rarely exceeded a light intensity level. Patients with IC spent half of their wakeful hours in
sedentary behavior and when active, walking was limited to short bursts followed by
several minutes of rest.24 This data suggests that individuals with IC likely adapt their
activity patterns to minimize claudication symptoms without conscious awareness of
compensatory behavioral changes. Patients with IC have a 12% higher mortality rate than
age matched controls25 and one in four patients with IC will have deterioration of
symptoms.26 It is estimated that for each symptomatic PAD patient, there are another
three to four patients with PAD who do not meet the clinical criteria for intermittent
claudication.23
Critical Limb Ischemia (CLI) represents the most severe clinical manifestation of
PAD, and is the major cause of ischemic amputations.27 In a recent review of insured
patients within the United States, approximately 11% of patients with PAD had CLI.27
Presentation patterns of CLI are not uniform. Longitudinal studies of patients with IC have
shown that these individuals rarely progress to develop CLI. Conversely, patients can
present with no recognized PAD symptoms as soon as six months prior to diagnosis of
CLI,28,29 and primary CLI is more common in patients with diabetes mellitus (DM).
Several risk factors are known to contribute to the development of PAD.
Advancing age is a major underlying risk factor, and is reflected by the 1% prevalence of
PAD in individuals at age 40 rising to 15-20% within individuals at age 70.3,17,30 An
individual’s gender (male > female),23 ethnicity (non-hispanic black > caucasian),23,31
socioeconomic status, and access to health care,32 contribute to risk of PAD. Family
history of PAD is also an independent risk factor, likely due to a genetic component of
PAD. Odds ratios of acquiring PAD are increased amongst monozygotic twins (OR: 17.7),
dizygotic twins (OR: 5.7), and siblings (OR: ~2.0).33,3435 Genetic factors may contribute to

4
the development of premature PAD, and candidate pathways include those involved in
thrombosis, inflammation, and lipid and homocysteine metabolism.35,36 Although causal
variants could not be identified by genetic linkage studies, several candidate susceptibility
genes were identified involving pathways of inflammation, coagulation, lipid metabolism,
blood pressure regulation, and vascular matrix regulation.37 Genome wide association
studies have revealed several attractive single nucleotide polymorphisms, however, the
odds ratios associated (1.13 – 1.31) are modest.35
Sedentary lifestyle is thought to be a significant avoidable risk factor. Additionally,
tobacco use, poor dietary intake, obesity, and management of co-morbid conditions,
particularly hypertension, diabetes, dyslipidemia, hyperhomocysteinemia, and renal
insufficiency, contribute to avoidable risk. A clear dose-response relationship exists with
tobacco use, with a strong increase in risk for PAD in heavy smokers, as well as a fourfold increase in risk of developing IC.23,38

Smokers have a greater relative risk for

developing PAD (RR: 2.71) than coronary artery disease (RR: 1.67),39 and smokers are
diagnosed approximately a decade earlier than non-smokers.38 Fortunately, smoking
cessation is associated with a decline in the incidence of IC.23
Diabetes and PAD are strongly linked. Insulin resistance raises the risk of PAD by
approximately 40-50%, even in individuals without diabetes.40 For every 1% increase in
hemoglobin A1c, there is a corresponding 26% increased risk for PAD. Additionally, the
natural course of PAD is worse in diabetics.41,42

Amongst PAD patients, IC is

approximately twice as common amongst diabetic versus non-diabetic patients.43
Additionally, patients with both PAD and diabetes have a five to ten times higher lifetime
risk of amputation compared to either disease alone.23,44-47 It has been proposed that
diabetes induces a state of inflammation and accelerates atherosclerosis by causing
endovascular dysfunction of the microvascular and macrovascular circulation.44,45,48
Insulin may increase total blood flow and stimulate glucose uptake within skeletal
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muscle.49,50 Interestingly, insulin recruitment of the microvasculature is normally rapid and
occurs at a lower concentration of insulin than is required to increase total blood flow.
Insulin may increase relaxation of terminal arterioles, thereby shunting blood flow from
non-nutritive pathways towards nutritive capillary beds that are typically under perfused
during rest, which greatly increases the surface area for nutrient exchange within skeletal
muscle. 49,52 However, in patients with diabetes, microvascular recruitment is impaired. 51
Insulin resistance is accompanied by defects in skeletal muscle vasculature and includes
loss of capillary density,53 possibly resulting in a reduced ability of insulin and nutrients to
reach myocytes.54

In the skeletal muscle of type II diabetic patients, microvascular

pathology was observed that included thickening of the microvascular basement
membrane, endothelial and pericyte degeneration, and acellular capillaries.55 Pericyte
degeneration destabilizes microvessels and reduces angiogenesis in several organs of
diabetic patients, and is best characterized in diabetic retinopathy. Advanced glycation
end products and oxidative damage are prevalent features of diabetes, and may induce
endothelial damage, thereby initiating the deleterious changes observed in the
microvasculature of patients with DM.

The Limb Dysfunction in Peripheral Artery Disease

Arterial atherosclerotic occlusion is thought to impair blood flow to the lower
extremities of PAD patients. However, the pathophysiology of PAD limb dysfunction is
complex and is not fully explained by simple supply and demand mismatch of blood flow
through the occluded arterial segments.

A longstanding belief was that PAD limb

dysfunction arose solely from IC. As individuals would begin walking, the metabolic
demands of the tissues distal to the stenosis would rise, and blood flow across the
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occlusion would be insufficient, generating brief periods of ischemia that would induce
pain and impairment. For this model to be correct, the extent of arterial stenosis and
collateral circulation would be the only mediators of PAD symptomology, and
revascularization of occluded arterial segments should restore limb function. However,
gait is improved but not restored after revascularization.

Six months after bilateral

revascularization, PAD patients with IC demonstrate improvements in quality of life,
walking distances, plantar flexor strength, and gait biomechanics of the ankle and knee.
However, there is a lack of improvement at the hip during pain-free gait as well as
worsened gait at the ankle, knee, and hip after the onset of claudication pain which
indicates that limb function does not resolve.56 Additionally, advanced biomechanical gait
analysis demonstrates that gait dysfunction precedes the onset of claudication. Although
arterial stenosis is critical to the onset of PAD pathophysiology, it is likely that a
subsequent myopathy develops which enhances limb dysfunction in PAD patients.
Studies comparing age-matched elderly patients with and without PAD have
demonstrated that the effect of ageing on gait is not nearly as significant as the changes
due to PAD.57 Slower walking speeds and shorter strides are observed in older individuals
with and without PAD. However, additional deficits are unique to PAD. Joint angle and
torque analyses demonstrate that muscle weakness is present across ankle, knee, and
hip joints of PAD patients with IC, and may be a fundamental source of PAD altered gait
patterns.57 Muscle weakness across plantar flexors, knee extensors, hip flexors, and hip
extensors resulted in decreased plantar flexor torque, knee extensor torque, and hip
extensor torque in early stance, as well as hip flexor torque during late stance in PAD
patients.57,58 Both kinetic and kinematic abnormalities are present before the onset of
claudication pain, and occur rapidly after initiation of walking, often within the first 3-4
steps, and worsen during and after the onset of claudication.58 The alterations of muscle
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strength may contribute to the joint angle and torque changes observed in PAD gait, and
are likely related to the extent of myopathy present.

The Myopathy of Peripheral Artery Disease

Skeletal muscle is the end organ most affected by PAD, leading to an ischemic
myopathy that is characterized by altered myofiber morphology and degeneration,
mitochondrial dysfunction, and impaired limb function.59-66 Our group and others have
demonstrated that myopathy is progressive as the severity of PAD advances.64 In early
stages of PAD myopathy, subtle changes in myocyte morphology arise and are
heterogeneously distributed. Myofibers can become enlarged or conversely undergo
degeneration and the polyhedral perimeter of myocytes can become rounded.61 Whereas
nuclei are normally found near the sarcolemma of myocytes, in PAD myopathy nuclei
become centralized.

Centralized myocyte nuclei are commonly encountered in

regenerating myofibers, which suggests that myofibers may be attempting to repair tissue
damage. Additionally, vacuolization within myofibers is commonly encountered and is
thought to correspond to proteins with oxidative damage that have accumulated within the
myocyte.

As the myopathy progresses, myofiber pathology worsens, increases in

frequency, and becomes more homogeneously distributed. Whereas fibrosis if relatively
limited in early PAD myopathy, increased fibrotic deposition of collagen around myofibers,
myofascicles, and microvessels occurs in later stages of PAD myopathy.67
Striking alterations are also observed within the vasculature of PAD limbs.
Atherosclerosis induces medial hypertrophy of affected arteries, with a concomitant
replacement of elastin with collagen.68 These alterations result in a stiffening of PAD
arteries, which may have deleterious effects on the transmission of mechanical force
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across the vascular wall, with subsequent alterations of mechanically induced cell
signaling, which ultimately may negatively impact blood flow regulation through myopathic
tissues.

Medial hypertrophy and hyperplasia are continuous across the arterial to

arteriolar interface and aberrantly extend into the microvasculature of PAD muscle.
Whereas VSMC are arranged to mediate vascular tone and contraction, the arrangement
of pericytes around the microvessels (>50μm) may be integral in facilitating and integrating
cellular communication69 within the myopathic microenvironment. Consequently, small
vessels in PAD leg muscles may sense ischemic hypoxia and induce VSMC hypertrophy
and hyperplasia, and may lead to fibroblast accumulation, myofibroblast differentiation,
and collagen deposition.67 Thus, microvessels may be the initiators and drivers of fibrosis
and PAD myopathy. However, the mechanism by which PAD microvessels influence
vascular remodeling and blood flow regulation remains poorly characterized.

Mitochondropathy and Oxidative Damage Contribute to PAD Myopathy

Chronic cycles of ischemia-reperfusion may induce the myopathic changes
observed in the lower limbs of PAD patients. Ischemia-reperfusion injury to skeletal
muscle may lead to a decline in the integrity and function of myofibers, and as a
consequence, sufficient myofiber degeneration may modify gait and ambulation. Initially,
these cycles are related to the atherosclerotic occlusion of the arterial supply to the
skeletal muscle of PAD patients. As patients begin to walk, the demand for oxygen and
nutrients increases, but the stenosed vessels present hemodynamic restrictions which
limit blood delivery to metabolically demanding tissues thereby producing a transient
ischemia.

As patients rest, metabolic demand decreases, and blood flow becomes

sufficient to re-perfuse these tissues. Additionally, as patients become more sedentary,
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venous and lymphatic clearance (via the muscle pump effect)70 may be decreased.
Stagnant blood may be populated with toxic metabolites that may be harmful to the
skeletal muscle, which may contribute to PAD myopathy.
Cycling between hypoxia and normoxia has been shown to be highly damaging to
end organs throughout the body.71

With repeated incidents of transient hypoxia,

reperfusion injury inflicts havoc on distal tissues indirectly through alterations in gene
expression profiles

72,73

and directly through intracellular damage via reactive oxygen

species (ROS).65 Such damage can induce cellular necrosis, which leads to the local
release of potent pro-inflammatory factors.

Additionally, oxidative damage and

mitochondrial dysfunction may play critical roles in the initiation and progression of PAD
myopathy.
Mitochondrial function is abnormal in patients with PAD.74 During exercise, skeletal
muscle preferentially utilizes oxidative phosphorylation to supply the energy demands of
the myocytes. Glucose and fatty acids are converted to acetyl-CoA and subsequently
acetyl-CoA condensation with oxaloacetate generates citrate within the mitochondrial
matrix. Citrate formation initiates the tricarboxylic acid cycle, the intermediates of which
reduce electron carriers (NADH and FADH2) and shuttle electrons to the electron transport
chain of the inner mitochondrial membrane. A membrane potential is thus created by the
resultant electro-chemical potential and is utilized by ATP synthase to phosphorylate
adenosine diphosphate (ADP) into adenosine triphosphate (ATP).75 PAD gastrocnemius
biopsy specimens displayed an accumulation of metabolic intermediates, including
acylcarnitine and lactate.64,66,76,77 This data suggests that PAD muscle inefficiently utilizes
glucose (anaerobic glucose oxidation), possibly due to a decreased capacity of
mitochondria to complete the tricarboxylic acid cycle yielding incomplete oxidation of fuel
substrates.
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Mitochondria control ATP flux through several steps in oxidative phosphorylation.
The electron transport chain capacity determines the pace of oxidation. Electron transport
chain capacity decreases with age and likely contributes to declines in muscle power
output and locomotor performance.78 In advanced PAD, mitochondrial complexes I, III,
and IV have significant reductions in respiratory capacity and enzymatic activity.74,79
Decreased complex I activity has been observed in PAD muscle and suggests that a
quantitative deficit in mitochondrial respiratory capacity in PAD.80

Successful oxidative

phosphorylation requires a terminal electron acceptor, which in mitochondria is molecular
O2. Mitochondrial coupling efficiency (the coupling of the cell’s ATP supply from oxygen
uptake) contributes to exercise efficiency and the capacity for sustained exercise.78
Inhibition of adenine nucleotide translocase (via atractyloside titration) yields lower
mitochondrial coupling control in PAD patients compared to control patients,80 which
suggests poorer quality of mitochondria in PAD myopathy.

Lastly, ATP synthesis

contributes to myocyte performance. ATP synthesis is dynamic, has several regulatory
checkpoints, and can provide as much as a 50-fold range of ATP flux between resting
muscle and exercise at the mitochondria’s maximal capacity.78
Phosphorus-31

nuclear

resonance

spectroscopy

demonstrated

Studies using
phosphocreatine

depletion and intracellular acidification were increased in PAD patients compared to
healthy controls during exercise. These data suggest that PAD mitochondria have an
impairment in oxidative ATP synthesis with a subsequent enhancement of non-oxidative
ATP synthesis that is likely compounded by reduced proton efflux.

Furthermore,

acidification prevented an increase in ADP concentration, limiting compensation for the
oxidative defect. Exercise induced changes in pH and phosphocreatine concentration
necessitated approximately twice as much ATP turnover per given muscle power output
in PAD patients relative to control patients.81
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In a recent study by Baum and colleagues, ultrastructural assessment of vastus
lateralus muscle biopsy samples demonstrated that capillary density, mitochondrial
volume density, and peak power output during leg extension exercise were lower in PAD
patients with IC than control. They also noted that the microvessels in these samples had
thickened BM.82 This suggests that alteration of the microvascular architecture may be
associated with both limitations at the capillary to mitochondrial interface and muscle
performance.

Mitochondrial enzyme activity may be reduced in association with

decreased mitochondrial density.74,82 Paradoxically, an increased volume density has
been observed in PAD gastrocnemius.83,84

PAD pathology is often worse in the

gastrocnemius than the vastus lateralis, and the elevated volume density of mitochondria
in the gastrocnemius may represent a more robust compensatory effort in the face of
limited oxygen delivery and poor mitochondrial function.

The relationships between

oxygen tension, mitochondrial function, muscle performance, microperfusion, and
microvascular architecture are also poorly characterized, particularly within the
gastrocnemius. Alterations of the microvascular architecture, such as BM thickening, may
directly contribute to diffusion limitations, which may result in aberrant mitochondrial
function and the generation of ROS, with consequent deleterious effects on muscle
performance. Hence, understanding the relationship between microvascular structural
alterations in PAD and oxidative stress is of particular interest and warrants further
investigation.
Chronic cycles of ischemia/reperfusion injury occur and worsen with increasing
atherosclerotic blockage of the arteries feeding the legs. During exercise when metabolic
demands are heightened and myocytes are most vulnerable to hypoxia, the supplydemand mismatch of arterial blood flow likely enhances skeletal muscle ischemia and
oxidative damage. Mitochondrial dysfunction contributes to the production of ROS and
stagnant blood may carry toxic metabolites that may also contribute to oxidative stress
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and tissue injury in PAD limbs. The capacity for PAD tissues to neutralize ROS is also
diminished. Studies have demonstrated that manganese superoxide dismutase, a major
antioxidant enzyme, is deficient in PAD skeletal muscle.

Thus, the generation,

accumulation, and inability to neutralize ROS collectively contribute to oxidative stress in
PAD limbs. ROS may be involved in cell signaling during normal physiological function.
Thus, elevated ROS may alter cellular functions, including promotion of cell survival,
angiogenesis, differentiation, and proliferation. ROS signaling may become continuous
and grow in intensity with advancing arterial flow limitations, and may contribute to
pathological tissue remodeling, including microvascular structural alterations and fibrosis.
Excessive ROS may also damage DNA and proteins, particularly within the mitochondria
where ROS concentrations are likely the greatest within the cell.
Ultrastructural analysis of mitochondrial structure supports the conclusion that
oxidative damage is greatest in mitochondria of PAD muscle. Mitochondria demonstrate
hypertrophy, hyperplasia, and hypercristae.

Mitochondria also acquire a transverse

orientation and gain paracrystalline inclusions and lipid vacuolizations.85,86 Mitochondrial
ROS contributes to the oxidative damage and addition of adducts to proteins (carbonyl)
and lipids (4-hydroxynonenal). Increases in carbonyl and 4-hydroxynonenal products
have been observed in the myofibers of PAD patients and were associated with loss of
myofibers and advancing PAD stage severity.61 Additionally, PAD muscles had increased
desmin and desmin gene transcripts, which corresponded to changes in myofiber
morphology. Desminopathy was also associated with decreased mitochondrial respiration
as well as decreased muscle strength and walking performance.59 These data support
that mitochondrial oxidative damage may directly contribute to myofiber degeneration, and
likely declining limb performance.
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Fibrosis is Progressive in PAD and Linked to Vascular TGF-1 Expression

Fibrosis is defined by the stiffening and/or scarring of tissues which is attributed to
excessive deposition of ECM components such as collagen.

In skeletal muscle,

myofibroblasts deposit collagen which subsequently compromises tissue architecture,
myofiber contractility, and ultimately muscle force production.58,61,64-66,80,85-92 Fibrosis is
thought to occur as a generalized healing response after inflammation. Stimuli such as
persistent infections, allergic reactions, autoimmunity, chemical or physical injury, and
radiation can induce fibrosis.93 However, in PAD patients, this fibrotic response arises
from chronic intermittent hypoxia, becomes persistent, and leads to scarring associated
with worsening myopathy and clinical symptoms. Our laboratory has shown that collagen
deposition increases with advancing PAD disease stage67. One of the most striking
pathological changes was the dense collagenous investment of the microvessels (5 -12
µm total diameter). In association with increased collagen deposition, we found a robust
expression of transforming growth factor 1 (TGF-β1), a potent pro-fibrotic cytokine, in the
VSMC of the small vessels (ca. 50

to 150 µm lumen diameter) of the affected

gastrocnemius of PAD patients67. Increased TGF-β1 is a persistent feature of PAD
myopathy61,67,87,88,92,94-96 and is likely to be a predominant factor in propagating the fibrotic
expansion of the ECM in the muscles of PAD limbs. Homogenates of gastrocnemius
biopsies from PAD patients demonstrate, on average, a three-fold increase in TGF-β197
compared to age matched control patients. Furthermore, fibrosis occurs in PAD legs and
leads to scarring that is associated with worsening myopathy and clinical symptoms which
are the most severe in elderly subjects.98
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Imaging Characteristics of PAD Skeletal Muscle

Various modalities have been used to assess arterial occlusion and skeletal
muscle myopathy in PAD. Magnetic resonance imaging (MRI) is a powerful imaging
modality for the visualization of tissue morphology. Work from our lab has recently
focused on characterizing PAD myopathy by analyzing the distribution of pixel intensity
across non-contrast enhanced T1 and T2 MRI-imaging sequences. Preliminary work from
our lab shows that both T1 and T2 mean pixel intensity are associated with extent of
macrovascular occlusion and muscle performance.

Ankle brachial index (ABI), a

surrogate measure for arterial occlusion, (Figure 1) and pain free peak plantarflexion
(Figure 2) are positively correlated with T1 mean pixel intensity in the PAD muscle. T2
mean pixel intensity is inversely correlated with the time to recover from ischemia after
exercise (Figure 3). Future studies are needed to characterize the relationship between
MRI characteristics and histological features of myopathy, including collagen deposition
and myocyte morphology, however, these data support that MRI may be able to noninvasively discriminate features that determine the extent and severity of PAD myopathy,
which may allow correlational analysis of patient outcomes after standard interventions
such as revascularization of supervised exercise therapy.
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Figure 1: The Association Between ABI and T1 Mean Pixel Intensity

Figure 1: The association between ABI and T1 Mean Pixel Intensity
As ABI decreases, T1 mean pixel intensity decreases in the lateral gastrocnemius (n = 22;
R = 0.37; p = 0.09), the medial gastrocnemius (n = 23; R = 0.45; p = 0.03), and the soleus
(n = 23; R = 0.46; p = 0.03). Linear relationships were assessed by Spearman Rank
Correlations.
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Figure 2: Pain Free Peak Plantarflexion is Associated with T1 Mean Pixel Intensity

Figure 2: Pain Free Peak Plantarflexion is Associated with T1 Mean Pixel Intensity
Pain free peak plantarflexion increases in association with increasing T1 mean pixel
intensity in the lateral gastrocnemius (n = 21; R = 0.55; p = 0.009), the medial
gastrocnemius (n = 22; R = 0.43; p = 0.05), and the soleus (n = 22; R = 0.55; p = 0.008).
Linear relationships were assessed by Spearman Rank Correlations.
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Figure 3: Duration of Recovery from Ischemia is Associated with T2 Mean Pixel
Intensity

Figure 3: Duration of Recovery from Ischemia is Associated with T2 Mean Pixel
Intensity.
The ischemic window measurement represents the severity of ischemic deficits present in
the limb, whereas the ischemic window time measures the duration of time from the
discontinuation of exercise to the recovery of pre-exercise ankle systolic pressure. An
inverse relationship is present between ischemic window time and T2 mean pixel intensity
in the lateral gastrocnemius (n = 22; R = -0.48; p = 0.03), the medial gastrocnemius (n =
23; R = -0.48; p = 0.03), and the soleus (n = 23; R = -0.46; p = 0.03). Linear relationships
were assessed by Spearman Rank Correlations.
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Traditional MRI offers superior spatial resolution for defining morphology, however,
additional MRI sequences and techniques are available to quantify hemodynamic
parameters, including perfusion. Magnetic resonance angiography (MRA) is frequently
used to visualize blood vessels including areas of vascular occlusion or stenosis. MRA
can be completed with or without contrast enhancement (gadolinium based). Although
peak arterial flow can be visualized by contrast-enhanced MRA techniques, MRA does
not offer good temporal resolution, particularly with regards to microvascular
hemodynamics. Computed Tomography Angiography (CTA) utilizes similar principles to
MRA and has also been used to visualize arterial pathology and flow.
Blood oxygenation level dependent (BOLD) MRI has recently been used to
characterize the hyperemic response of PAD legs. BOLD MRI imaging works on the
principle that deoxygenated hemoglobin is paramagnetic, and consequently conversion
from oxygenated to deoxygenated hemoglobin can be detected as localized magnetic field
distortions. Thus, ratios of oxygenated to deoxygenated hemoglobin can be quantified,
which yields information about muscle oxygenation state, perfusion, and metabolic
demand. BOLD signal is also dependent on blood volume, hemoglobin concentration,
blood pH, and local metabolic products such as lactate and phosphate.99 In addition to
the multifactorial contribution to BOLD responses, BOLD MRI has limited reproducibility,
with a coefficient of variation as high as 50.9%.100 Ledermann and colleagues compared
the BOLD response in calf muscles from PAD patients and healthy controls using a postocclusive reactive hyperemia paradigm. The T2* time course (BOLD response) was
reduced during reactive hyperemia in PAD patients compared to controls and the time to
peak T2* signal was prolonged.101 This suggests that muscle perfusion is delayed and
decreased during reactive hyperemia in patients with PAD, however, the specific
contribution of microvascular pathology could not be determined in this study.
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Single photon emission computed tomography (SPECT) and positron emission
tomography (PET) have also been used in studies addressing microvascular perfusion in
PAD. Both SPECT and PET offer high sensitivity. However, these imaging modalities are
riddled with disadvantages. PET imaging has limited access, is costly, and offers relatively
modest spatial resolution. SPECT imaging also has modest spatial resolution and is
difficult to quantify. PET and SPECT, like CT, also rely on the use of ionizing radiation.
Thus, the use of these imaging modalities is of limited use in clinical evaluation of
microvascular perfusion.
Although

radiological

standard

modalities

cannot

accurately

evaluate

microperfusion102, a relatively new imaging modality, contrast enhanced ultrasonography
(CEU), may be able to evaluate microperfusion abnormalities in PAD legs. CEU offers
the ability to visualize perfusion of large vessels as well as small vessels. CEU has
excellent spatial and temporal resolution, which allows the visualization of flow
redistribution (or lack thereof) between nutritive and non-nutritive circuits within PAD
muscle during exercise.103 CEU relies on the use of microbubble contrast agents which
remain confined within the vascular system, and thus do not distribute to the interstitium
of tissues.99 CEU imaging has a resolution that can discriminate vessels as small as 100
m,104 making this imaging modality a potent means for evaluating microvascular
hemodynamics.
The basic premise of CEU imaging begins with the composition and physical
properties of microbubbles. Microbubbles are typically <5 m in diameter, which allows
them to pass unimpeded through capillary beds.105 Microbubbles are encapsulated within
lipid, protein, or biopolymer shells. Gas diffusion across the shell needs to remain limited,
thus these shells must have sufficient barrier function and low surface tension.105
Contemporary microbubble gases, such as octafluoropropane, sulfurhexafluoride, and
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perfluorobutane, are less diffusible and less soluble in aqueous solutions (lower Ostwald
coefficient) than first generation low molecular weight microbubbles.105 These newer
microbubble gaseous formulations have substantially greater longevity within the
circulation, which enables more robust and accurate signal detection.

Microbubble

contrast agents also have unique physical properties that enhance the discriminatory
capability between contrast and tissue signals. As the ultrasound transducer emits sound
waves, rapid variations in acoustic pressure are propagated through the tissue. These
sound waves induce resonant volumetric oscillations in the microbubbles, which produces
asymmetric changes in microbubble diameter.106 The degree of oscillation is dependent
on the density of the gas core, microbubble shell components, ultrasound characteristics,
and the surrounding medium.105 Asymmetric changes in microbubble size lead to sound
wave reflections that have strong non-linear components as well as harmonic overtones
that are multiples of the transmitting frequency. Conversely, tissue and tissue motion
reflect linear components back to the transducer.105,106 Thus algorithms constructed
around pulse correlation can detect and discriminate the non-linear microbubble signal
from linear tissue signals.

Microbubbles that oscillate without significant loss of

microbubble integrity are in a state of stable cavitation.

However, with increasing

frequency or pressure amplitude, microbubbles can rupture and result in inertial
cavitation.105
Low-power, real-time CEU utilizes signals are produced by microbubble stable
cavitation. Two methodologies (bolus microbubble infusion kinetics and replenishment
kinetics) have been used in the studies of human skeletal muscle in PAD muscle. Early
CEU studies delivered a single bolus of microbubbles, thereby allowing the
characterization of the wash in and wash out kinetics, the time to peak (TTP) contrast
signal, the slope of the rise to maximal signal intensity, the maximum signal intensity, and
the area under the curve (AUC) generated by contrast influx, which is an approximation
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of blood volume. TTP likely reflects both macro- and microcirculation since achieving
maximal contrast intensity requires microbubble delivery through both arterial and
microvascular vessels.107 Likewise, maximal signal intensity and AUC are influenced by
arterial inflow and microvascular perfusion.

The slope to maximal signal intensity,

however, may be the most specific measurement of microcirculation.102

However,

dynamic CEU can be biased by several factors, including systemic flow and instability of
contrast concentration in the blood pool, which limits the quantification and interpretation
of microvascular hemodynamic performance.
In order to exclude the influence of macroperfusion and determine only
microperfusion, replenishment kinetics must be assessed.108 To assess these kinetics,
contrast is continuously infused until a steady state is achieved. Subsequently, inertial
cavitation is induced to destroy all microbubbles in the transducer’s field.

The

replenishment of microbubbles from adjacent vessels into the field is recorded at each low
power pulsing interval.

Measurement of the rate of replenishment is thus directly

proportional to the regional blood flow rate.106 Quantification of replenishment kinetics is
independent of systemic flow, and reflects microvascular flow.109-113 Time intensity curves
(TIC) are comprised of serial measurements of the signal intensity as a function of time
after inertial cavitation, and when plotted as a non-linear equation can produce estimations
of red blood cell velocity or blood flux rate, relative blood volume, and microvascular blood
flow. The TIC reflects intravascular transit times.106
CEU has been used to assess the severity of PAD, as well as alterations of
microperfusion. CEU has offered the opportunity to examine the influence of collateral
perfusion on PAD, as well as large and small vessel physiologic effects on PAD limb
perfusion.110 In several studies, a relationship between CEU parameters and ABI was
absent. This suggests that CEU provides information about PAD severity beyond what
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ABI produces, and importantly CEU reveals information of hemodynamic relevance to
myopathic areas, particularly microvascular dysfunction.109,114

Microperfusion is Altered in PAD Myopathic Skeletal Muscle

Increasing arterial stenosis contributes to flow limitations in PAD, particularly
during exercise.
vascular tree.

Distal to the stenosis, vascular remodeling occurs throughout the
This remodeling includes stiffening of the vessels, hypertrophy and

hyperplasia of VSMC, perivascular collagen deposition, and microvascular structural
alterations. Although arterial flow limitations are fairly well characterized, relatively few
studies have addressed microvascular perfusion deficits in PAD patients.

However,

recent studies using CEU demonstrate that PAD pathology may have a microvascular
component.
Several animal models have attempted to characterize microvascular perfusion
deficits. In a porcine model of PAD, Bragadeesh and colleagues surgically created a
gradient of stenosis across the femoral artery of pig hindlimbs. They observed that as the
severity of stenosis increased, resting femoral blood flow decreased.

Interestingly,

skeletal muscle blood flow was preserved in moderate stenosis, and only became limited
in severe stenosis.110 This suggests that in moderate stenosis, collateral arteries may be
able to compensate for the decreased flow across the stenosed artery and that the
contribution of collateral circulation is inadequate in severe stenosis. Diminished resting
microvascular blood flow was attributed to decreased microvascular blood flux rate.
During adenosine induced hyperemia, blood flux rate increased, but was blunted with
increasing stenosis. With exercise, microvascular blood volume decreased more than
blood flux rate in association with increasing stenosis severity.110 It is possible that the
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decline in blood volume reflects the muscle pump effect, in which contracting muscles
squeeze venous blood and encourage venous return to the heart. Conversely, reduction
in microvascular blood volume during exercise may reflect active de-recruitment of
capillary circuits, possibly via constriction at pre-capillary sphincters, as a means to
preserve precapillary pressure and maintain blood flux through a subset of capillary
beds.110,115,116 Microvascular flow reserve is calculated as the ratio of microvascular blood
flow during hyperemia to microvascular blood flow at rest. Flow reserve was nearly
completely lost in animals with severe stenosis. As stenosis severity increased flow
reserve decreased after both adenosine-induced hyperemia and exercise in association
with stenotic pressure gradients.110
In a rodent hindlimb ischemia model, Pascotto and colleagues used CEU to assess
specific components of perfusion alongside histological analysis. They segregated blood
flow into three categories: 1) arterial; 2) non-capillary microvessels (arterioles); and 3)
capillaries.

On completion of the surgical ligation, capillary blood flow decreased by

approximately 30% relative to the intact contralateral limb. Capillary blood flux rate was
affected to a greater extent than blood volume. Over the following two weeks, large
collateral vessels expanded and reorganized, and changes in perfusion, predominantly
non-capillary blood volume, were temporally related to arteriogenesis and expansion of
the collateral network.

Histological review revealed an increase in the number of

microvessels (20 – 40 m) within myofibers, as well as enlargement of larger arterioles
that bridged myofascicles. Thus, it was suggested that large collateral circuits are the
most rapidly effective means of restoring tissue perfusion after ligation, but only if
remodeling of more distal arterioles has occurred. These alterations may allow reductions
in distal resistance in the presence of persistently low perfusion pressures. Interestingly,
changes in capillary flow did not occur until after remodeling of non-capillary microvessels.
The greatest changes observed in capillary flow were attributable to microvascular blood
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flux rate, possibly as a result of pressure correction at the precapillary level. 117 Taken
together, these data suggest that as arterial stenosis worsens, a distal remodeling of noncapillary microvessels occurs to optimize collateral network conductance and
connections. As these networks become enhanced, terminal microvascular beds begin
to augment flow patterns, likely to reduce the total network resistance and improve blood
distribution across microvascular beds.
One of the greatest limitations of animal models of PAD includes the temporal
aspects of arterial occlusion. Arterial stenosis is induced surgically in animals, and as a
result, induction of ischemia is immediate. In humans, the perfusion limiting stenosis is
gained gradually over the course of several years. Thus, human alterations in collateral
vessel formation and microvascular pathology may not mirror the adaptations observed in
animals. Furthermore, several important risk factors such as chronic smoking, alcohol
consumption, and poor dietary intake cannot be readily duplicated in animals, and these
factors may be strong contributors to the formation of microvascular pathology in PAD.
For example, insulin resistance and smoking are associated with detrimental alterations
in microvascular blood flow through skeletal muscle.
Microvascular physiology during exercise in humans is complex. Blood velocity
decreases as it travels distally, and the slowest flow is observed within the terminal
microvascular beds, which have the greatest surface area. However, blood volume is
largest within the veins.109 At rest, approximately 25 – 40% of capillaries are actively
perfused within skeletal muscle. Increases in blood flow result in increased blood flux
through capillaries, typically with a concomitant increase in number of perfused capillaries.
Thus, a high capacity for microvascular blood flow is present in healthy skeletal muscle,
which when coupled with a low basal flow rate potentiates a high flow reserve.118-120
Muscle metabolism influences blood flow regulation, likely at the level of the capillaries
and arterioles.107,121,122 As muscle begins to contract and muscle metabolism increases,
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blood flow rapidly increases and stabilizes.123

Using CEU and venous occlusion

plethysmography (VOP), Krix and colleagues quantified several components of
hemodyanamic responses to exercise. They observed that with higher levels of exercise,
global flow, as assessed by VOP, increased as CEU blood volume decreased. The
decrease in blood volume correlated to spent muscle work. They postulated that the
decrease in blood flow was a result of diameter reduction of the veins via increased
intramuscular pressure during muscle contraction. As participants discontinued exercise,
blood volume increased rapidly in proportion to the performed muscle force.107 The role
of venous blood flow during muscle training may be of particular interest in PAD patients.
A combination of muscle blood flow restriction and slow walking training (Kaatsu walking)
have been shown to induce muscle hypertrophy and strength gain without measurable
muscle damage.124 Thus, Kaatsu walking may be of utility in improving walking function
for patients with severe walking limitations.
Healthy aging is associated with several functional alterations that may alter
skeletal muscle hyperemic responses. Endothelium-dependent dilation may be limited in
response to increased shear stress within medium and small vessels, and changes of
nitric oxide-mediated signaling may occur within elderly patients.125-129

Additionally,

elevations in resting sympathetic outflow and sensitivity to acute sympathetic stimulation
may contribute to increased vasoconstriction, especially during exercise. 130,131 These
functional modifications may account for the longer TTP and dampened reperfusion
responses observed in elderly patients.132
A handful of studies have been conducted using CEU that compared control and
PAD patients microperfusion. When compared to controls, PAD patients have similar
resting microvascular blood flow.133 Conflicting results have been obtained for several
CEU parameters, including TTP and AUC. The majority of studies have observed a
delayed TTP in PAD patients relative to controls after exercise and post-occlusive reactive
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hyperemia,99,102,108,109,133-136 however, other studies did not observe a significant
difference.137,138 Duerschmied and colleagues analyzed both angiographic and CEU
images and determined that PAD patients that were classified as “poorly” collateralized
had prolonged TTP, which did not correspond with a decreased ABI. Additionally, patients
in more advanced stages of PAD had a prolonged TTP.109

Post-occlusive reactive

hyperemia TTP was inversely correlated with ABI, whereas post-exercise TTP was not
significantly correlated to ABI.108,135 The slope to maximum intensity after post-occlusive
reactive hyperemia was decreased in PAD patients relative to controls as was the
AUC.102,108 Surprisingly, maximum intensity and AUC were larger in PAD patients relative
to elderly control patients, which may reflect an expanded network of arterioles and
capillaries secondary to hypoxia-induced angiogenesis.132

Revascularization surgery

shortened TTP in PAD patients immediately after surgery, and TTP was further shortened
3 – 5 months post operatively.102,139 Additionally, the slope to maximum intensity after
post-occlusive reactive hyperemia was increased after revascularization, as was the
maximum intensity.102
Smoking may have an impact on microvascular perfusion and is likely a
confounder in studies of PAD microcirculation. Mancini and colleagues demonstrated that
in a cohort of patients with diabetes, TTP was delayed in current versus never smokers.
Furthermore, the transit time of contrast agent to reach the tissue was delayed, as was
the duration of time required for microbubbles to traverse through the gastrocnemius in
smokers versus non-smokers. Each patient enrolled in this study was assessed for the
presence of PAD, and approximately half of both smokers and non-smokers had a history
of IC. In a sub-analysis, they observed that there was no difference in TTP between nonPAD and PAD patients in all Fontaine stages.137 This data suggests that when stratified
by smoking status, the relationship between TTP prolongation and PAD is lost. However,
the cohort of patients assessed in this study was small (11 PAD versus 15 non-PAD), and
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the severity of PAD was poorly characterized. Additionally, all of the participants had
diabetes and it remains unclear if the remaining comorbidities were equally distributed
between groups.

Smokers experience a complex alteration in regulation of

microperfusion.137

Studies have reported impaired endothelium-dependent dilation,

inappropriate resting dilation, and reduction in VSMC relaxation of the microcirculation, as
well as declines in arterial elasticity in the vasculature of smokers.140-143 Additional studies
are merited to determine the contribution of smoking status (never, former, current) on
PAD microcirculatory performance in patients with and without diabetes.
Ultrasonography has the capability to discriminate and quantify blood flow through
arteries, veins, and the microcirculation. By using color coded duplex mode, ROIs can be
selected that represent arterial and venous vessels. Switching to B mode enables the
quantification of the flow. Contrast transit velocity (CTV) can then be estimated based on
the distance between the selected ROIs.

Duerschmied and colleagues utilized this

strategy and assessed the contrast transit time (CTT) to the artery, the microcirculation,
and the vein within the gastrocnemius of control, PAD, and DM patients. The greatest
differences between groups were observed when comparing the composite transit times
between the artery and the vein, and the CTVs. Blood traversed the muscle more rapidly
in the controls (CTT artery to vein = 11 s; CTV = 2.0 – 3.3 mm/s) compared to PAD (CTT
artery to vein = 22 s; CTV = 0.7 – 1.9 mm/s), and was substantially slower in late diabetic
syndrome (CTT artery to vein = 43 s; CTV = 0.3 – 0.9 mm/s).136 The delays in CTT arose
predominantly from slower progression through the microvascular compartment. These
data support that CEU can discriminate microcirculation from small arteries and veins.
Additionally, the results of this study suggest that significant alterations of microperfusion
are present in PAD, and are exaggerated in DM. However, the microvasculature was not
characterized at the tissue level, so it remains unclear if these findings reflect functional
changes, structural alterations of microvessels, or the number of microvessels.
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A handful of studies have assessed the replenishment kinetics within PAD legs.
Surprisingly, resting microvascular blood flow (MBF) did not differ between controls and
PAD patients in multiple studies.133,144 It has been postulated that healthy individuals have
greater metabolic efficiency and thus a lower resting tissue demand. Conversely, PAD
patients have lower arterial flow which limits perfusion and subsequently induces muscle
atrophy and loss, effectively normalizing muscle mass to perfusion.133 Post-occlusive
reactive hyperemia is also altered in PAD microcirculation. Whereas control and PAD
patients do not differ in the peak microvascular blood volume obtained on cuff release,
PAD patients achieve this peak much more slowly. This may be due in part to the
diminished increase in microvascular blood velocity that was observed during reactive
hyperemia. Post-occlusion whole leg blood flow was associated with reperfusion MBF,
and both whole leg blood flow and MBF were decreased in PAD patients relative to
controls.138 Vasodilator stress can be induced by administering dipyridamole. In PAD
patients, dipyridamole was observed to increase the blood transit rate in large vessels and
modestly increase the microvascular flux rate without significant augmentation of
microvascular flow at rest.

The response to dipyridamole did not differ significantly

between control and PAD subjects.144
In comparison, the hyperemic response after contractile exercise is more robust in
control versus PAD patients.103,144 During moderate contractile exercise, microvascular
blood volume was slightly lower than controls, whereas microvascular blood velocity was
substantially diminished in PAD patients.

144

Similarly, in coronary artery disease, MBF

augmentation in response to stress or metabolic demand is also limited. 114 In PAD
patients, the diminished increase in MBF in response to exercise resulted in decreased
flow reserve in PAD patients.103 After adjusting for diabetes, exercise MBF (OR: 0.67) and
flow reserve (OR: 0.46) could predict severity of disease defined by the claudication
threshold.103

In a subset of patients who were evaluated both before and after
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revascularization surgery, exercise MBF increased substantially post-operatively.144
Furthermore, the hyperemic response during exercise, but not during dipyridamole, is
associated with the degree of flow impairment in PAD and potentially the degree of
improvement with revascularization.144 However, substantial variation in flow reserve has
been observed from fairly homogeneous cohorts of both control and PAD patients.114
Since resting MBF is typically very low, small absolute differences in hyperemic flow can
create deceptively large flow reserves. Thus, the degree of hyperemic MBF may be a
more reliable parameter by which to determine the presence or severity of PAD.114
Additionally, the spatial heterogeneity of MBF distribution likely represents microdomains
of severe ischemia in PAD patients,114 however, this has yet to be confirmed by
histological analysis. In a study of the relationship between total leg and microvascular
flow in response to exercise, Meneses and colleagues demonstrated that during
submaximal leg exercise, both total leg flow and MBF did not differ between PAD and
control patients. However, after the conclusion of exercise, PAD patients had a higher
microvascular blood volume than control.138
Alteration of microperfusion likely reflects both disease severity and compensatory
mechanisms. It has been speculated that enhancing blood volume is compensatory for
declining microvascular blood velocity, potentially by reducing microvascular resistance
and increasing oxygen and nutrient delivery to a greater area.138 It is also possible that
increased blood volumes reflect an increase in angiogenesis and microvascular density.
Conversely, elevations in microvascular blood volume may reflect weakened muscle
contraction and reduced venous clearance (muscle pump effect). Although these studies
illuminate that microvascular flow limitations exist in PAD patients, additional studies are
necessary to determine the mechanisms by which MBF is altered during exercise, as well
as the contribution of large vessel stenosis to microperfusion deficits.

In particular,

histological analysis of microvascular architecture and density in parallel with
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microperfusion assessment may clarify the etiology of microcirculatory deficits, as well as
the significance of microvascular pathology in PAD.
In addition to visualizing perfusion in PAD limbs, CEU may have future applications
as a therapy for PAD. Studies have shown that under the right ultrasound settings,
microbubbles may stimulate improvements in MBF.

Microbubbles are capable of

convective motion, or microstreaming, which can encourage shear-mediated endothelial
production of nitric oxide. In a model of PAD, delivery of microbubbles at high acoustic
powers have been shown to reverse moderate tissue ischemia.145 Although still in the
early experimental stages, CEU may be a powerful clinical tool in the diagnosis and
treatment of PAD.

Endothelial Dysfunction Contributes to PAD Pathophysiology

Atherosclerotic blockage of arteries leading to the lower limbs leads to
hemodynamic changes and consequently macrovascular and microvascular adaptations.
It is believed that as the arterial occlusion worsens, inflammation and ischemia/reperfusion
become more frequent, which initiates vascular remodeling including arteriogenesis and
angiogenesis.

Arterial occlusion leads to inefficient delivery of oxygen and toxic

metabolite clearance, which results in the accumulation of ROS, tissue necrosis, and
microcirculatory damage, ultimately resulting in irreversible deterioration and injury to the
endothelium.146-148
Endothelial dysfunction is a feature of many chronic diseases, including
hypertension, DM, renal disease, and obesity.149-151 The pathophysiology of endothelial
dysfunction likely arises from the imbalance of ROS signaling to nitric oxide (NO), as well
as overexpression of pro-inflammatory mediators. Inflammatory signals, such as tumor
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necrosis factor- (TNF-), are produced by atherosclerotic plaques and may travel distally
to microvascular beds. TNF- has been shown to stimulate endothelial expression of
selectin and adhesion molecules which enable the interaction of endothelial cells with
leukocytes and platelets, thus creating a localized pro-inflammatory and pro-thrombotic
microenvironment.152 Activated endothelial cells express cell surface adhesion molecules
such as intracellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule1 (VCAM-1), which are both elevated in PAD patients and are associated with poorer lower
extremity performance.153-155
Several studies have shown that the production of NO, an important component in
the regulation of vascular resistance and blood flow distribution,156 is decreased in PAD
patients.157,158 In the microcirculation, endothelial dysfunction may also be related to the
ratio of endothelin-1 to NO.159 Sedentary lifestyle and obesity may exacerbate the deficits
in NO production.

Excess body fat is linked to elevated production of inflammatory

cytokines and adipokines that reduce NO and other vascular signaling substances.159
Declines in blood flow yield lower flow-mediated shear stress, and consequently shearmediated production of NO.

During periods of reperfusion, surplus oxygen may

overwhelm the endothelial antioxidant capacity, leading to oxidative stress and
peroxynitrite formation.

Consequently, endothelial nitric oxide synthase (eNOS) is

inhibited and the production of NO is decreased, which further limits endothelial
function.160 The capacity for vasodilation declines as NO production decreases, which
may lead to increased vasoconstriction and limited delivery of blood to terminal
microvascular beds.
In a recent study by Baum and colleagues, patients with IC had more capillary
walls composed of swollen endothelial cells compared to controls.82 Endothelial swelling
has been shown to be aggravated by clamp-induced ischemia before femorodistal bypass
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surgery in the muscles of patients with CLI,161 which suggests that endothelial cell swelling
also occurs in acute muscle ischemia in conjunction with reperfusion.162-164 Ischemic
muscles have a low pH and addition of muscle activity may create a local acidosis. In the
setting of shock, acidosis is associated with both endothelial swelling, possibly mediated
by the influx of sodium into the endothelial cell, and with the addition of hypovolemia,
narrowing of the capillary lumen is also observed.165,166 In rodent models of hindlimb
ischemia, two weeks of intermittent hindlimb muscle stimulation demonstrated a significant
increase in the percentage of swollen capillary endothelial cells, both locally, and
systemically.167 Swollen endothelial cells are also observed in the skeletal muscle of
humans after application of a tourniquet for 1 – 3 hours.164 It has been proposed that
endothelial swelling is in part mediated by Ca2+ influx, likely arising from the accumulation
of adenosine in ischemic muscles.162 ROS may also be involved in endothelial swelling.162
In ischemic muscles, the breakdown of high-energy phosphates during muscle contraction
results in the production of hypoxanthine. Xanthine oxidase converts hypoxanthine to
xanthine and oxygen free radicals when oxygen becomes available during reperfusion. In
studies of prolonged muscle stimulation, endothelial swelling has been shown to decrease
the volume of the capillary lumen, which is thought to increase the duration of red blood
cell transit through the capillaries, thereby improving oxygen extraction.168

Thus

endothelial swelling in PAD may initially be a physiologic response to ischemia, but in the
setting of chronic intermittent ischemia may reflect endothelial damage and dysfunction.
Damage to endothelial cells may have a significant impact in PAD muscle.
Endothelial cell death may have a detrimental effect on angiogenesis. Constant loss of
endothelial cells or ineffective communication with pericytes may challenge the ability of
pericytes to stabilize vulnerable endothelial sprouts.169 Furthermore, lack of pericyte
coverage likely leads to leaky microvessels that may further enhance inflammation.
Endothelial dysfunction and death may thus lead to both mature and immature vessel
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instability, microvascular regression, and deleterious alterations in microvascular flow,
which may further contribute to PAD tissue ischemia. Importantly, chronic loss and repair
of endothelial cells may contribute to the pathological remodeling of microvascular BM55,170
observed in PAD muscles.82,171-174

Microvascular Remodeling in PAD Myopathy

Structural changes occur within the microvascular basement membrane (BM) of
skeletal muscle with age, physical activity, and diseases such as hypertension, DM, and
congestive heart failure.172,175,176 In a recent study, Bigler and colleagues demonstrated
that the BM thickness increases with age and may differ by gender. No relationship was
observed between thickening BM and pericyte coverage.175

However, with age the

connectivity between endothelial cells and pericytes becomes altered. A higher proportion
of empty sockets is present in both endothelial cells and pericytes, and the filopodia that
bridge these cells are shorter. This suggests that there is a regression of pegs from
sockets. These alterations may lead to decreased mechanical coupling between the
endothelium and pericytes, as well as a decline in the stability of the microvessel and
impairment of pericyte-mediated vasoconstriction. As a result, a compensatory thickening
of the BM may occur in the elderly.175 BM thickness increases, likely in relationship to the
orthostatic blood pressure, in a distal-proximal gradient.55,175

In other words, BM

thickening of microvessels is greatest at the feet and becomes progressively thinner as
microvessels ascend towards the head. There is considerable variability in the BM of
microvessels, even within the same muscle, and often between adjacent capillaries.175
Physical activity can reduce the thickness of the BM, including the microvessels of
the elderly.172,175 Baum and colleagues demonstrated that strenuous endurance exercise

34
can both thin the microvascular BM and stimulate angiogenesis with subsequent
increases in capillary density. With strenuous endurance exercise, increases in the
thickness of endothelial cells and pericytes were observed and pericyte coverage was
increased. Interestingly, these microvascular changes occurred without a change in
myofiber size. In a separate cohort undergoing moderate endurance training, endothelial
cell thickness was enhanced, but the BM thickness, pericyte thickness, pericyte coverage,
and capillary density did not change.177
Alterations of microvascular ultrastructure have been observed in PAD skeletal
muscle. Although some level of debate remains whether microvascular BM thickening is
progressive in PAD, studies have demonstrated that the microvascular BM is thickened in
patients with IC and CLI.82,85,171,173,178 Comparisons of the gastrocnemius and rectus
femoris between patients with Fontaine Stage II & III PAD and young controls (mean of
37 years) revealed no significant difference between total capillary area (combination of
BM, pericytes, endothelial cells, and lumen areas). However, the BM was thicker and the
lumen was smaller in PAD patients, and appeared to worsen with PAD symptom
severity.85 Relative to an age-matched cohort of controls, PAD patients had significantly
increased BM thickness.82,171,173,178 In a comparison of the tibialis anterior muscles of agematched controls (n = 4), PAD patients with IC (n = 4), and PAD patients with CLI (n =
10), significant differences were observed between PAD (IC combined with CLI) compared
to control, but a marginally significant difference was observed between PAD patients with
IC versus CLI, suggesting that this analysis was statistically underpowered. Comparison
across groups suggested that a relationship existed between BM thickness, DM, and
age.171

PAD patients with CLI have been shown to have up to a 50-fold thicker

microvascular BM than controls.173
In a recent study, Baum and colleagues executed a detailed analysis of the
ultrastructure of skeletal muscle in patients with IC (n = 14) and controls (n = 10). They
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observed a 24% increase in the volume density of BM in PAD capillaries, as well as a 23%
increase in arithmetic thickness, which corresponded to a 24% decrease in the
mitochondria of adjacent myofibers. Peak power output diminished by 45% in PAD
patients.

There was no alteration in pericyte coverage.

Linear associations were

observed between several parameters when compared across control and PAD, however
all of these associations were lost when analyzed in the PAD cohort alone.82
The number of capillaries present in PAD muscle may be associated with
microvascular architecture. The capillary to fiber ratio is elevated in the gastrocnemius,
but not the rectus femoris, of PAD patients and increased with symptom severity in PAD
patients with IC.174 Likewise, in the vastus lateralis, capillary density is decreased and
capillary to fiber ratios are unchanged in patients with IC relative to controls.82 Ho and
colleagues demonstrated that the capillary density was enhanced in the gastrocnemius of
CLI patients relative to controls, although a non-significant increase in SMA+ capillaries
was observed.173 Conversely, Baum and colleagues demonstrated that the proportion of
SMA+ capillaries was increased in PAD relative to control patients. When encountered,
the SMA immunoreactivity formed dense rings around microvessels and coincided with
gaps within Collagen IV, suggesting an “arteriolization” of the capillary beds of PAD
patients.171

The measurement of the number and proportion of SMA+ capillaries

deserves further characterization, as it remains unclear if the number of SMA+ cells
around individual capillaries is increased, as well as the cell type expressing the SMA
(i.e. pericytes, myofibroblasts, fibroblasts, VSMC, endothelial cells).
Several abnormalities have been observed in PAD microvascular endothelial cells,
including increased presence of large vacuoles, increased number of protrusions into the
lumen, and numerous pinocytotic vesicles, and nuclear abnormalities such as substantial
reduction in chromatin content.173,174

Necrosis of endothelial cells as well as endothelial
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swelling are observed in PAD microvessels.82,171,174 Slit like capillaries are also more
frequently encountered in PAD muscle.82 This suggests that endothelial necrosis is
occurring within PAD capillaries or conversely that these capillaries are not perfused.
Interestingly, the endothelial cells from CLI patients no longer demonstrated features
suggestive of angiogenesis.173 In support of this finding, PAD endothelium did not express
vascular endothelial growth factor (VEGF), but rather expressed fibroblast growth factor 2
(FGF-2).171
Increases in BM thickness of microvessels in PAD may be significant to the
pathogenesis of PAD.

In addition to limiting diffusion (Fick’s principle), altering

microvascular blood flow, and hindering angiogenesis, the presence of additional ECM
around microvessels may modulate local regenerative and pathological responses.
Alteration of perivascular extracellular matrix (ECM) may have a direct deleterious effect
on endothelial function. In DM, non-enzymatic glycosylation (glycation) of the ECM alters
endothelial cell function and is implicated with atherosclerotic plaque development.
Endothelial cell cultures grown on native collagen versus glycated collagen responded
differently to shear stress. Furthermore, endothelial cells grown on glycated collagen
released half as much NO than those grown on native collagen, and this decrease
correlated with decreased eNOS phosphorylation. Alteration of the endothelial integrin
interactions with the collagen matrix likely mediated the diminished response to shear
stress mechanotransduction, possibly through attenuated focal adhesion kinase (FAK)
activation.179

Pericyte Mediated Modulation of Microenvironments, from ProRegenerative to Pro-Fibrotic
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The Role of Pericytes in Angiogenesis and Microvascular Vasomotion

Pericytes are closely associated with endothelial cells and are contained within a
common BM which is continuous around the microvessel.180 Pericytes are considered to
be ubiquitous in higher order vessels, including pre-capillary arterioles, post-capillary
venules, and veins, and absent in lymphatic vasculature181-183 and the reported range of
pericyte to endothelial cell ratios within skeletal muscle is broad (1:10 - 1: 100).180,184 185,186
Morphologically pericytes appear to be fibroblast-like with a prominent nucleus, meager
cytoplasm, and multiple projections.187 Pericytes can be identified by their location and
the positive expression of several markers including -smooth muscle actin (SMA),
platelet derived growth factor receptor- (PDGFR-), neuro/glial antigen-2 (NG2),
regulator of G-protein signaling-5 (RGS-5), CD146, as well as the mesenchymal stem cell
markers CD44, CD73, CD90, and CD105.181 However, pericyte identification using these
markers alone is challenging as marker expression can vary greatly between pericytes,
even within the same tissue bed.

No single marker has been discovered that can

definitively and specifically identify pericytes. Of note, pericytes express neither the
endothelial and hematopoietic markers CD31, CD34, and von Willebrand factor nor the
neural cell and myogenic marker CD56.181
Pericytes have a crucial role in vascular homeostasis and angiogenesis. During
angiogenesis, pericytes stabilize the sprouting endothelial tubes and are responsible for
microvessel maturation.54,187,188

Endothelial cells are stimulated to sprout by pro-

angiogenic factors such as VEGF. Subsequently, they secrete proteases to degrade the
ECM, proliferate, and migrate to form new, but unstable, vessels. To encourage migration
of pericytes to the vascular sprout, endothelial cells secrete platelet derived growth factor (PDGF-) (a structural homolog of VEGF), S1P-1, and angiopoietins.49,187,189,190
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Endothelial cells and pericytes have substantial crosstalk during angiogenesis. TGF- and
activin-like kinase receptor-5 (ALK5) stimulate proliferation and differentiation of both
endothelial cells and pericytes,187 which not only contributes to vessel sprouting and
stabilization, but are also critical in vessel maturation. Pericyte density and coverage are
in part organ specific, but also directly correlate with endothelial barrier properties and
orthostatic (gravitational) blood pressure and inversely correlate with endothelial cell
turnover.55,181,191-193

Taken together, these observations point to the central role of

pericytes in the regulation of endothelial proliferation, microvascular barriers, and
microvessel diameter.191 Pericytes are also thought to have a role in immunological
defense, coagulation, repair processes, and VSMC contractility and tone.187
Pericytes maintain close communication with endothelial cells and signal directly
through peg-and-socket contacts as well as indirectly through paracrine signaling.194,195
The peg-and-socket contacts consist of several components including tight junctions,
adherence junctions (both -catenin and N-cadherin), and gap junctions.194 Adhesion
plaques support the transmission of contractile and shear stress forces and stabilize gap
junctions.192,196-198 Additionally, gap junctions may be further stabilized by fibronectin in the
ECM.198 Connexin 43, a gap junction protein, is rich in contact sites between pericytes
and endothelial cells as well as between pericytes.

192,197,199

Dye transfer studies have

shown that dye is rapidly transferred to endothelial cells and adjacent pericytes,200 likely
via gap junctions. The direct gap junction exchange of small molecules and ions between
cells may reinforce cell-cell signals.

The parallel arrangement of pericytes to the

endothelial axis thus appears to be related to the facilitation and integration of endothelialpericyte communication.69 Integrin signaling also communicates the mechanical forces
present between the ECM, endothelial cells, and pericytes. Multiple types of signaling
interactions, including gap junctions and integrins communication, suggests that these
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cells compose a functional intercommunicating unit in the vasculature that is capable of
integrating and coordinating neighboring endothelial cell responses as well as regulating
the distribution of the mechanical contractile forces generated by VSMC. 181,188,194,198,201
The arrangement of VSMC around vessels differs from pericytes. The perpendicular
arrangement of VSMC to the endothelial axis facilitates contraction and the mediation of
vascular tone.69 Interestingly, functional coupling is absent between pericytes and
VSMC,181 which suggests that pericyte-mediated regulation of the vasculature is either
indirect or independent of VSMC.181
VSMC are important in vasoconstriction and vasodilation in larger vessels,
however, pericytes may be influential in regulation of microvascular vasomotion. Pericytes
have several actin-like sub-structural proteins located near the endothelial side of the cell.
These proteins include αSMA, desmin, and vimentin, and may contribute to vessel
constriction, thus potentially regulating microvessel diameter.196,202

The pre-capillary

arteriolar pericytes express a high concentration of contractile proteins, suggesting that
they may act as pre-capillary sphincters.203 Recent studies utilizing in vitro microfluidics
and in vivo intravital microscopy demonstrated the presence of pericyte-dependent
capillary constriction.204-206 Notably, capillary-mediated functional hyperemia was absent,
which supports arterioles as the mediators of functional hyperemia.204 αSMA is expressed
in both VSMC and pericytes and is associated with vasomotion and blood pressure
control.207 It has been proposed that the pericyte response to vasomotion may contribute
to increased vessel wall stiffness, possibly as a compensatory mechanism to counteract
elevated blood pressure. This process may be partially mediated by calpain-induced
remodeling of cytoskeletal proteins which in turn increases the stiffness of pericyte
subcellular contractile structures.196,208
In the setting of traumatic brain injury, increased αSMA expression was induced
by endothelin-1 (ET-1) through endothelin receptor A (ETA) and B (ETB), and inhibition of
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ETA signaling resulted in decreased pericyte αSMA expression. SMA expression was
positively associated with constriction of both arterioles and capillaries,209 which supports
that αSMA+ pericytes are contractile. Brain pericytes can adjust capillary diameter and
blood flow in response to chemical and electrical stimuli.192

Studies have shown that

hyperoxic conditions trigger pericyte contraction whereas increased levels of carbon
dioxide induce pericyte relaxation.210,211 Activation of pericyte cell-surface receptors by
vasoactive agents such as ET-1, angiotensin-2 (ANG2), serotonin, and histamine induce
vasoconstriction whereas NO and cholinergic agonists induce vasodilation.196,212
Pericytes, including those that express αSMA, can also secrete vasoactive agents and
express α2- and 2-adrenergic receptors,

187,212

which also supports the role of pericytes

in microvascular blood flow regulation. Importantly, pericyte-mediated vasoconstriction
has been implicated in the “no reflow” phenomenon that occurs as a complication of
reperfusion after acute organ/limb (e.g. brain, heart, leg) ischemia. Strikingly, pericyte
vasoconstriction persisted even after restoration of flow through the occluded
vessels.213,214

Oxidative and nitrative stress may also induce pericyte-mediated

vasoconstriction and contributes to ischemia/reperfusion injury.202,215,216 Understanding
the contribution of pericytes to vasomotion, particularly in the setting of chronic intermittent
hypoxia, may yield novel insights into the pathogenesis of PAD myopathy.
Skeletal muscle pericytes have been shown to have therapeutic potential in postischemic neovascularization in mouse limb ischemia models.41,217-221

Ten days post

induction of limb ischemia, nestin+/NG2+ pericytes improved recovery by incorporating into
the murine neovasculature.217 Skeletal muscle pericyte therapy also improved blood flow
recovery via collateral artery enlargement, but did not improve angiogenesis in wild type
mice. Formation of collateral circulation in PAD contributes to better limb perfusion and
may have subsequent positive effects on terminal microvascular beds. However, Type 2
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diabetic mice displayed neither improvements in blood flow nor collateral artery
enlargement, likely as a result of limited pericyte incorporation into the newly formed
collateral arteries.41

Localization of pericytes to forming collateral arteries may be

mediated by Notch signaling. Notch signaling has been shown to autonomously and
independently specify arterial characteristics in both endothelial cells and pericytes.69
Furthermore, Notch signaling can stimulate pericytes to differentiate to VSMC,222 and may
contribute to the expansion of VSMC in PAD skeletal muscle. It is also possible that the
“arteriolization” observed in PAD microvessels171 reflects arteriolar enlargement as a
means to expand collateral networks. However, microvascular alterations in PAD remain
poorly characterized, as do the mechanisms by which they arise.

The Myogenic Potential of Pericytes After Muscle Injury

The role of pericytes in skeletal muscle is not limited to vascular development and
homeostasis. There is increasing evidence that pericytes may be a possible reservoir of
stem or progenitor cells in adult skeletal muscle.191 Purified and cultured pericytes from
multiple adult tissues retained perivascular markers (NG2, CD146, and PDGFR-) but
also expressed several mesenchymal stem cell (MSC) markers.223-225 These pericytes did
not express hematopoietic, endothelial, or myogenic cell markers. Crisan and colleagues
demonstrated that pericytes isolated from adult skeletal muscle were myogenic in vitro
and in vivo and retained myogenicity when long-term cultured. Skeletal muscle pericytes
at the clonal level had chondrogenic, osteogenic, and adipogenic potential. MSC markers
were expressed in both cultured and native cells, which suggests that pericytes have multilineage long term differentiation capacity.223

Moreover, it has been suggested that

pericytes from skeletal muscle present a broader range of differentiation abilities than
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MSCs.198

During acute muscle injury, pericytes contribute to a regenerative

microenvironment by coordinating neovascularization, modulating local immune
responses, releasing trophic factors, and differentiating into myofibers.181,226 Additionally,
pericytes may sense hypoxia and hypoglycemia, and thereby mediate adaptive tissue
protective responses.69 Several potent cytokines, growth factors, and chemokines are
implicated in pericyte injury response including VEGF, TGF-1, PDGF-, angiopoietin 1
and 2, basic FGF, epidermal growth factor, thrombopoietin, stem cell factor, and stromal
cell-derived factor-1.181,227-229
The myogenic potential of pericytes obtained from human skeletal muscle is
strikingly high. It has been shown that 20 – 40% of cultured patient-derived pericytes
exposed to muscle-differentiation medium spontaneously differentiate and form myosin+
multinucleated myotubes.230

These myogenic precursor pericytes are distinct from

satellite cells, both by location and marker expression. Unlike pericytes that are located
within the BM of microvessels, satellite cells reside within the BM of myocytes. Satellite
cells express MyoD, Pax7, Myf5, MEF2C, CD56, and M-cadherin whereas pericytes do
not.

Myogenic precursor pericytes uniquely express NG2 and alkaline phosphatase

(ALP). NG2+ pericytes are progressively associated with post-natal muscle stem cells.
Only on terminal differentiation do pericytes express MyoD and Myf5, which suggests that
the kinetics of myogenic differentiation are different between satellite cells and
pericytes.230

Furthermore, pericytes likely coordinate the myogenic response by

promoting myogenic cell differentiation through insulin-like growth factor 1 and satellite
cell quiescence through angiopoietin 1. In support of this, it has been observed that
pericyte ablation in growing mice yields myofiber hypotrophy and impairs the transition of
satellite cells into quiescence.231 In human skeletal muscle, the number of pericytes
declines in response to resistance exercise in association with increases in
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CD90+/PDGFR-+ MSC pools and Pax7+ satellite pools.232 Taken together, these studies
suggest that pericytes may regulate the expansion of the muscle progenitor pool during
exercise and possibly after acute injury by increasing pericyte myogenic differentiation
and regulating satellite cell quiescence. Interestingly, the regenerative capacity of
pericytes differs in aging microenvironments.

Pericytes have a lower regenerative

capacity when transplanted into older mice. Bribrair and colleagues demonstrated that
with age, Type 2 pro-myogenic pericytes (Nestin-GFP+/NG2-DsRed+) are more quiescent
and Type 1 pro-fibrotic pericytes (Nestin-GFP-/NG2-DsRed+) are more active.233
Additionally, a subset of skeletal muscle pericytes have several similarities to Schwann
cells and may be neural progenitor cells.234 It is speculated that these pericytes may be
involved in coordinating muscle reinnervation after injury.181,234 The contribution of
pericytes to muscle repair in PAD remains mostly unknown.

However, given the

propensity for pericytes to favor fibrosis at the expense of myogenesis with age, pericytes
are a promising target for therapies that may be able to coax pericytes into a proregenerative role.

Pericytes and Inflammation

Pericytes are implicated in the inflammatory response that follows injury in several
organs. In brain, pericytes are thought to have a bidirectional and modulatory effect of
neuroinflammation and neurodegeneration.235,236

Furthermore, pericytes are a key

mediator of the inflammatory response during skeletal muscle regeneration. 186 A subset
of pericytes (lacking expression of Collagen I and Foxd1) express several immune
surveillance and effector genes, which suggests that they may act as sentinels of the
innate immune response.237-243

Pericytes may coordinate leukocyte and macrophage
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trafficking to inflamed tissues by expressing ICAM-1 and secreting chemoattractants such
as macrophage migration-inhibitory factor (MIF) and monocyte chemoattractant protein-1
(MCP-1).244-246 Pericytes may also alter the responsiveness of these immune cells after
migration into the interstitial tissue.245 Muscle pericytes highly express several other
immunoregulatory cytokines and chemokines including COX2, heme oxygenase 1,
leukemia inhibitory factor, hypoxia inducible factor-1 (HIF-1), and IL6.246 Inflammatory
signals, such as MCP-1, are linked to angiogenesis.186,247 In a C2C12 coculture model of
muscle injury, pericytes secreted MCP-1. Knockdown of the transcription factor CCAAT
enhance binding protein- (C/EBP) in culture lead to enhanced pericyte-mediated
inflammation by increasing MCP-1 production.

C/EBP regulates activation of

macrophages and expression of genes involved in both immune and inflammatory
responses. Knockdown of C/EBP in pericytes also lead to increased ICAM1, IL8, and
IL-1 expression and reduced superoxide dismutase-2 (SOD2) and COX2 production,248
which suggests that pericyte C/EBP expression is involved with switching between proand anti-inflammatory programs.
Pericyte gene expression patterns also suggest that pericytes may also function
similarly to macrophages.243,249-251 Pericytes express several macrophage markers (CR3
compliment receptor, CD4, and class I & II major histocompatibility complex).252 Pericytes
also have phagocytic activity and can perform antibody-dependent phagocytosis via Fc
receptors.187,252,253 Pericyte pinocytosis has been shown to have an important role in
cleaning cerebrospinal fluid254 and exchange of metabolites in liver.187 Thus, pericyte
pinocytosis allows sampling of the local microenvironment for toxins and metabolites,
which may induce pro-inflammatory responses in pericytes.
Activation of the nuclear factor-B (NF-B) transcription family plays a central role
in inflammation by its ability to induce transcription of pro-inflammatory genes after
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stimulation by signals related to pathogens or stress.255,256 NF-B activation regulates
myogenesis during skeletal muscle injury and disease.186,257,258 Within 3 hours of muscle
damage induced by eccentric exercise in human quadriceps, NF-B is activated.186,259
Pericyte NF-B enhances not only inflammation but also angiogenic crosstalk by
increasing translation and secretion of GM-CSF, MCP-1, and IL-8, which has potential
downstream effects on vascular growth, endothelial proliferation, and angiogenesis.186,260
Several pro-inflammatory cytokines stimulate pericytes. IL-1 activates pericytes
and increases pericyte matrix production, whereas IL-1 decreases fibroblast matrix
deposition.261,262 Locally administered IL-1 or TNF can induce a morphological change
in pericytes that yields transient gaps between pericytes that allow the migration of
neutrophils into the interstitium.243 Interestingly, pericyte matrix deposition alters
endothelial ICAM-1 expression and sensitizes endothelial cells to IL-1 activation which
encourages neutrophil transmigration. Endothelial cells cultured on collagen I responded
to IL-1 differently than endothelial cells cultured on fibronectin. Collagen I cultured
endothelial cells had significantly less neutrophil transmigration than fibronectin cultured
endothelial cells. This suggests that pro-inflammatory activation of pericytes induces
deposition of compositionally distinct ECM that may promote local inflammation impacting
surrounding cell functions.261 Endothelial cells present integrins at their cell surface that
interact with this remodeled ECM and induce a pro-angiogenic state. Consequently,
endothelial cells display increases in migration, cell survival, and sensitivity to circulating
cytokines.261 Taken together, this data suggests that alterations of the ECM can be highly
influential in promoting inflammation.261,263 Although pericytes are stimulated by several
pro-inflammatory cytokines, they have minimal expression of IL-1alpha, TNF, and
interferon-, even under hypoxic conditions.246
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The pro-inflammatory cytokine IL-6 may also be of great importance in muscle
damage and repair. IL-6 is produced during inflammation. Depending on the muscle
mass and intensity and duration exercise, mechanical load increases IL-6 production
which may impact metabolism. Addition of recombinant IL-6 enhances insulin-stimulated
fatty acid oxidation and glucose disposal in myotubes in culture.264 Interestingly, muscle
derived IL-6 may dampen the effects of other inflammatory cytokines, such as TNF,

264

suggesting that muscle derived IL-6 may induce muscle repair after exercise without
inflammation, or may trigger inflammation past an unknown threshold.

In samples

acquired from lungs of patients with pulmonary arterial hypertension (PAH), IL-6 levels
were markedly elevated.54

Addition of IL-6 to cultured pulmonary pericytes induced

pericyte migration whereas anti-IL-6 neutralizing antibodies substantially attenuated
pericyte migration.54 Delivery of exogenous IL-6 to rodents induces pulmonary vascular
remodeling, which is exaggerated in response to hypoxia.265,266

Exogenous delivery of

IL-6 to murine retinas increased αSMA+ pericyte coverage. Strikingly, in neonatal mice,
pericyte coverage increased by approximately 35-40% in response to recombinant IL-6
and increased pericyte coverage was abolished with addition of anti-IL-6 neutralizing
antibodies.54
It has been suggested that with chronic inflammation, pericytes escape the
microvascular BM and differentiate into myofibroblasts that contribute to the deposition of
collagen during wound healing and fibrosis.69 Depending on the pro-inflammatory or profibrotic signaling milieu, pericytes can modulate the ratio of fibronectin to collagen I within
the microvascular ECM.261 Pericytes and myofibroblasts have similar responses to proinflammatory signals, which supports the notion that pericytes may indirectly regulate
inflammation, possibly through ECM deposition,261 and are likely candidates to respond to
chronic inflammatory signals and initiate microvascular remodeling in PAD myopathy.
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Pericytes and Microvascular Remodeling

Microvascular remodeling, particularly BM thickening of the smallest microvessels,
has been observed in the pathology of a diverse set of organs.
thickening is a common feature amongst immune-based diseases.

Microvascular BM
In delayed type

hypersensitivity reactions, several epithelial abnormalities are present in conjunction with
thickened microvessels.267-269 Infectious disease initiates an immune response, and in
patients with Chagas disease, several skeletal muscle microvascular abnormalities were
observed.

The most prominent feature was microvascular BM thickening, however

capillary reduplication and occlusion were also noted.

During immune responses,

pericytes and endothelial cells also demonstrate abnormalities at the ultrastructural
level.270 Alterations of microvascular structure, particularly BM thickening, have been
observed in autoimmune diseases and inflammatory myopathies such as scleroderma,
rheumatoid myositis, polymyositis, and dermatomyositis.270-273 Interestingly, in patients
with autoimmunity of the nervous system associated with muscloskeletal pathology
(i.e.Guillain-Barre Syndrome, multiple sclerosis, amyotrophic lateral sclerosis, and
carcinomatous neuromyopathy), skeletal muscle also had microvascular alterations and
increases in BM thickness.270,274 In patients with systemic lupus erythematosus (SLE) and
mixed connective tissue disease (MCTD), microvascular BM thickness was associated
with the level of plasma complement protein C3dg, suggesting that auto-antibodies or
immune complex deposition damages endothelial cells or pericytes. Microvascular BM
thickening had an inverse relationship with steroid treatment,275 suggesting that reduction
of immune responses may limit microvascular remodeling. Circulating cytokines are
thought to also contribute to the BM thickening of SLE microvessels by activating
endothelial cells, subsequently inducing expression of adhesion molecules such as Eselectin, ICAM-1 and VCAM-1.275,276

In SLE and MCTD skeletal muscle, increased
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pericyte coverage was associated to ANA titer275, supporting that both endothelial cells
and pericytes are activated in the auto-immune response.
Microvascular and airway remodeling of the lung are also thought to arise from a
chronic inflammatory process.249,277 In chronic asthma, myofibroblast accumulation and
vascular remodeling are considered key mediators of asthma complications.277 Chronic
asthma is characterized by thickening of the VSMC layer of arterioles, endothelial cell
proliferation, and perivascular fibrosis.249 It is thought that pericytes may have an integral
role in microvascular remodeling in asthma.277 In PAH, excessive pericyte coverage is
seen in the distal pulmonary microvasculature and is directly linked to endothelial
dysfunction.54
hyperplasia,

Like asthma, PAH arterioles experience VSMC hypertrophy and
with

microvascularture.

increased

muscularization

by

αSMA+

cells

in

the

distal

Both in situ and in vivo studies revealed that increased pericyte

coverage contributes to pulmonary vascular remodeling, and is likely the source of these
contractile αSMA+ cells.54
A classic finding in diabetic microvascular pathology is altered microvascular
architecture. Pericyte changes are associated with diabetes, particularly with regards to
microvascular complications.49

Diabetic neuropathy is characterized by thickened

microvessels, pericyte degeneration, and reduced blood flow.278 Pericyte degeneration is
a hallmark finding of diabetic retinopathy, with loss of pericyte coverage leading to
microvascular instability and microhemorrhages. The skeletal muscle microvasculature is
also altered in patients with DM. Tilton and colleagues demonstrated that skeletal muscle
microvascular BM thickness was greater in diabetics versus non-diabetics.

Cellular

debris were commonly encountered within the thickened BM, with approximately 35%
more debris incorporation in diabetic versus healthy microvascular BM.279 Degenerating
pericytes were the likely culprit for the debris generated and collected within the BM.
Orthostatic and venous pressure are thought to contribute to these microvascular
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alterations, as BM thickness, pericyte degeneration, and acellular capillaries increased
progressively from the head to the foot in diabetic patients, with the gastrocnemius
paradoxically having greater microvascular alteration than the foot.55,180 Pericytes in
diabetes show ultrastructural alterations and gain a differentiation bias towards
adipogenesis, likely at the expense of myogenesis and angiogenesis.220 This is consistent
with the observations that capillary density is decreased in the skeletal muscle of patients
with DM. Thus, insulin resistance and vascular defects are likely linked within skeletal
muscle, with insulin resistance encouraging a shift towards a vasoconstrictive state.49 In
support of this, studies utilizing CEU and 1-methylxanthine metabolism

(capillaries

contain xanthine oxidase which metabolizes 1-methylxanthine and provides an estimate
of the extent of perfusion280) demonstrated that insulin can induce capillary recruitment via
increasing muscle microvascular blood volume without alteration of the total blood flow.281283

Furthermore, it has been proposed that loss of VSMC and pericytes may increase

vessel dilation, and thus muscle perfusion, with a beneficial increase of capillary surface
area for nutrient delivery and exchange.49
PDGFR-+ pericytes may regulate microvascular remodeling and BM deposition.
PDGFR-+ pericytes express several fibroblast-associated markers and contribute to scar
formation during wound healing.244 In addition to displaying several fibroblast surface
proteins, PDGFR-+ pericytes also produce collagen I, collagen IV, and fibonectin.284
Rgs5, a regulator of G-protein signaling, is normally expressed in relatively few pericytes,
however, Rgs5 expression is up-regulated transiently as angiogenic sprouts become
covered with pericytes, suggesting that Rgs5 is a key mediator of vessel stabilization and
maturation.285 In line with these findings, Rgs5 pericytes are associated with pathological
vascular remodeling, including microvascular regression, rarefaction, and altered
vasomotion.284 Rgs5 can potentiate PDGFR signaling, and thus may enhance the activity
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of PDGFR-+ pericytes.285,286 Goritz and colleagues demonstrated that after spinal cord
injury, a subset of PDGFR-+ pericytes increased three fold in number, migrated from the
vessel wall, produced fibronectin, and expressed αSMA.

Within the spinal lesion,

pericytes also deposited abundant ECM within their basal lamina encasement and likely
differentiated into myofibroblasts.287 In the kidney, pericytes that underwent a pericyte to
myofibroblast transition increased the expression of the disintegrin ADAMTS1 and
decreased expression of the metalloproteinase TIMP3.288 ADAMST1 is involved with BM
degradation and may be a key mediator of pericyte detachment from the microvessel and
migration into the interstitium. Inhibition of ADAMTS1 abolished pericyte detachment with
a resultant decrease in fibrosis. In mice deficient in TIMP3, kidney pericytes were
susceptible to injury-induced microvascular rarefaction and fibrosis.288 In kidney fibrosis,
Ren and colleagues demonstrated that pericyte activation, detachment, and transition to
myofibroblasts were inhibited by Dickkopf-related protein 1 (DKK-1). This resulted in
improvements of capillary rarefaction, inflammation, and attenuated fibrogenesis. DKK-1
also blocked pericyte proliferation in response to PDGFR-, pericyte migration, gene
activation, and TGF-1-induced cytoskeletal rearrangement.289

The predominant

mechanism of action of DKK-1 was on the inhibition of PDGF- and TGF-- signaling
cascades, 289 which may be critical in stimulating pericyte BM deposition. Taken together,
these studies support the notion that pericytes are mediators of the creation and
degradation of BM.
BM thickness is altered as a response to mechanical stress and injury. In the
skeletal muscle of patients with hypertension, BM becomes thickened and reduplicated as
concentric layers of BM, the flow lumen becomes constricted, and total diameter remains
unchanged.290 Decreased flow lumen likely reflects microvessel occlusion, degeneration,
and the increased incidence of endothelial in-folding into the lumen.290 Tissue injury
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induces wound healing programs within tissues, with chronic injury yielding fibrosis. In
several organs, pericytes have been implicated as initiators of fibrosis, which suggests
that fibrosis is a disease that is originated and coordinated by microvessels. It is possible
that fibrosis is initially localized to microvessels and is manifested only as alterations of
microvascular BM. Pericytes and endothelial cells are the sole occupants within the
microvascular BM.

Fibroblasts and other perivascular cells are not found within

microvascular BM,180 which strongly supports the role of pericytes in the initiation and
propagation of BM thickening.

With increasing changes of the microenvironment,

pericytes undergo differentiation,54 suggesting that architectural remodeling of the BM
occurs primarily via pericyte BM deposition and secondarily by differentiation into profibrotic progenitors which may expand ECM deposition around and beyond the
microvasculature.

Cross talk with endothelial cells is likely critical in microvascular

remodeling, as studies have shown that the presence of both endothelial cells and
pericytes is required for the formation of the BM. Endothelial cells have the machinery to
synthesize many of the BM components, however, pericytes are required for BM assembly
and regulation of synthesis.191,196,291,292 In co-cultures of endothelial cells and pericytes,
ECM binding integrins are upregulated, a finding that is absent when endothelial cells are
cultured alone. Mechanical injury of these co-cultured cells induces to shifts of ECM
component concentrations, including the ratio of collagen I and fibronectin, with
deleterious effects on endothelial function.261
A wealth of structural components are located within the microvascular BM. Both
pharmacological and genetic studies have shown that loss of nearly any ECM component
can lead to a myopathy that often includes fibrosis and fatty degeneration.264 Collagen IV,
laminin, fibronectin, perlecans, and nidogens are the best characterized BM components
in health and disease states. Collagen IV is involved in membrane stability and is crucial
in providing the structural integrity of the vessel.196,293 Laminin is an essential scaffold
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protein and is important in the organization of the BM.196 Working in parallel, collagen IV
and laminin produce the three dimensional network of the BM. Perlecan and nidogen act
as bridges between the collagen IV-laminin network, thus stabilizing the BM.211 IL-1
activates pericyte deposition of collagen IV and fibronectin, whereas TGF-1 upregulates
the deposition of laminin.261 Deposition of ECM components, including microvascular BM,
provides structural scaffolding to regenerating muscle, which supports satellite cell
migration and myogenesis.294. Thus, differential deposition of ECM components by
pericytes may alter the microenvironment and deter myogenesis in favor of fibrosis.
In addition to providing structure to tissues, the BM is also capable of supplying
signals to vessels and surrounding cells. BM is highly glycosylated, which yields a high
binding capacity and affinity for secreted growth factors.295 These factors are potent
directors of cell proliferation and activation. Proteolytic cleavage can release growth
factors such as FGF-2, TGF-, VEGF, and PDGF.54 TGF-1 signaling can then induce
additional deposition of ECM components, including Collagen I and IV, fibronectin, and
laminin.296 BM also provides a depot of chemotactic factors that likely contribute to
immune surveillance.295
Considering the similarities present in microvascular remodeling across diverse
tissues (e.g. heart, lung, brain, muscle, eye, kidney) and pathologies (i.e. injury, ischemia,
auto-immunity), it appears that a common mechanism may be present that induces
microvascular architectural remodeling. It is likely that injury to endothelial cells and
activation of pericytes initiate the deleterious process of BM remodeling. With chronic
inflammation and insult, death of pericytes and endothelial cells becomes common and
induces repair paradigms, including angiogenesis, thus actively participating in a cycle of
degeneration and regeneration.55,69,290,297

When damage and inflammation become

recurrent and frequent (like during the episodes of ischemia and reperfusion that occur
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each time a PAD patient walks) they may lead to an advanced stage of vascular
regeneration170,271,298,299 that becomes “frustrated”. As endothelial cells and pericytes
perish, the BM remains intact as a scaffold and regenerating endothelial cells and
pericytes may add new inner layers of BM,170 which results in pathological modifications
in the injured microvessels and subsequently promotion of a fibrotic response. Although
the initiation and progression of microvascular changes in PAD remains largely unknown,
such a mechanism may occur in the genesis of microvascular pathology in PAD myopathy.

Pericytes, Myofibroblasts, and Fibrosis

In acute muscle injury, pericytes coordinate a regenerative response by creating a
favorable microenvironment for muscle repair. However, in the face of chronic injury (i.e.
inflammation, hypoxia, mechanical trauma), normal pericyte processes become
deregulated and pericytes coordinate the development of pathological fibrosis, heterotopic
ossification, and calcification.181,191

Fibrosis of skeletal muscle leads to significant

functional impairment and predisposes the muscle to additional injury.96,181,300 As patients
become older, the capacity for muscle repair is lowered, and may be related to the
transition of pericytes differentiation programs from pro-regenerative to pro-fibrotic.233
PDGFR-+ pericytes are implicated in fibrosis. PDGFR-+ pericytes have the ability
to transition to αSMA+, collagen producing myofibroblasts in injured skeletal muscle.
Ablation of these cells abrogates collagen deposition and the generation of pro-fibrotic
cells after muscle injury.301

Additionally, PDGFR-+ pericytes express fibroblast-

associated markers, including fibroblast surface proteins, fibronectin, and collagen IV. 244
Blockade of PDGF- signaling attenuated kidney fibrosis and capillary rarefaction after
unilateral ureteral obstruction.302

In isolated lung cell cultures, PDGF- treatment
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enhanced proliferation and migration of fibroblasts, but not pericytes.237 Additionally, in
allergic airway disease, PDGF- has been shown to work synergistically with TGF- to
stimulate VSMC cell migration.277,303 Thus, PDGFR-+ pericytes may contribute to the
regulation of fibroblast and VSMC migration and proliferation.
TGF-1 is strongly implicated in fibrogenesis.243 Early fibrosis is associated with a
substantial increase in pro-fibrotic TGF-1 and pro-inflammatory IL-1.261

TGF-1

stimulates differentiation and proliferation of both endothelial cells and pericytes. 69
Integrins are likely regulators of TGF-1 activation perhaps through directing
conformational changes of latent TGF-1 to the active form,304 possibly via cell
constriction-mediated tensile force,305 or indirectly directing MMP activation of latent TGF1.306

Production of TGF-1 may require connexin 43 gap junction-mediated

communication between endothelial cells and pericytes.69,191,307 Not surprisingly, TGF-1
receptors are located on both endothelial cells and pericytes.

243

Juxtaposition and

collaboration of endothelial cells and pericytes are required to activate latent TGF-1.308
309

Deficiencies in TGF- signaling lead to loss of pericyte coverage.243 Additionally,

inhibition of TGF- release by endothelial cells limits the differentiation of PDGFR-+
pericytes into αSMA+ pericytes. Pericyte secretion of TGF-1 suppresses endothelial cell
growth and migration. These data suggest that normally TGF- is involved in pericyte and
vessel maturation, as well as endothelial barrier function.196
TGF- can stimulate pericyte production of contractile, ECM, and BM proteins,
197,296

which may, alternatively, contribute to fibrosis. TGF- pathway overactivation is

observed in PAH and is associated with PAH progression. Strikingly, phosphorylated
Smad2 immunofluorescence was prominent across pericytes of PAH lung specimens, with
approximately 45% of pericytes demonstrating TGF-1-mediated activation of Smad2
signaling compared to approximately 6% of pericytes in healthy lung tissue. 54 TGF-1
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may have a more powerful effect on a select subset of pericytes, particularly pericytes that
may be involved in fibrotic responses and myofibroblast differentiation. In a recent study,
Hung and colleagues demonstrated that Foxd1 progenitor-derived pulmonary pericytes
are enriched in genes related to angiogenesis, immune regulation, and migration. Within
this lineage, a subset of these pericytes expressed PDGFR- and NG2, and had a
transcriptionally distinct signature which resembled fibroblasts.237 Interestingly, in cocultures of Foxd1 progenitor-derived pericytes and fibroblasts, pericytes activated high
levels of collagen I production. When co-cultures were stimulated with TGF-, PDGF-,
and PDGF-, fibroblasts increased migratory activity.

Additionally, TGF- activated

pericyte αSMA protein expression and stress fiber formation.237
TGF-1 has context-dependent effects. TGF-1 stimulation of ALK on endothelial
cells can induce signaling via ALK1/Smad1/5 which is promoted by endoglin and incites
proliferation.310

TGF-1 may also activate ALK5/Smad2/3 pathways which leads to

differentiation of both endothelial cells and pericytes.311 ALK1 and ALK5 receptors are
also located on pericytes. Disruption of endothelial TGF-1 signaling impacts pericytes,
possibly by impairing TGF-/ALK5 signaling, and inhibits pericyte-mediated stabilization
of endothelial sprouts and differentiation into VSMC.311

In addition to mediating

differentiation to VSMC, activation of pericyte ALK5/Smad2/3 pathways promotes mitotic
and migratory quiescence.312,313 Pericyte activation of ALK1/Smad1/5 also stimulates
proliferation and migration while limiting differentiation to VSMC.312,313

Taken together,

these studies suggest that ALK1/Smad1/5 pathway activation promotes vascular
sprouting, whereas ALK5/Smad2/3 pathways promote vessel maturation.191 Undoubtedly,
the net effect of TGF-1 depends on relative levels of ALK1/5 signaling.191 However, TGF1 signal strength and duration are likely critical in the progression towards fibrosis.
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TGF-1 strongly induces pericytes to express αSMA.54 In one study of PAH, 68%
of αSMA+ cells were pericyte derived.237 In lung cell culture, TGF-1 stimulated pericytes
to become contractile and express αSMA, calponin, and SM22.54 Lung pericytes that have
been stimulated with TGF-1 also increase expression of NG2, snail, and collagens, and
undergo myofibroblast transition.284 It is important to note that these αSMA+ pericytes
show great heterogeneity and may be representative of select subsets of pericytes.
Regardless, the phenotypic changes observed in these pericytes suggests that they are
contributing to collagen production, myofibroblast pools, and potentially increased
vasoconstriction across affected microvascular beds.
It is well established that a critical step in fibrogenesis is the activation of
myofibroblasts. Myofibroblasts express αSMA, generate contractile force, remodel and
deposit excessive ECM, and are directly linked to the extent of fibrosis.191,243 The origin
of myofibroblasts remains elusive, although there is increasing evidence to suggest that
pericytes differentiate into myofibroblasts during fibrogenesis, and are a significant source
of the myofibroblast pool. Bleomycin treatment induced lung Foxd1 progenitor-derived
pericytes expansion, expression of αSMA and collagen I that was limited to fibrotic foci,
suggesting that in response to injury these pericytes become a myofibroblast precursor
population.237 In line with this finding, pericytes expressed fibroblast specific protein-1
(FSP1) and the number of NG2+/FSP1+ pericytes significantly increased in remodeled
pulmonary vessels.314 Moreover, lineage tracing experiments have demonstrated that
pericytes and resident fibroblasts are the predominant source of pulmonary myofibroblasts
during development, normal state, and after injury.69,237,315,316 In the setting of spinal cord
injury, pericytes have been shown to proliferate, migrate, differentiate, and contribute to
fibrotic repair.235,287 Analysis of the lesion demonstrated that a subset of pericytes
expressed fibronectin, PDGFR-, and αSMA, and were attributed as the cells responsible
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for deposition of ECM components into vessel BM and scar connective tissues,287 likely
via differentiation into myofibroblasts. These pericytes were particularly proliferative within
the first few days after injury.287 Pericytes have been implicated as a major source of
collagen producing myofibroblasts in several other organs, including skeletal muscle,
kidney, and liver, as well as in systemic sclerosis.191,249,289,302,317-320
The transition from pericyte to myofibroblast includes detachment from the
endothelium and likely contributes to loss of vascular homeostasis.191,243,284 Pericyte
departure may result in leaky vessels, ineffective angiogenesis, and ultimately vessel
destruction.237 In a model of cardiac fibrosis induced by ANGII infusion, αSMA+ pericytes
that adopted myofibroblast fates expressed Gli1. Collagen rich areas of the myocardium
displayed an abundance of Gli1-labeled cells following acute MI and analysis of the
infarcted myocardium revealed that approximately 60% of myofibroblasts were derived
from Gli1+cells.321

As stated previously, TGF-1 signaling is likely critical in the

differentiation of pericytes to myofibroblasts.284 Gene analysis suggests that pericytes that
become myofibroblasts have the greatest gene expression profile changes in immunity,
inflammation, wound healing, and cytokine response.289 Intriguingly, evidence is arising
that as pericytes become myofibroblasts, they become insensitive to hypoxia.289

Pericytes in the Setting of Ischemia

Ischemia exacerbates the fibrotic response of several organs, such as skeletal
muscle, lung, and kidney. Microvessel pathology may contribute to ischemia, particularly
in the non-proliferative phases of microvascular remodeling. The hypoxia produced by
loss of microvessels may then drive the excessive growth response in capillary density
seen in late vascular remodeling.196,197,289,322,323 Furthermore, during the proliferative stage
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of vascular remodeling pericytes detach from the endothelium and differentiate into
myofibroblasts, leaving the poorly supported endothelium vulnerable to regression.196
Thus, pericytes contribute to fibrosis by several mechanisms: 1) mediation of
inflammation; 2) ECM deposition, including BM thickening that limits diffusion; 3)
differentiation into myofibroblasts; 3) contribution to microvessel regression and
subsequent hypoxia.
Ischemia-reperfusion injury triggers oxidative stress in affected tissues, and likely
contributes to pathological pericyte activity.

Skeletal muscle pericytes demonstrated

increased oxidant stress when harvested from diabetic PAD patients with CLI versus
control.41,220 Pericytes from diabetic PAD patients had weakened anti-oxidative protection
and increased levels of ROS, and the resultant oxidative stress negatively affected
pericyte and endothelial function.41,220 The redox imbalance reflects decreased SOD1 and
catalase production as well as activation of mitochondrial adaptor proteins and redox
enzymes that are involved in promoting mitochondrial apoptosis.220 In pericytes obtained
from fibrotic kidneys, gene expression analysis shows that several processes that are
involved in mitochondrial function are downregulated.289 Likewise, PAH lung pericytes
demonstrate significant enrichment of genes involved in metabolic processes.324 Pyruvate
dehydrogenase Kinase 4 (PDK4) is particularly upregulated.324 The PDK4 gene gives rise
to an enzyme involved with suppressing mitochondrial activity in favor of glycolysis. This
decoupling of glycolysis and glucose oxidation leads to inefficient cellular metabolism.
Hypoxia may increase expression of PDK4 as it is regulated by various transcription
factors, including HIF-1.325 Yuan and colleagues demonstrated that in PAH, PDK4
expression was associated with higher rates of pericyte glycolysis, proliferation, and
survival.

Reduction of PDK4 levels restored mitochondrial metabolism, decreased

pericyte proliferation, and improved pericyte-endothelial interactions. Thus, hypoxia likely
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induces changes in pericyte gene expression that limit mitochondrial function and alter
pericyte metabolism with negative consequences on pericyte and endothelial functions.
Undoubtedly, hypoxia is a key mediator in vascular remodeling. In PAH, the HIF hydroxylase system is associated with pathological alterations of the microvasculature.
HIF-1α is degraded when it is complexed with von Hippel-Lindau protein and oxygensensing prolyl hydroxylase domain proteins (PHD). HIF-2 activation induced vascular
remodeling and loss of HIF-2 regulation by PHD2 in endothelial cells was associated
with hyperplasia of arterial medial layers, perivascular fibrosis, and pericyte expression of
FSP-1. Loss of PHD2 expression also increased pericyte coverage induced by TGF-1
and Notch-3 signaling.314 Pericyte expression of αSMA is greatly enhanced in response
to chronic hypoxia54 which may augment vasomotion towards preferential vasoconstriction
of microvascular beds.
Pericyte damage may directly contribute to microvascular perfusion deficits with
consequent ischemic tissue damage. Recent studies have shown that following traumatic
brain injury, ET-1 is upregulated, which resulted in increased αSMA expression in
pericytes,

reduction

hypoperfusion.209,326

of
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diameter
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to

pericyte

contraction,

and

It is useful to note that vasoactive compounds converge onto

signaling pathways that transiently raise intracellular calcium.196 Dysfunctional pericyte
contractility has also been shown in response to ischemic events. In both cerebral stroke
and myocardial infarction (MI) models, ischemia evoked pericyte-mediated microvascular
constriction. Subsequently, pericytes perished in rigor, irreversibly constricting capillaries.
Elevated ROS interaction with ion transport molecules may allow increased influx of
calcium into the intracellular space where contractile proteins become activated by
calcium-activated phosphorylation thereby initiating rigor.

Despite restoration of flow

through occluded vessels, pericytes remained contracted, effectively obstructing
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microvascular blood flow, which may account for the “no-reflow” phenomenon observed
in cerebral ischemia and MI.213,214 It remains unknown if intermittent hypoxia can induce
similar consequences in the legs of PAD patients.

Pericytes in PAD Myopathy

Surprisingly little is known about pericytes in PAD myopathy. Very few studies
have directly assessed the contribution of pericytes to initiation or progression of PAD
myopathy. Augmenting pericyte function may have a considerable therapeutic potential
in PAD skeletal muscle. With age, pericytes lose regenerative capacity, predisposing the
aging and ischemic muscle of PAD patients to aberrant wound healing and fibrosis.
However, understanding the signaling pathways and micro-environmental cues that
predispose pericytes towards this shift could potentially yield novel approaches
decreasing muscle degeneration or limiting fibrosis, thereby improving microperfusion and
nutrient delivery to ischemic muscle and improving leg performance in PAD patients. A
better understanding of microvascular pathology can therefore be critical to the
development of better diagnostic strategies, treatment efficacy, and prediction of favorable
responses to standard therapies for PAD such as revascularization surgery and exercise
therapy.

Current Management Strategies for the Treatment of PAD

Early detection and diagnosis of PAD may allow for maximal preventative
intervention. By managing risk and controlling comorbidities, it may be possible to prevent
or limit the progression of atherosclerotic occlusion. Additional benefit may be seen at the
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level of the affected skeletal muscle, particularly through limiting the ischemia/reperfusion
injury to the legs. Several modalities are available to detect PAD. The most readily
available, cost effective, and widely used test is the measurement of the ABI.
Hemodynamically significant arterial stenosis is indicative of an ABI 0.90, and is often
considered a hemodynamic definition of PAD.23 Table 1 summarizes characteristics of
the utility of ABI in PAD diagnosis and research. Medical management is the mainstay of
PAD treatment, and is typically centered around minimizing risk factors, smoking
cessation, exercise training, and improving diet. Structured walking exercise protocols
are effective in relieving claudication,327 however, our laboratory has data that suggest
that structured exercise protocols may exacerbate the progression of myopathy in PAD
legs in a subset of patients.
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Table 1: Overview of the Ankle Brachial Index (ABI)

ABI
Practicality

Very practical. Easily performed at any clinic visit.

Reliability

High328

Validity

High, ABI is a component in establishing diagnosis4
Using multivariate logistic regression, odds ratios for the
false negative result of ABI were 4.36 in patients with
diabetes mellitus (DM), 3.41 in patients with distal
lesions, 3.02 in elderly patients, and 1.13 in patients with
mild stenosis329

Specificity

Highly specific (also increases with decreasing ABI)
99% at ABI >0.8328,330

Responsiveness

MCID= 0.15 mmHG

Table 1: Overview of the Ankle Brachial Index (ABI).
MCID: Minimal Clinically Important Difference
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Furthermore, the quality of life reported by patients who complete the structured exercise
protocol is reduced compared to patients undergoing revascularization surgery.331
Medications are typically given to manage hypertension, hypercholesterolemia,
inflammation, and diabetes.

Both cilostazol and pentoxifylline can be prescribed to

alleviate claudication pain, and are thought to work by dilating arteries, decreasing platelet
aggregation, and decreasing blood viscosity- all of which can improve blood flow.
Currently, there is no pharmacological intervention available to treat either atherosclerosis
or PAD myopathy directly. All therapies are targeting symptom reduction or alleviation.
For patients with CLI or PAD symptoms that significantly interfere with their ability
to execute activities of daily living, revascularization becomes an option for therapy.
Revascularization of PAD limbs can be achieved by either open bypass surgery (veins
grafted proximally and distally to the atherosclerotic occlusion) or endovascular surgery
(percutaneous balloon angioplasty and/or stenting). Revascularization surgery is known
to improve both walking function and quality of life in patients, however, endovascular and
especially open revascularizations are invasive and include significant risks to the patient.
Additionally, it remains unclear to what extent the myopathy of PAD limbs is improved
after revascularization.
Several tests and surveys have been developed to help assess PAD severity, as
well as the efficacy of interventions. The Walking Impairment Questionnaire (WIQ) was
formulated to assess ambulation deficits and is more PAD specific than the Short Form36 (SF-36), which is general Quality of Life Instrument. The WIQ has been validated in
patients with IC as a physical function quality of life survey.330,332 The WIQ is scored on a
scale from 0 to 100, with lower scores representing greater functional limitations within
that category. The subcategory of pain describes the amount of difficulty the patient has
with walking that is due to pain in the lower limbs. The distance category describes the
amount of difficulty a patient experiences when walking specific distances, with the range
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of distances covering 50 – 1500 feet. The speed subcategory captures the difficulty the
patient experiences in traveling one block at various speeds, which span from a slow walk
to a run or jog. The final subcategory, stair climbing, assesses the difficulty patients
experience in climbing 1-3 flights of stairs. Table 2 provides an overview of the utility of
the WIQ in a clinical and research setting. The WIQ pain, speed, and distance subscales
are the measures that correlated the best with the ambulatory limitation of patients with
symptomatic peripheral arterial disease. Thus, the WIQ is the most specific questionnaire
for documenting the qualitative walking deficits of patients with IC while concurrently
providing strong relationships with the quantitative measures of arterial disease.10
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Table 2: Overview of the Walking Impairment Questionnaire (WIQ)

WIQ
Practicality

Highly practical. Easily administered and scored.

Reliability

High. Cronbach  of 0.82-0.9 when compared to initial
claudication distance and absolute claudication distance.333

Validity

The Pearson coefficient between the WIQ and absolute
claudication distance was 0.58. WIQ may not be as accurate
for patients with variable/ highly atypical claudication.334

Specificity

Area under the curve analysis using cutoffs for overall WIQ
scores had a sensitivity of 0.90 and specificity of 0.73 for low
performers. For high performers, a combined subscale score
of distance and stairs above a specified threshold had a
sensitivity of 0.41 and specificity of 0.90.335

Responsiveness

The WIQ can detect improvement or deterioration and has a
history of use in clinical trials.334,336

Table 2: Overview of the Walking Impairment Questionnaire (WIQ).
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Quantitative measures of walking performance have also been developed and
include the six minute walk test, initial claudication distance and absolute claudication
distance (Table 3). The six minute walking test requires the patient to walk at sub-maximal
exertion along a corridor of at least 100 ft in length. At six minutes after the initiation of
walking, the test is concluded, and the total distance traversed by the patient is recorded.
This paradigm allows patients to rest, although time continues to elapse. Although the six
minute walk test replicates normal walking ability in PAD patients, it is susceptible to
environmental factors, particularly since this test is done under submaximal exercise. The
Gardner protocol is typically used in the assessment of PAD patient walking performance
and is considered the gold standard in assessment of claudication pain onset and maximal
walking duration.

The Gardner protocol consists of patients walking on a treadmill

beginning at a zero degree incline and 2 mph velocity which is incrementally increased by
a 2% grade every 2 minutes.337 The onset of this protocol is typically tolerated very well
by PAD patients, and the incline and speed are thought to replicate low-intensity activities
encountered in normal daily routines. As the grade (incline and velocity) increase, patients
have increasing difficulty and begin to experience pain, which marks both the claudication
onset time and initial claudication distance. Over time, PAD patients have pain that limits
further participation, and they must discontinue the treadmill walking task to rest, which
marks the absolute claudication distance corresponding peak walking time.
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Table 3: Comparison of Quantitative Measures of PAD Walking Performance

Reliability *

Six Minute Walk
Test

Initial
Claudication
Distance

Absolute
Claudication
Distance

94%338,339

73.7%340

87.6%340

Validity

High338,341
ICC= 0.94-0.97338

Specificity

Literature unclear

Practicality

Practicality is limited by the patient’s ability and time to travel
to conduct the tests. Usually, walking tests can be coordinated
to the same visit as the clinical evaluation or prior to biopsy
acquisition. The six minute walk test can be done on any level
surface, however the initial and absolute claudication times
utilize the Gardner Protocol which requires a treadmill.

Responsiveness

The MCID is not established for walking performance
measures in PAD.341 In frail elderly, a small MCID is 20 meters
and a substantial MCID is 50 meters for the six minute walk
test. In non-elderly, non-PAD patients, a 52 meter increase is
the smallest detected clinical difference via self-report.338

High, considered the gold standard
ICC= 0.90341

High when used with ABI339

Table 3: Comparison of Quantitative Measures of PAD Walking Performance.
ICC: Interclass Correlation Coefficient
MCID: Minimal Clinically Important Difference
* Obtained via test-retest comparisons
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Inhibitors of the angiotensin system including ACE inhibitors and Angiotensin
Receptor Blockers are promising candidates for the medical management of PAD and
have been shown to reduce fibrosis in multiple organ systems.342-344 Ramipril, an ACE
inhibitor, reduces coronary fibrosis and improves arterial compliance in patients with
cardiovascular disease. In PAD patients, six months of treatment with Ramipril produces
improvements in walking distances comparable to those produced by supervised exercise
therapy and revascularization,344 however, the mechanism(s) by which Ramipril improves
walking performance in PAD patients is unknown. Preliminary data from our laboratory
suggests that ACE inhibitors slow progression and improve PAD myopathy in association
with improved walking performance. The ACE inhibitor Ramipril has shown efficacy in
ameliorating PAD symptoms in several recent randomized trials.7,23,344-348
Although Ramipril is a promising therapeutic option,349 the mechanism(s) by which
it improves PAD myopathy remains unclear. The benefit of ACE inhibitors may occur at
the macrovascular level.344,349-351 Treatment with ACE inhibitors increase arterial
compliance351 and may be expected to reduce arterial stiffness in PAD patients.344
Additionally, ACE inhibitors may stabilize atherosclerotic plaques and promote plaque
regression.350 However, treatment of PAD patients with six months of Ramipril produced
no significant change in the ankle brachial index (ABI), suggesting that the most beneficial
effects of Ramipril may not be at the macrovascular level. ACE inhibitors prevent the
cleavage of angiotensin I to angiotensin II (ANGII).

Stimulation of ANGII sensitive

receptors on endothelial cells generates a significant pro-inflammatory effect, as well as
reactive oxygen species production at the endothelial cell membrane.352,353

Chronic

inflammation and oxidative damage may induce reactive changes in microvascular
structure,353 such as thickening of the BM which may result in loss of flexibility of
microvascular beds. ANGII also promotes migration, proliferation, and hypertrophy of the
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vascular smooth muscle cells (VSMC) surrounding the arterioles,353,29 potentially altering
arteriolar compliance and vasomotion. Inhibition of ANGII stimulation is associated with
reduced secretion of endothelin-1349, which promotes increased blood flow and improves
the maintenance of collateral circulation.354-356 Currently it is unknown whether ANGII
inhibition impacts the microperfusion of capillary beds in PAD legs.
It is predicted that Ramipril may exert its beneficial effects in PAD limbs partially
via immunomodulation. ANGII is known to increase the expression of pro-inflammatory
cytokines in arterial VSMC in the setting of atherosclerosis. 357-359 Inflammation has been
implicated in PAD pathogenesis, and is suspected to play a critical role in the initiation and
progression of PAD.360 In particular, the microvascular response to inflammatory signals
may be crucial in the development of PAD myopathic changes and the microvasculature
may be amenable to early therapeutic intervention.

Of note, inflammation in PAD

significantly predisposes an individual to developing Coronary Artery Disease (CAD),
which greatly increases the risk of cardiovascular death and total mortality.361 Therefore,
it would be of tremendous value to understand the interaction of the renin-angiotensin
system with the inflammation that occurs within PAD legs, particularly when considering
subsets of patients who would be ideal candidates for ACE-Inhibitor therapies.

We

anticipate that microvascular pathology is progressive in PAD, and that the
microvasculature may act as a nidus of the fibrosis present in PAD. Inhibition of ANGII
activation with a therapeutic intervention such as Ramipril is most likely to impact the
microvasculature, and if so, we anticipate seeing stabilization or regression of
microvascular pathology that is concordant with improvements in fibrosis (Figure 4).

70

Figure 4: Conceptual Framework of Microvascular Pathology and Fibrosis with
Advancing PAD Severity

Figure 4: Conceptual Framework of Microvascular Pathology and Fibrosis with
Advancing PAD Severity.
A relationship likely exists between microvascular pathology and fibrosis.
As
microvascular architecture worsens, fibrosis increases.
Targeted treatment of
microvascular pathology may improve microvascular structure, performance, and fibrosis.
It is anticipated that six months of Ramipril treatment will improve microvascular structure
and fibrosis.
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Hypothesis and Specific Aims
Review of the literature suggests that PAD myopathy is progressive, and has
detrimental impact to patient walking performance, quality of life, morbidity, and mortality.
Thus, understanding the mechanisms by which PAD myopathy develops and progresses
is of utmost importance for the development of more effective treatment strategies.
Microvascular pathology may be essential in the induction and propagation of the
myopathic changes observed in PAD skeletal muscle. Ultrastructural studies suggest that
microvascular architecture is altered in PAD patients. Increases in BM thickness, in
particular, are striking features of PAD pathology. However, the mechanism by which
microvascular remodeling occurs remains exceptionally poorly characterized in PAD
muscle. Currently no direct comparisons of microvascular architecture across PAD have
been conducted. Furthermore, the relationship between microvascular architecture and
oxygen delivery, hemodynamics, and walking performance are unknown. The present
studies are designed to investigate the microvascular architectural alterations that are
present across stages of PAD myopathy. We will characterize pericyte phenotypes that
may be contributory to microvascular remodeling. Furthermore, we will demonstrate the
relationship between microvascular architecture and macrovascular occlusion, muscle
oxygenation, microperfusion, and walking performance in patients with IC. Finally, we will
examine the effect of Ramipril on microvascular architecture and microperfusion. Our
overall hypothesis is that microvascular pathology is present in PAD muscle,
worsens with increasing macrovascular hemodynamic restrictions, and advances
with PAD severity in association with increasing αSMA+ pericytes and fibrosis and
decreasing microperfusion, muscle oxygenation, and walking performance. We will
test our hypothesis by evaluating macrovascular hemodynamic restriction, microvascular
architecture, pericyte characteristics, microvascular density, and fibrosis in patients from
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control, Stage II, and Stage IV PAD patient groups. The parameters will be expanded in
the Stage II PAD cohort to quantify 1) microvascular architecture; 2) fibrosis; 3)
microvascular density; 4) microperfusion; 5) muscle oxygenation; and 6) walking
performance and 7) macrovascular occlusion. We will implement the following Specific
Aims.

Specific Aim #1: To determine if microvascular pathology is progressive across stages
of PAD.

We will measure microvascular BM thickness, inner BM diameter, and

microvascular total diameter, quantify microvascular density and collagen I and IV
deposition, total collagen, and characterize pericyte phenotype in the gastrocnemious
biopsy specimens of control, Stage II and Stage IV PAD.

We hypothesize that

microvascular pathology worsens with advancing stage in association with increasing
fibrosis.

Specific Aim #2: To determine if microvascular pathology is influenced by macrovascular
occlusion and characterize the relationship between microvascular architecture and
microperfusion in patients with IC. We will quantify microvascular architecture, as in
Specific Aim 1, and determine if microvascular architecture is associated with arterial
occlusion as assessed by ABI at rest and after post-occlusive reactive hyperemia, and
microperfusion as assessed by flow reserve and microvascular blood velocity, volume,
and blood flow before and after an ischemic stress. We hypothesize that microvascular
pathology is associated with macrovascular hemodynamic limitations, and that
microvascular architecture is associated with microperfusion deficits.

Specific Aim #3: To determine if microvascular pathology influences muscle oxygenation
and walking performance in patients with IC. We will quantify microvascular architecture,
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as in Specific Aim 1 and 2, and determine if microvascular architecture is associated with
qualitative (WIQ) and quantitative measures (COT and PWT) of walking performance and
muscle oxygen saturation. We hypothesize that as microvascular architecture worsens,
the time to reach the minimum oxygen saturation shortens and patient walking
performance deteriorates.

If our overall hypothesis is correct, we will have demonstrated that microvascular
pathology is progressive in PAD, independent of macrovascular hemodynamic restriction,
and associated with microperfusion deficits. We will have shown that pericyte phenotype
is altered in association with increasing microvascular pathology. Additionally, we will
have demonstrated that microvascular architectural alterations are linked to limitations in
muscle oxygen delivery and patient walking performance.
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Chapter II: Microvascular Pathology is Progressive Across
Stages of PAD

Introduction

Peripheral Artery Disease (PAD) is a progressive disease that begins with
the atherosclerotic narrowing of arteries supplying the lower extremities leading to
failure of the vascular system to deliver adequate levels of oxygenated blood to
the peripheral tissues.4 PAD is estimated to affect approximately 202 million
individuals globally, including 8.5 million Americans,5,6 and the prevalence of PAD
is anticipated to rise as populations age.3 The Fontaine schema clinically classifies
PAD into four stages. Asymptomatic patients with blocked arteries are classified
as Fontaine Stage I.4,19 Most symptomatic PAD patients suffer from claudication,
presenting as walking-induced, ischemic pain of the affected legs (Fontaine Stage
II).

19,20

In later stages, PAD patients experience severe pain at rest (Fontaine

Stage III)

19,21,22

and progress to develop variable degrees of tissue loss and

gangrene (Fontaine Stage IV).19,21
Poor perfusion affects all tissues of PAD legs, however, skeletal muscle is
the most extensively studied due to its functional significance for walking. Studies
of the muscles from PAD legs by our group and others demonstrate an ischemic
myopathy that is characterized by a number of histological abnormalities, most
importantly myofiber degeneration and fibrosis.59-66,362 In a recent examination of
fibrosis in PAD, our group demonstrated that collagen deposition occurs initially
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around abnormally thickened microvessels and subsequently expands into the
extracellular matrix (ECM) between myofibers and around myofascicles. 67 These
thickened microvessels are surrounded by increased layers of proliferative and
synthetic vascular smooth muscle cells (VSMC) that express large amounts of the
pro-fibrotic cytokine TGF-1. Microvessels with diameters around 50 - 150 μm
were the primary focus of that study, but our findings suggested the possibility of
pathological changes in the smallest vessels with diameters less than 15 μm,
which includes capillaries.

Structural alterations have been observed in the

capillaries of PAD muscle. Transmission electron microscopy studies revealed
that the BM of capillaries is thickened in PAD muscle. 82,171-173 Currently, the
observation that BM thickening is progressive across stages of PAD remains
mostly qualitative, and debate remains on whether additional BM thickening occurs
in CLI relative to patients with claudication. Likewise, quantification of SMA+
capillary numbers between control and PAD muscle has yielded conflicting
results.127,171

Furthermore, it remains unclear if the SMA immunoreactivity

around PAD microvessels represents VSMC, pericytes, or myofibroblasts. These
cell types have differing functions in normal physiology and may have unique
contributions to PAD pathology, particularly fibrosis. The relationship between
microvascular architectural alterations, microperfusion, and fibrosis remains
unknown.

Thus, characterization of the cells involved in expanding SMA+

reactivity around PAD microvessels may provide insight into the mechanism of
microvascular pathogenesis by determining if myofibroblast accumulation occurs
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around microvessels or if inappropriate muscularization is occurring within terminal
microvascular beds.
We hypothesized that microvascular pathology is present in the calf muscle
of PAD patients compared to controls and that the microvessels are more diseased
in Fontaine Stage IV patients compared to Stage II patients. This hypothesis was
tested by investigating (1) microvessel architecture, including BM thickness, inner
BM diameter, and total microvessel diameter; (2) deposition of Collagen I and
Collagen IV around the microvasculature; (3) SMA+ pericyte abundance and
pericyte expression of the profibrotic cytokine TGF-1 in microvessels and (4)
fibrotic burden within the skeletal muscle specimens; in gastrocnemius samples
from age matched control patients, Fontaine Stage II and Stage IV PAD patients.
Methods

Human Subjects

The experimental protocol was approved by the University of Nebraska Medical Center
and the Veterans Affairs Nebraska-Western Iowa Institutional Review Boards. All subjects
gave informed consent.

Control Group

We recruited 14 control patients who were undergoing vascular operations for abdominal
aortic aneurysm repair. Control patients led sedentary lifestyles and had no history of
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PAD symptoms. Control patients had normal blood flow to their lower limbs as indicated
by normal lower extremity pulses at examination and normal ABI at rest and after stress.

PAD Groups

We recruited 15 patients with claudication (Fontaine Stage II) and 16 patients presenting
with tissue loss (Fontaine Stage IV) who were undergoing lower extremity operations for
symptomatic PAD. Medical history, physical examination, decreased ankle brachial index
(ABI< 0.9), and computerized or standard arteriography that revealed stenotic and/or
occluded arteries supplying the lower extremity were evaluated to establish the diagnosis
for each PAD patient. Stage II PAD patients presented with intermittent claudication, but
no rest pain or tissue loss. Stage IV PAD patients presented with non-healing ulcers
and/or gangrene.

Biopsy

Gastrocnemius samples weighing approximately 250 mg were obtained from the
anteromedial aspect of the muscle belly, 10 cm distal to the tibial tuberosity. All biopsies
were obtained with a 6 mm Bergstrom needle. Samples were immediately placed into
cold methacarn and fixed for 48 hours. Specimens were transferred to cold 50% ethanol,
and subsequently embedded in paraffin.

Fluorescence Microscopy

Specimen Labeling
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General

Paraffin-embedded biopsies were sectioned at 4 m.

Slide specimens were

deparaffinized with xylene and rehydrated via a series of ethanol washes and distilled
water. The rehydrated slide specimens were heated at 85 C in either 10 mM citrate buffer
(pH 6.0) or 10 mM tris with EDTA buffer (pH 9.0) for 15 minutes and then allowed to cool
for 20 minutes. Subsequently, slide specimens were washed in Super-Sensitive Wash
buffer (BioGenex Laboratories, Freemont, CA) for 30 minutes, followed by a 10 minute
was in Dulbecco’s Phosphate Buffered Saline. A programmable autostainer (BioGenex
i6000, BioGenex Laboratories) was used to label specimens. Washes with super sensitive
wash buffer were done prior to blocking and after treatment with primary and secondary
antibodies (Abs). Washes in Dulbecco’s Phosphate Buffered Saline were done prior to
application of Prolong Diamond Mounting Media with the nuclear label 4’,6-diamidino-2phenylindole (Invitrogen, Carlsbad, CA). Specimens were treated with primary Ab or
isotype control overnight, at 4 C and with secondary Ab for 1 hour, at room temperature.
All labeling protocols included duplicate slides with corresponding isotype controls.

Collagen I and Collagen IV

Specimens were blocked with 10% goat serum (cat# 500622, Life Technologies,
Carlsbad, CA) and were treated with a mixture of mouse monoclonal anti-collagen IV (10
μg/mL, clone M3F7, Developmental Studies Hybridoma Bank, Iowa City, Iowa) and rabbit
monoclonal anti-collagen I (2 μg/mL, cat# ab138492) Abcam, Cambridge, MA) Abs.
Isotype control specimens were treated with a mixture of mouse IgG1κ (10 μg/mL, ref#
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14-4714-85 Ebioscience, San Diego, CA) and rabbit monoclonal IgG (2 μg/mL,
cat#ab172730, Abcam, Cambridge, MA) . Subsequently, the specimens were treated with
a mixture of goat anti-mouse IgG-Alexa Fluor 647 (2 μg/mL, cat# A21236, Molecular
Probes, Eugene, OR) and goat anti-rabbit IgG-Alexa Fluor 555 (2 μg/mL, cat# A21429,
Molecular Probes, Eugene OR) Abs.

Collagen IV, αSMA, CD31

Specimens were blocked with 10% donkey serum (cat# ab7475, Abcam, Cambridge, MA)
and were treated with a mixture of mouse monoclonal anti-collagen IV, rabbit polyclonal
anti-αSMA (1 μg/mL, cat# ab5694, Abcam, Cambridge, MA), and sheep polyclonal antiCD31 (3.5 μg/mL, cat# AF806-SP, R&D Systems, Minneapolis, MN) Abs. Isotype control
specimens were treated with a mixture of mouse IgG1κ, normal rabbit polyclonal IgG (1
μg/mL, cat# AB-105-C, R&D System, Minneapolis, MN), and normal sheep polyclonal IgG
(3.5 μg/mL, cat# 5-001-A, R&D Systems, Minneapolis, MN) . Subsequently, the slides
were treated with a mixture of donkey anti-mouse IgG-Alexa Fluor 488 (2 μg/mL, cat#
A21202, Molecular Probes, Eugene, OR), donkey anti-rabbit IgG-Alexa Fluor 555 (2
μg/mL, cat# A31572, Molecular Probes, Eugene, OR), and donkey anti-sheep IgG-Alexa
Fluor 647 (2 μg/mL, cat# A21448, Molecular Probes, Eugene, OR) Abs.

Collagen IV, TGF-β1, CD31

Specimens were blocked with 10% donkey serum and were treated with a mixture of
mouse monoclonal anti-collagen IV, rabbit polyclonal anti-TGF-β1 (5 μg/mL, cat#
ab92486, Abcam, Cambridge, MA), and sheep polyclonal anti-CD31 antibodies. Isotype
control specimens were treated with a mixture of mouse IgG1κ, normal rabbit polyclonal
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IgG, and sheep polyclonal IgG. Subsequently, the slides were treated with a mixture of
donkey anti-mouse IgG-Alexa Fluor 488, donkey anti-rabbit IgG-Alexa Fluor 555, and
donkey anti-sheep IgG-Alexa Fluor 647 Abs.

Image Acquisition

General

Gray-scale (12-bit) fluorescence images (1344 x 1044) were captured with a wide-field,
epifluorescence microscope (Leica DMRXA2; North Central Instruments, Plymouth, MN)
(x10 objective; 0.5128 m/pixel, 40x objective; 0.129 um/pixel), a B/W CCD camera (Orca
ER C4742-95; Hamamatsu Photonics, Bridgewater, NJ) and HCImage Hamamatsu
software (64-bit version, 4.2.5; Hamamatsu Photonics).

Microvascular Collagen I and Collagen IV

An acquisition matrix was programmed into HCImage to cover the whole muscle specimen
area using the 10x objective, acquiring 70-150 microscopic frames per field for the
collagen IV fluorophore channel. The frames were montaged in one large image to
represent the given (whole) specimen.

Subsequently, 12 representative regions of

interest (ROI) were selected per biopsy specimen for microvascular architecture
measurements with a 40x objective. Three ROIs were selected for acquisition from the
isotype controls.

An acquisition matrix was programmed into HCImage to collect 4

microscopic frames per ROI. At each ROI location, images were collected and montaged
in fluorescence channels corresponding to each fluorophore; 1) 4’,6-diamidino-2phenylindole (DAPI, a nuclear stain) with an excitation maximum at 358 nm and emission
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maximum at 461 nm, 2) Alexa Fluor 555 (collagen I) with an excitation maximum at 553
and emission maximum at 568 nm, 3) Alexa Fluor 647 (collagen IV) with an excitation
maximum 650 nm and emission maximum at 668 nm.

Collagen IV, CD31, αSMA, and TGF-β1

Serial sections were labeled in duplicate to characterize pericyte phenotype. The following
combinations of antibodies were used: (1) Collagen IV, αSMA, and CD31; (2) Collagen
IV, TGF-β1, and CD31. Using the 40x objective, 5 ROIs were captured per muscle
specimen.

At each ROI location, images were collected in fluorescence channels

corresponding to each fluorophore; 1) DAPI, a nuclear stain, 2) Alexa Fluor 488 (Collagen
IV) with an excitation maximum at 495 nm and emission maximum at 519 nm, 3) Alexa
Fluor 555 (αSMA or TGF-β1), 4) Alexa Fluor 647 (CD31). Corresponding ROIs were
collected from the isotype control specimens.

Multi-Spectral Imaging

Specimen Labeling

Paraffin-embedded biopsies were sectioned at 4 microns. Slides were stained in duplicate
with the Thermo Scientific Richard-Allan Scientific Chromaview Masson Trichrome
staining kit (Fisher catalog number 22-110-648). The standard staining protocol was used
with the following modifications. Slides were in Biebrich Scarlet-Acid Fuchsin Solution for
3 to 3 ½ minutes. After 3 minutes, slides were moved in pairs to deionized water at 10
second intervals. After 30 seconds in water, the first pair moved to phosphotungsticphosphomolybdic solution with subsequent pairs moving every 10 seconds. After 5
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minutes, the first pair moved to aniline blue stain solution and remained there for 10 ½
minutes. The remaining pairs moved into the stain solution at 10 second intervals with the
last pair staining for 10 minutes. Remaining steps follow the standard protocol. After the
last xylene bath, the cover slip was attached using paramount (Fisher Catalog Number
Sp15-500).

Image Acquisition

Slides were viewed using a Leica DM RXA2 microscope, with a 20X objective. Image
Cubes were generated from five different Regions of Interest (ROI) per slide using the
Nuance Multispectral Imaging System 3.0.2 (PerkinElmer N-MSI-EX Model, Waltham,
MA) that incorporates a CCD camera and liquid crystal tunable filter. Muscle tissue
completely filled each selected field. The Nuance system generates an absorbance
spectrum (450 nm to 700 nm) at each pixel of a two-dimensional spatial image of the
specimen. Extracted images were acquired for each of the three colors produced by
Masson trichrome stain: collagen(blue) and the muscle tissue (red) and nuclei (black).
Thereafter, a specific collagen spectrum is generated with the Nuance software which
quantitatively extracts the collagen spectrum at each pixel, producing a grey scale image
of the deposited collagen.

Image Analysis and Quantification

All image analysis and quantification was performed blinded from group status.
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Microvascular Architecture; Basement Membrane Thickness, Inner Basement
Membrane Diameter, and Total Microvessel Diameter

Grey scale images of Collagen IV labeled basement membranes were obtained and
transferred into the Image Pro® Plus image analysis environment (Media Cybernetics,
Warrendale, PA). Background pixel intensity was determined and subtracted from the
image. Images were then transferred into AutoQuant deconvolution software (Media
Cybernetics, Warrendale, PA)(Figure 5).

Deconvolution improves the point spread

function that is inherent to light microscopy, thereby greatly improving both the image
resolution and contrast. Each image underwent 4 iterations of 2D deconvolution. Image
segmentation and microvessel architecture measurement was done with a custom-made
Matlab algorithm (R2012a; MathWorks Inc, Natick, MA). Briefly, two perpendicular lines
are drawn through each microvessel wall, with the initial line being placed across the
longest microvessel axis, and corresponding intensity profiles are extracted (Figure 5).
Automated capture of the microvascular wall and inner basement membrane diameter
utilized a Gaussian Mixture Model alongside the Expectation Maximization algorithm. A
ratio of the total microvessel diameter from each line was calculated to determine
circularity of the microvessel. To avoid artificially biasing architecture measurements,
microvessels with ratios below 0.75 were excluded from analysis. For each microvessel
wall thickness, a 95% confidence interval of basement membrane thickness was obtained.
Inner basement membrane diameter was calculated as the distance between the two
luminal boundaries of the microvessel basement membrane. Means of four thickness
values and two inner basement membrane diameter were calculated for each individual
vessel. Total microvessel diameter was calculated as the inner basement membrane
diameter plus twice the basement membrane thickness (Figure 6). Approximately 50-250
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microvessels were assessed per biopsy specimen, with variability in the number of
microvessels quantified per ROI reflecting the microvascular density present in the
specimen. The mean of individual microvessel basement membrane thickness, inner
basement membrane diameter, and total microvessel diameter were calculated for each
patient.
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Figure 5: Image Acquisition, Preparation, and Quantification for Measurement of
Microvascular Architecture

Figure 5: Acquisition of Microvascular Measurements.
Collagen IV-labelled specimens are imaged with a 40x objective. Image preparation
includes image deconvolution to reduce light scatter and better delineate microvessel
architecture. Subsequently, images are imported into custom MatLab software for
quantification. For each vessel, two line profiles are generated which represent the pixel
intensity across the distance of the line. Gaussian distributions (red) are fit to the actual
pixel intensities (blue), with individual thickness measurements consisting of the distance
contained with the 95% confidence interval of the approximated distribution. Means of
four thicknesses are acquired per each vessel. Inner BM diameter is calculated as the
distance between the two inner boundaries of the vessel thickness curves, with the mean
of two measurements being acquired for each individual vessel.
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Figure 6: Schematic Representation of Microvascular Architectural
Measurements

Figure 6: Schematic Representation of Microvascular Architectural and Collagen I
& IV Measurements.
Cartoon depictions of microvessels are depicted. The red represents pericytes, the blue
represents endothelial cells, and the grey represents basement membrane. The black
bars denote the measurements made to determine BM thickness (A), inner BM diameter
(B), and microvessel total diameter (C). The density of Collagen I and abundance of
Collagen IV are measured around each microvessel. The area within the dashed circle
represents the area analyzed for microvascular collagen deposition (D).
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Microvascular Collagen IV Abundance and Collagen I Density

Specimens of gastrocnemius biopsies were labelled with Collagen I and Collagen IV. The
12 ROIs generated for the microvascular architectural analysis were analyzed for
microvascular Collagen I & IV. Three ROIs were analyzed from the isotype controls. Grey
scale montages (12 bit) were acquired for both Collagen I and Collagen IV and transferred
to the Image Pro® Plus environment. A circular Area of Interest (AOI) was placed around
each microvessel (Figure 6). Subsequently the AOIs were partitioned and both event
area and mean pixel intensity were determined. For each ROI, an average of the mean
pixel intensities and event areas of individual vessels was obtained. The Collagen IV
abundance was calculated as the product of microvessel event area and mean Collagen
IV pixel intensity (gsu•μm2). Collagen IV abundance measurements from 12 ROIs were
averaged to determine the mean patient Collagen IV abundance. Identical AOIs were
used to determine Collagen I area weighted mean density, which was calculated as the
sum of the products of microvessel event area and mean Collagen I pixel intensity of all
positive events per microscopic field divided by the sum of the event areas (gsu).

Total Extracellular Matrix Collagen

Grey scale images obtained from the multi-spectral imaging of duplicate Masson
trichrome stained slides were imported into the Image Pro® Premiere 9.3 (Media
Cybernetics, Warrendale, PA) environment for quantification of collagen area and
intensity mean values (12-bit grey scale). Total collagen abundance was determined as
area multiplied by intensity (gsu•μm2) for each ROI generated.
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Microvascular Density

Grey scale images obtained from Collagen I & IV labeling were transferred into the
Image Pro® Plus environment. Collagen IV label uniformly identified microvessel
structure and was used to create partitions that yielded accurate vessel identification.
The number of microvessels and total tissue area were determined. A ratio of
microvessels per total tissue area was calculated to determine microvascular density per
ROI.

Pericyte Identification and Characterization

Slides labeled with Collagen IV, αSMA, and CD31 were qualitatively reviewed. αSMA
has been shown to be variably expressed in pericytes of various tissues, including
skeletal muscle. Candidate cells were considered pericytes if they were abluminal to the
endothelium (CD31 label) and within the microvascular basement membrane (Collagen
IV label). Grey scale images were transferred into Image Pro® Plus software, and the
abundance of microvascular αSMA+ pericytes was calculated as the product of event
area by mean pixel intensity (gsu•μm2). Microvessels greater than 15 μm in diameter
were excluded from the analysis of αSMA+ pericyte abundance. Adjacent slides were
labeled with Collagen IV, TGF-β1, and CD31 to qualitatively determine the presence and
location of TGF-β1 expression within the microvessel structure.

Statistical Analysis
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To assess how balanced the three PAD groups (Control, Stage II, and Stage IV)
are, they were compared using the nonparametric Kruskal-Wallis test for continuous
predictor variables, and the Chi-square test for categorical predictor variables, All
biological parameters were assessed for normality, and transformed if nonnormal.
When two groups had to be compared, the two-sided independent t-test was performed
for normally distributed parameters, whereas the non-parametric Mann-Whitney U test
was used when nonnormality was encountered. In order to avoid confounding, the
three PAD groups (Control, Stage II, and Stage IV) were compared with respect to each
of the response variables using by a multivariable general linear model while controlling
for the rest of the predictor covariates. Parametric simple linear regressions were
performed to assess the relationship between variables. The overall level of statistical
significance was kept at alpha 0.05 in all analyses. The basic statistical analyses were
performed with NCSS 12 Statistical Software, whereas the multivariable analyses were
performed using SAS 9.4 (SAS Inst, Cary, NC).

Results

Patient Demographics

Limited cohorts of control (n = 14), Stage II PAD (n = 15), and Stage IV PAD
patients (n = 16) were analyzed due to the detailed and extensive nature of characterizing
microvascular features. Previous studies of microvascular structure were able to detect
differences between microvessels from PAD patients versus control with cohorts of 8 – 14
patients.(20-23) Thus, we utilized a minimum of 14 patients per group. Demographic data
for Control, Stage II, and Stage IV PAD are presented in Table 4. ABI differed between
control and Stage II PAD patients (p < 0.0001), between control and Stage IV PAD patients
(p < 0.0001), and Stage II PAD and Stage IV PAD patients (p = 0.0002). The Stage IV
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PAD cohort had a greater percentage of diabetes mellitus than control (p = 0.04) and
Stage II PAD (p = 0.03). The Stage IV PAD cohort also had a greater percentage of rental
insufficiency than control (p = 0.03) and Stage II PAD (p < 0.005). Family history of
cardiovascular disease was greater in Stage IV PAD patients than control (p = 0.05) and
Stage II PAD (p = 0.01). Age, gender, smoking status, hypertension, coronary and
cerebrovascular disease, obesity (body mass index >30), dyslipidemia, Chronic
Obstructive Pulmonary Disease, and statin use did not differ between groups (p > 0.05).
Significant variables were treated as covariates in all subsequent analyses.
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Table 4: Patient Demographics; Control, Stage II, and Stage IV PAD

Table 4: Patient Demographics.
Note: Continuous variables were analyzed by Kruskal-Wallis test and are presented as
mean ± S.E.M. Categorical variables were analyzed by Chi-square test and are presented
as percentages.
* Significant difference from control (p < 0.05)
** Significant difference from control (p < 0.005)
†
Significant difference from Stage II PAD (p < 0.05)
‡ Significant difference from Stage II PAD (p < 0.005)
A Transient Ischemic Attack
B Body Mass Index > 30
C Creatinine clearance < 60ml/min.1.73m2
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Altered microvascular architecture is an early feature of PAD myopathy and
worsens with PAD severity

To investigate the structural changes in PAD microvessels, we measured
microvessel BM thickness, inner BM diameter, and total microvessel diameter.

We

observed that a progressive thickening is present between control (1.408  0.025 m) and
Stage II PAD (1.577  0.030 m; p=0.0002), as well as, Stage II PAD and Stage IV PAD
(1.747  0.060 m; p=0.02). Whereas BM thickening appeared to be an early feature in
PAD myopathy, inner BM diameter increases were found in advanced PAD. Microvessel
inner BM diameter was similar between control (3.243  0.094 m) and Stage II PAD
(3.295  0.064 m). Interestingly, we observed a significant increase in Stage IV PAD
inner BM diameter (3.972  0.124 m) compared to control (p=0.00007) and Stage II PAD
(p=0.00007). Total microvessel diameter was significantly greater in Stage IV PAD (7.466
 0.224 m) compared to control (6.058  0.111 m; p=0.00001) and Stage II PAD (6.448
 0.112 m; p =0.0005) (Table 5). Multivariate analysis revealed that the stage of PAD
was the predominant predictor of BM thickness (p = 0.0005), inner BM diameter (p =
0.0048), and microvascular total diameter (p < 0.0001). The presence of cerebrovascular
disease influenced BM thickness (p = 0.046), and inner BM diameter (p = 0.008), and
marginally influenced microvascular total diameter (p = 0.057). Hypertension (p = 0.035)
contributed to inner BM diameter. The contribution of diabetes to inner BM diameter was
marginally significant (p = 0.082).
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Table 5: Microvascular Architecture Measurements Across Stages of
Peripheral Artery Disease

Table 5: Microvascular Architecture Measurements Across Stages of Peripheral
Artery Disease.
Gastronemius biopsy specimens were labeled with Collagen IV and microvascular
architectural features were measured. Measurements were obtained for approximately
50 - 200 microvessels per each biopsy specimen. Control (n = 14), PAD Stage II (n = 15),
and PAD Stage IV (n = 16). Measurements are presented as mean ± S.E.M.
* : significant difference from Control (p < 0.001)
† : significant difference from Stage II PAD (p = 0.02)
# : significant difference from Stage II PAD (p > 0.001)
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Collagen IV deposition is increased around PAD microvessels

Quantitative fluorescence microscopy (QFM) revealed increased Collagen IV deposition
in PAD gastrocnemius. Collagen IV labeling was most intense around the microvessels
and was also observed around individual myocytes. Qualitative review of specimens
demonstrated an increased deposition of Collagen IV around microvessels, but not
myocytes, in PAD microvessels (Figure 7A-C).

PAD microvessels appeared to be

thickened by Collagen IV, with greater thickening around microvessels in advanced PAD
(Figure 7D-F). Interestingly, microvascular thickening was not homogeneous in Stage II
PAD muscle and instead demonstrated a skip lesion phenomenon. However, thickened
microvasculature appeared ubiquitous across Stage IV PAD muscle. To characterize the
extent of Collagen IV deposition around the microvasculature we measured microvessel
Collagen IV abundance. We observed a trend for increase in Collagen IV deposition from
control (16,670 gsu•m2, IQR = 12,778 ) to Stage II PAD (22,378 gsu•m2, IQR = 14,860)
to Stage IV PAD (29,165 gsu•m2, IQR = 27,286). Microvascular Collagen IV abundance
was significantly greater in Stage IV than control (p=0.029), but did not reach significance
between control and Stage II (p=0.59), or Stage II and Stage IV (p= 0.15) (Figure 7G).
When adjusted for covariates, Collagen IV abundance was marginally significant (p =
0.056).
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Figure 7: Collagen IV is Increased Around PAD Microvessels

Figure 7: Collagen IV deposition is enhanced around PAD microvessels.
Gastrocnemius biopsy specimens were labelled with Collagen IV. Qualitative review
shows progressive increases in deposition of collagen IV between control (A), Stage II
PAD (B), and Stage IV PAD (C). Callout boxes in A-C are enlarged in D-F, respectively.
Collagen IV abundance was significantly elevated in Stage IV PAD compared to control
(p = 0.029) (F).
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Next, we explored the relationship between early and late microvascular
architectural alterations. A positive linear relationship is present between microvascular
BM thickness and inner BM diameter (R= 0.72, R2= 0.52; p>0.0001), suggesting that
changes in microvascular architecture may be continuous with PAD progression (Figure
8A).

To determine if microvascular architectural changes limited the formation of

additional microvessels, we quantified microvascular density. Compared to control (4.8 ±
0.7 microvessels per 103 m2), both Stage II PAD (5.6 ± 0.7 microvessels per 103 m2; p>
0.00001) and Stage IV PAD (6.1 ± 0.9 microvessels per 103 m2; p>0.00001) had elevated
microvascular density. Stage IV PAD microvascular density was larger than Stage II PAD,
however, the difference between these groups was marginally significant (p=0.053)
(Figure 8B).

Covariate analysis yielded no significant influence of DM, FH, renal

insufficiency, or age on microvascular architecture or microvascular density.
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Figure 8: Relationships Between Microvascular Architectural Parameters and
Microvascular Density with PAD Severity

Figure 8: Microvascular Thickness is Associated with Inner BM Diameter and
Microvascular Density Increases Across Stages of PAD.
Microvascular BM thickness is positively associated with inner BM diameter across stages
of PAD (R2 = 0.52; p < 0.0001) (A). Microvascular density is progressively increased with
stage severity. Stage IV PAD microvascular density was greater than Stage II PAD (p =
0.053), which was greater than control (p < 0.00001) (B). Data presented as mean ±
S.E.M.
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Collagen I is preferentially deposited around PAD microvessels

Collagen I is present within healthy skeletal muscle and provides tensile support
to these tissues. Aberrant Collagen I deposition has been implicated in the fibrosis of
various organs, including PAD skeletal muscle.

58,61,64-66,80,85-92

We assessed the

distribution of Collagen I deposition within control and PAD gastrocnemius. A subset of
thickened PAD microvessels gained a secondary investment of Collagen I around and
within the microvascular BM (Figure 9A-B).

Collagen I deposition varied in PAD

specimens and included interstitial deposition between myocytes. In areas with limited
fibrosis, Collagen I was found mainly around microvessels (triangles), while in areas with
pronounced fibrosis Collagen I was found around microvessels and extended into the
interstitial space (arrows), suggesting that collagen I deposition may arise from the
microvasculature (Figure 9C).
Quantitative fluorescence microvscopy revealed that Collagen I is discretely
present around myofibers and microvessels of control gastrocnemius (Figure 9D). In
Stage II PAD, fibrosis was increased but modest. Isolated areas of increased Collagen I
deposition were encountered and were preferentially deposited around Stage II PAD
microvessels (Figure 9E). In Stage IV PAD, fibrosis was pronounced and Collagen I
deposition was present diffusely with Stage IV PAD microvessels being frequently
encapsulated by Collagen I (Figure 9F).

Quantification of microvascular Collagen I

density demonstrated similar medians between control (132.6 gsu, IQR = 316.9) and
Stage II PAD (159.7 gsu, IQR = 302.0). Microvascular collagen I deposition was increased
in Stage IV PAD (427.9 gsu, IQR = 914.6) compared to Stage II PAD (p=0.023) and control
(p=0.044). Adjustment for covariates revealed that PAD stage was the predominant
predictor of Collagen I density (p = 0.027).
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Figure 9: Collagen I is Preferentially Depositied Around Microvessels

Figure 9: Collagen I is Preferentially Deposited Around PAD Microvessels.
Collagen I (red) is heterogeneously deposited in Stage II PAD muscle and is preferentially
deposited around collagen IV-thickened microvessels (green) in areas of limited fibrosis
(A). Enlargement of the callout box (b) reveals that collagen I is deposited as a second
annulus around and within the microvascular basement membrane (B). Fibrotic areas of
Stage II muscle show that collagen I deposition is prominent around microvessels
(triangles) which appears to extend from the microvessels into the surrounding interstitium
(arrows)(C). Microvascular Collagen I deposition is restricted and uniform in control (D),
enhanced in select areas of Stage II PAD (E), and prominent in Stage IV PAD (F).
Microvascular Collagen I density is greater in Stage IV PAD relative to Stage II PAD (p =
0.023) and control (p = 0.044)(G).
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Fibrotic burden is increased in PAD

To determine the fibrotic burden present within the gastrocnemius, we utilized Masson
trichrome stain to determine the abundance of total collagen present within the biopsy
specimens. We observed uniform collagen distribution in control (Figure 10A,D), areas
of increased collagen deposition in Stage II PAD (Figure 10B,E) and areas of overt fibrosis
in Stage IV PAD (Figure 10C,F). Dense collagenous investment of microvessels was
observed. Collagen label was extracted from Masson trichrome stained sections (Figure
10D-F) and quantified by spectral analysis. Total collagen abundance was increased in
Stage IV PAD (1066 gsu•m2, IQR = 734) compared to Stage II PAD (358 gsu•m2, IQR
= 256; p=0.0001) and control (287 gsu•m2, IQR = 168; p=0.00003). Total collagen
abundance was increased in Stage II PAD compared to control, although this difference
was marginally significant (p=0.055). Multivariate analysis revealed that PAD stage was
the predominant predictor of total collagen abundance (p <0.0001).
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Figure 10: Fibrotic Burden is Increased in PAD

Figure 10: Fibrotic burden is increased in PAD.
Masson Trichrome stained sections reveal that collagen deposition is limited in control
muscle (A), heterogeneously increased in select regions of Stage II PAD (B), and
extensive in Stage IV PAD (C). Corresponding collagen extractions are presented from
A-C and show dense collagenous deposition around microvessels in areas of fibrosis (DF, respectively). Collagen quantification revealed increased total collagen abundance in
Stage IV compared to Stage II (p = 0.0001) and control (p= 0.00003)(G).
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PAD pericytes acquire an SMA+ phenotype, increase in abundance with PAD
severity, and express TGF-1

Our assessment of microvascular architecture focused on the structure of
microvascular matrix proteins, Collagen I & IV. The finding that the microvascular inner
BM diameter expanded with advancing disease prompted exploration of cellular changes
within the collagenous annulus. CD31+ endothelial cells were encountered within the
Collagen IV annulus; however qualitative review of the endothelial lumen diameter did not
yield luminal enlargement between control and Stage II or Stage IV PAD.

Instead,

endothelial swelling was frequently encountered in advanced PAD. Pericytes can express
SMA and reside within a shared basement membrane with endothelial cells with which
they maintain close contact with through gap junctions, adhesion junctions, and peg and
socket contacts.180,194
Quantitative fluorescence microscopy labeling of specimens with CD31, SMA,
and Collagen IV revealed increased numbers of SMA+ pericytes in and around PAD
microvessels which were most prominent within thickened microvessels.

Control

microvessels (5-15m) demonstrated rare SMA+ pericyte cell bodies, but SMA+ puncta,
likely representing pericyte processes, were present (Figure 11A).

Stage II PAD

microvessels demonstrated SMA+ puncta as well as frequent SMA+ cell bodies (Figure
11B). Stage IV PAD microvessels had a striking increase in SMA+ cell bodies, with
multiple SMA+ pericytes being present around individual microvessels. In slightly larger
microvessels (15-30m), multiple layers of SMA+ pericytes were present within the
thickened Collagen IV network (arrow).

Additionally, acellular microvessels were

encountered (arrowheads) (Figure 11C).

Quantification of SMA abundance was

restricted to pericytes from microvessels with a total diameter of <15m. As PAD severity
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advanced, SMA+ pericyte abundance increased. Stage IV PAD (32957 gsu•m2, IQR =
69876) had a greater SMA+ pericyte abundance than Stage II PAD (20308 gsu•m2, IQR
= 13771; p=0.00027), and Stage II PAD had a greater SMA+ pericyte abundance than
control (7156 gsu•m2, IQR = 7035; p<0.00001)(Figure 11D).

After adjusting for

covariates, PAD stage remained the predominant predictor of sum of SMA+ pericyte area
(p = 0.0003). BMI had a marginal contribution to the sum of SMA+ pericyte area (p =
0.081).

Adjacent sections were labeled with CD31, TGF-1, and Collagen IV. The

SMA+ pericytes encased in thickened PAD microvessels (5-15m) (Figure 12A) also
express TGF-1 (Figure 12B).
Increasing SMA+ pericyte abundance and expression of TGF-1 point to a
potential relationship between pericytes, microvascular architectural alteration, and perimicrovascular fibrosis.

We observed that SMA+ pericyte abundance increased in

association with increasing BM thickness (R = 0.69, p = 0.004), inner BM diameter (R =
0.53, p = 0.04), and total diameter (R = 0.76, p = 0.001). There was a strong positive
linear relationship between SMA+ pericyte abundance and peri-microvascular Collagen
IV abundance (R = 0.74, p = 0.002). Additionally, we observed a strong relationship with
increasing SMA+ pericyte abundance and increasing peri-microvascular Collagen I
density (R = 0.65, p = 0.008).
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Figure 11: SMA Positive Pericyte Abundance Increases with PAD Severity

Figure 11: SMA+ Pericyte Abundance Increases with PAD Severity.
Specimens were labeled for collagen IV (blue), SMA (red), CD-31 (green), and DAPI
(grey). Control microvessels had few SMA+ pericytes (A). Thickened microvessels had
increased SMA+ pericyte coverage in Stage II PAD (B). The number of SMA+ pericytes
was substantially increased in Stage IV PAD. Multiple SMA+ pericytes were present on
terminal microvessels which appeared “arteriolarized” (arrow). Acellular microvessels
were also commonly encountered (arrowheads) (C). SMA+ pericyte abundance
progressively increased with PAD severity. Stage IV PAD had a greater abundance of
SMA+ pericytes than Stage II PAD (p = 0.0003), and Stage II PAD was greater than
control (p < 0.00001)(D).
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Figure 12: In PAD Microvessels, SMA+ Pericytes Express TGF-1

Figure 12: SMA+ Pericytes Express TGF-1 in PAD Microvasculature.
Serial sections were labeled for Collagen IV (teal), CD-31 (green), DAPI (blue) and either
SMA (magenta)(A) or TGF-1 (red)(B). SMA and TGF-1 labeling was present on
pericytes from the same microvessels (arrows).
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Discussion

PAD starts as atherosclerotic occlusive disease of the named inflow arteries
(macrovascular disease) supplying the legs, most commonly affecting the aortic
bifurcation, the superficial femoral artery at Hunter’s hiatus and the popliteal trifurcation.
Our study established that the vascular pathology of PAD extends beyond macrovascular
atherosclerosis and produces a microvascular disease in the ischemic muscles of PAD
limbs. We have previously shown that small vessels (diameters of 50 – 150 m) are
diseased in PAD limbs,67 and in the current study we extend these findings to demonstrate
that the smallest microvessels (<15 m) are also affected by PAD.

Microvascular

pathology is present in the calf muscle of claudicating patients and is substantially more
advanced in patients with CLI. Using quantitative methods, we have shown that in PAD
muscle, pathological changes are present in microvessels less than 15 m in diameter
and include thickening of the BM, mainly due to deposition of Collagen I and IV, diameter
enlargement of the BM ring, and a rise in the abundance of SMA+ pericytes. All of these
microvascular alterations increase in parallel with advancing disease severity. As PAD
severity advanced from Stage II to Stage IV, the fibrotic burden increased alongside
microvascular architectural alterations. Substantial thickening of the Collagen IV annulus
was observed in advanced PAD, and the microvascular annulus was further thickened by
a secondary layer of Collagen I.

The abundance of SMA+ pericytes was also

substantially increased around these thickened microvessels. Furthermore, late stage
PAD patients had a significantly enlarged inner BM diameter, which does not appear to
represent an increase the luminal flow diameter, but rather represented the
accommodation of the more numerous pericytes within the thickened BM (Figure 13). BM
thickness positively correlated with inner BM diameter, which supports that pericyte
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proliferation and excessive BM synthesis are progressive in PAD myopathy. Moreover,
the abnormally increased SMA+ pericytes expressed TGF-1 (Figure 12), which likely
induces pericyte secretion and peri-microvascular deposition of Collagen I and IV. In
support of this, we observed strong associations between increasing SMA+ pericyte
abundance, and increasing microvascular BM thickness, inner BM diameter, total
microvessel diameter, Collagen IV abundance and Collagen I density. Collagen I
deposition circumscribed microvessels and extended around the myofibers and
myofascicles. Taken together, these data suggest that microvascular pathology may be
central to PAD myopathy. Microvascular disease may have a substantial deleterious
effect of muscle perfusion and is a likely source of myofibrosis within ischemic PAD
muscle.
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Figure 13: Schematic Representation of Microvascular Remodeling in PAD

Figure 13: Schematic Representation of Microvascular Remodeling in PAD.
Microvascular architectural alterations across stages of PAD are depicted in the cartoon.
The number of SMA+ pericytes (red cells) increases with PAD severity around the
endothelium (blue cells) of microvessels less than 15 m in diameter. The BM (grey) is
thickened in the microvessels of PAD patients. As the abundance of SMA+ pericytes
increases, the BM becomes thicker and the diameter of the BM annulus expands to
accommodate more pericytes. However, the endothelial diameter does not expand.
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The results of this study expand upon previous ultrastructural studies of BM
thickening in PAD capillaries. Our results are in agreement with previous reports that BM
thickness is increased around PAD microvessels,171 particularly in CLI patients.173 Baum
and colleagues compared BM thickness across controls (n = 4), PAD patients with
intermittent claudication (n = 4), and PAD patients with CLI (n = 10). Although BM
thickness was significantly greater in PAD patients relative to controls, they did not
observe differences between PAD cohorts.171 The absence of a significant difference
between PAD patients with claudication and CLI may reflect the methodology used to
identify and quantify BM thickness or insufficient statistical power due to the limited cohort
size. In the current study, we developed a methodology to produce highly reliable and
reproducible identification and quantification of microvascular BM thickness and inner BM
diameter. In comparing microvascular architecture across advancing stages of PAD
severity, we observed qualitative and quantitative increases in BM thickness between
controls, patients with claudication, and patients with CLI, which suggests that
microvascular pathology is progressive in PAD.
Cross talk between pericytes and endothelial cells is likely critical in the process of
microvascular remodeling. Studies have shown that the presence of both endothelial cells
and pericytes are required for the formation of the BM. Pericytes are closely associated
with endothelial cells and are ensheathed by a common basement membrane which is
continuous around the microvessel.363 Endothelial cells have the machinery to synthesize
many of the BM components, however, pericytes are required for BM assembly and
regulation of synthesis.191,196,291,292 In PAD muscle, inflammation and hypoxia lead to
endothelial cell injury and subsequently the activation of pericytes, which likely initiates
the deleterious process of BM remodeling.

Elaboration of cytokines from the

atherosclerotic plaques bath the distal microvessels and may be the initiating cause of the
pathological endothelial and pericyte responses seen in PAD microcirculation, which are
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further worsened by the reperfusion/ischemia injury that arises with arterial stenosis.
Microvascular remodeling likely begins with endothelial death and a preliminary regression
of microvessels. The hypoxia produced by loss of microvessels may then drive the
excessive growth response seen, particularly in the late phases of microvascular
remodeling.196,197,289,322,323

With chronic inflammation, ischemia, and injury, death of

pericytes and endothelial cells becomes common and may induce repair paradigms,
including

angiogenesis,

regeneration.55,69,290,297

thus

beginning

a

cycle

of

degeneration

and

In line with this putative mechanism, we observed that

microvascular density is elevated in PAD muscles and increases with microvascular
disease severity. Continuous damage and inflammation may lead to an advanced stage
of vascular regeneration170,271,298,299 that becomes exhausted in PAD muscles. As
endothelial cells and pericytes perish, the BM remains intact and regenerating endothelial
cells and pericytes synthesize a new inner layer of BM,170 which likely results in the
cumulative thickening of the microvascular BM and the increased prevalence of acellular
microvessels observed in our analysis. Furthermore, during the proliferative stage of
vascular remodeling, pericytes can detach from the endothelium and differentiate into
myofibroblasts, leaving the denuded endothelium vulnerable to regression,196 which
subsequently propagates both fibrosis and additional deleterious microvascular
remodeling. It is possible that PAD myopathy starts as an adaptation of the affected
skeletal muscles to the low flow state and the abnormal metabolic, hemodynamic, and
inflammatory milieu produced by the atherosclerotic obstruction of the main feeding
arteries. However, over time the myopathy becomes independently pathogenic and selfperpetuating. In this sense, the myopathy of PAD appears to have substantial similarities
to the myocardial remodeling seen in patients with chronic coronary artery disease and
heart failure.
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In acute muscle injury, pericytes coordinate a regenerative response by creating a
favorable microenvironment for muscle repair. Deposition of ECM components, including
microvascular BM, provides structural scaffolding to regenerating muscle and supports
satellite cell migration and myogenesis.294. Thus, differential deposition of ECM
components by perictyes may alter the microenvironment and deter myogenesis in favor
of fibrosis. Furthermore, in the setting of chronic injury, pericytes can coordinate the
development and possibly initiation of pathological fibrosis.181,191 A novel finding of this
study is that in PAD muscle, SMA+ pericyte expansion and expression of TGF-1 is
coupled with alterations of microvascular architecture and perivascular deposition of
Collagen I and IV. Pericytes have been shown to overproduce ECM components including
Collagen I and IV in response to TGF-1 in brain and kidney.197,296 Therefore, it is likely
that in the skeletal muscle of patients with PAD, pericytes may directly contribute to
microvessel thickening by depositing products to the microvascular BM.191 Additionally,
pericytes have been implicated as a major source of collagen producing myofibroblasts in
several organs, including skeletal muscle, kidney, and liver, as well as in systemic
sclerosis.191,249,289,302,317-320
Pericytes may differentiate and migrate from the microvessel as collagenproducing myofibroblasts,69,181,364 further exacerbating both interstitial and perivascular
fibrosis in PAD muscle.

Myofibroblasts express SMA, generate contractile force,

remodel and deposit excessive ECM, and are directly linked to the extent of fibrosis.191,243
In a model of cardiac fibrosis after acute myocardial infarction, analysis of the infarcted
myocardium revealed that approximately 60% of myofibroblasts were derived from
pericytes.321

TGF-1 signaling is likely critical in the differentiation of pericytes to

myofibroblasts.284

TGF-1 is typically involved in pericyte and vessel maturation,196

however, TGF-1 can also stimulate differentiation and proliferation of both endothelial

112
cells and pericytes.69 Thus, enhancement of TGF-1 expression in PAD may initially arise
as a pro-angiogenic signal. Resolution of ischemia becomes progressively limited as the
arterial stenosis worsens, and the intensity and duration of TGF-1 signaling in PAD may
alter pericyte responses in favor of fibrosis by stimulating pericyte SMA expression54 and
collagen production.284

SMA+ pericyte production of TGF-1 may also recruit and

stimulate fibroblasts to deposit collagen or enhance accumulation of the ECM by inhibiting
matrix proteases and ECM degradation.296
The microvascular remodeling observed in PAD is strikingly similar to that
observed in Pulmonary Arterial Hypertension (PAH).

PAH is characterized by an

increased number of TGF-1 -producing VSMC in the pulmonary microvessels,54,314 and
TGF-1 has been found to enhance the differentiation potential of pulmonary pericytes
into SMA+ VSMC-like cells. Moreover, increased pulmonary pericyte coverage and
myofibroblast differentiation were observed in association with TGF-1 and chronic
hypoxia314 and

TGF-1 pathway overactivation was linked to PAH progression.54

Recently, our laboratory demonstrated that PAD patients across Fontaine stages had
progressively greater expression of TGF-1 by proliferative and synthetic VSMCs of
microvessels with diameters between around 50-150 μm, which suggests that the severity
of occlusive disease and resulting ischemia and ischemia/reperfusion induce proliferation
and greater TGF-1 expression by subendothelial VSMC.67 Our new finding that SMA+
pericytes of the smallest vessels also proliferate and express increased levels of TGF-1
that is significant in Stage II PAD but even worse in Stage IV PAD patients, suggests that
chronically reduced blood flow is a critical factor in the progressive alterations of the
microvascular architecture and physiology observed in PAD myopathy.
Previous reports have generated conflicting results on whether or not the number
or proportion of SMA+ microvessels is increased in PAD patients relative to controls.171,173
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In our study, we observed that microvessels in PAD muscle had greater expression of
SMA, and specifically, the abundance of SMA+ pericytes around vessels less than 15
µm increased with PAD stage severity. We observed that microvessels between 15 - 25
µm in diameter are inappropriately muscularized in PAD muscle, and that even smaller
vessels had increased SMA+ pericyte coverage, which was mostly absent in control
muscle. Pericytes play a crucial role in vascular homeostasis and participate in vascular
development, stabilization, maturation, and remodeling.54,187,188,365 In normal physiology,
pericyte

density

and

angiogenesis,54,187,188
pressure,55,181,191-193

coverage

correlate

endothelial

barrier

with

microvessel

properties,

and

maturation

during

orthostatic

blood

which supports pericyte involvement in the regulation of

angiogenesis, microvascular barriers, and microvascular vasomotion. It is possible that
the increase in SMA+ pericyte abundance is initially a compensatory response to
diminished blood flow across stenotic arteries. In an animal model of PAD, microperfusion
was assessed in parallel with increasing arterial stenosis. Interestingly, resting skeletal
muscle blood flow was preserved in moderate stenosis, and only became limited in severe
stenosis. With exercise, microvascular blood volume decreased more than blood flux rate
in association with increasing stenosis severity.110 Taken together, these data suggest
that the early microvascular adaptation to decreased arterial flow is to reduce
microvascular blood volume, particularly during exercise, which may reflect active derecruitment of capillary circuits, possibly via SMA+ pericyte constriction at pre-capillary
sphincters, as a means to preserve precapillary pressure and maintain blood flux through
a subset of capillary beds.110,115,116
Collagenous investment of microvessels may result in loss of flexibility,
hemodynamic dysfunction, and decreased local diffusion capacity for oxygen and
nutrients, exacerbating the ischemic state experienced by the myofibers and other
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components of PAD muscle.171,366

Our data support prior reports that angiogenic

responses can increase the number but unfortunately not the quality of microvessels in
the ischemic tissues. The architectural changes observed in this study are in line with
prior reports of microperfusion deficits in PAD patients. Several studies have observed a
delayed time to peak microvascular blood flow in PAD patients relative to controls after
exercise and post-occlusive reactive hyperemia.99,102,108,109,133-136

During moderate

contractile exercise, microvascular blood volume was slightly lower than controls, whereas
microvascular blood velocity was substantially diminished in PAD patients.144 The BM
thickening of PAD microvessels observed in this study may directly contribute to the
slowing microperfusion by increasing resistance across stiffening microvascular beds.
Pericyte damage or dysfunction may directly contribute to microvascular perfusion
deficits with consequent ischemic tissue damage. Pericyte expression of αSMA has been
shown to be greatly enhanced in response to chronic hypoxia.54 Ischemia-reperfusion
injury triggers oxidative stress in PAD muscle and likely contributes to pathological
pericyte activity. Recent studies have shown that following traumatic brain injury, SMA
expression is increased in pericytes alongside pericyte-mediated reductions of vessel
diameter and hypoperfusion.209,326

Dysfunctional pericyte contractility has also been

shown in response to ischemic events. In both cerebral stroke and MI models, ischemia
evoked pericyte-mediated microvascular constriction. Subsequently, pericytes perished
in rigor, irreversibly constricting capillaries, a finding which may account for the “no reflow”
phenomenon, in which vasoconstriction and ischemia persist even after restoration of flow
through occluded vessels.213,214 It is likely that pericyte dysfunction contributes to PAD
myopathy and pericyte-mediated microcirculatory occlusion leads to localized ischemic
damage that may account for the spatial heterogeneity of microvascular blood flow114 and
damage observed in PAD muscle.
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The results from the multivariable general linear model showed that the main
predictor variable (Control, Stage II, Stage IV) was statistically significant for each of the
response variables microvascular BM thickness (P = 0.0005), inner BM diameter (P =
0.0048), microvessel total diameter (P < 0.0001), Collagen I density (P = 0.0265), sum of
αSMA+ pericyte area (P = 0.0003), and total Collagen abundance (P < 0.0001), and
marginally significant for the response variable Collagen IV abundance (P = 0.0561). This
has helped avoiding confounding, and has added confidence to our conclusions about the
predictive value of main predictor variable, PAD grouping.
A limitation of this study is the relatively small number of patients analyzed. We
interrogated the contribution of DM, family history, and renal insufficiency to microvascular
pathology in our covariate analysis. Although we found no significant effects, the small
number of patients per group limited the statistical power of the analysis. Microvessel
thickening has been observed in the microvascular beds of several organs in patients with
DM and patients with renal insufficiency but in the cohorts of patients analyzed in this
study, BM thickening, inner BM diameter expansion, increasing sum of pericyte area,
microvascular fibrosis, and myofibrosis did not differ remarkably between patients with
and without DM or renal insufficiency, which suggests that PAD alone is sufficient to
induce and propagate microvascular pathology.

DM microangiopathy is fairly well

characterized in several organs. Death of pericytes and, consequently, microvascular
instability and decreased capillary density are hallmark features of diabetic microvascular
complications and are well documented features of diabetic retinopathy. Our observations
that microvascular density and sum of pericyte area are increased in PAD with and without
DM patients suggests that the microangiopathy of PAD is different from, and likely
dominant to the microangiopathy observed in DM. Additional studies are necessary to
better characterize the contribution of insulin resistance and DM to PAD microvascular
pathology.
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In regards to the microvascular disease several questions remain. Future research
needs to address whether the microcirculatory pathology is present in other tissues of the
affected PAD legs like nerves, skin, bones, joints subcutaneous fat and the degree to
which it may contribute to the manifestations of PAD, including the muscle dysfunction,
the neuropathy of PAD, the development of ulcers and gangrene of the ischemic limbs
and their failure to heal. Understanding the relationship between microvascular pathology
and microperfusion offers a unique opportunity for development of non-invasive diagnostic
assessment of PAD limbs and may have great utility in the assessment of therapeutic
efficacy.

Furthermore, non-invasive imaging modalities, such as contrast enhanced

ultrasonography, could aid in understanding the functional alterations of the
microvasculature of PAD limbs and help dissociate macro- from the micro- vascular
disease. Further exploration of the pathogenetic mechanisms of microvascular disease
may aid in the identification of patients at risk for progressing from Stage II to Stage III or
IV PAD. Understanding PAD microvascular pathology may also offer opportunities for
more individualized therapies, which may include ACE-inhibitors, anti-hypertensives,
statins, and DM medications, and may aid in the identification of patients who are likely to
have a favorable response after revascularization surgery.

Conclusions

PAD produces a myopathy in the legs of affected patients and the myopathy is
characterized by myofiber degeneration and expansion of the extracellular matrix
(fibrosis). The present study introduces microvascular disease as a central component of
this myopathy. Microvascular disease is characterized by thickening of the basement
membrane, proliferation of TGF-1-producing SMA+ pericytes and perivascular fibrosis

117
and is tightly connected to both the fibrosis and the myofiber degeneration of PAD
myopathy.
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Chapter III: Microperfusion Deficits in Patients with PAD

Introduction:

Microvascular changes are progressive in PAD myopathy and likely lead to
compromises in microvascular perfusion.

In chapter II we demonstrated that

microvascular architectural changes are present in PAD myopathy. Microvascular BM
thickness increases with advancing severity of PAD, and in advanced PAD the inner BM
diameter is significantly increased, reflecting the accommodation of increased numbers of
SMA+ pericytes and swollen endothelial cells within the microvascular basement
membrane. SMA is considered to be a marker of contractile ability. Although the
capacity of pericytes to regulate microvascular perfusion remains largely unknown, some
studies have demonstrated that SMA+ pericytes on pre-capillary arterioles can
vasoconstrict and limit perfusion through capillary beds. Hypertrophy of both VSMC,
which moderate arteriolar constriction, and pericytes around the normally non-muscular
microvessels of PAD skeletal muscle suggests that PAD vasculature may have an
increased potential to be in a vasoconstrictive state.
Previous studies utilizing Contrast Enhanced Ultrasonography (CEU) have
demonstrated that there are indeed significant alterations of microvascular perfusion.
Reduced flow reserve (FR), a ratio of microvascular blood flow at reperfusion after an
ischemic stress to microvascular blood flow at rest, have been observed in PAD patients.
Reductions of FR could reflect either limited capacity of microvascular beds to engage in
longitudinal recruitment in response to ischemia or metabolic demand.

Conversely,

microvascular beds may be nearly at maximal flow capacity at baseline. Endothelial
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dysfunction is a well characterized feature of PAD muscle, which taken together with the
proliferation of SMA+ pericytes suggests that microvascular hemodynamic regulation
may be dysfunctional. Microvascular perfusion deficits remain poorly characterized and
the relationship of these perfusion deficits to structural microvascular features is unknown.
In chapter III we will test the hypothesis that microvascular perfusion is related to
microvascular architectural features in PAD patients with IC. We will demonstrate that the
extent of hemodynamic restriction present in the large arteries contributes to, but does not
determine, the severity of microvascular architectural and perfusion changes. We will
demonstrate that the microvascular architectural alterations associated with microvascular
density are different between patients with IC and CLI. Additionally, we will describe the
relationship between microvascular architecture and microperfusion.

Methods

Human Subjects

The experimental protocol was approved by the University of Nebraska Medical Center
and the Veterans Affairs Nebraska-Western Iowa Institutional Review Boards. All subjects
gave informed consent.

Control Group

We recruited 14 control patients who were undergoing vascular operations for abdominal
aortic aneurysm repair. Control patients led sedentary lifestyles and had no history of
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PAD symptoms. Control patients had normal blood flow to their lower limbs as indicated
by normal lower extremity pulses at examination and normal ABI at rest and after stress.

PAD Patient Recruitment

We recruited 40 patients with intermittent claudication (Fontaine Stage II) and 16 patients
presenting with tissue loss (Fontaine Stage IV) who were undergoing lower extremity
operations for symptomatic PAD.. Medical history, physical examination, decreased ankle
brachial index (ABI< 0.9), and computerized or standard arteriography that revealed
stenotic and/or occluded arteries supplying the lower extremity were evaluated to establish
the diagnosis for each PAD patient. Stage II PAD patients presented with intermittent
claudication, but no rest pain or tissue loss. Stage IV PAD patients presented with nonhealing ulcers and/or gangrene. Patients with rest pain or tissue loss were excluded from
CEU analysis.

Overview of Endpoints measured in PAD patients

All forty patients underwent measurement of Ankle Brachial Index at rest and after postocclusive

Reactive

Hyperemia,

and

Contrast

Enhanced

Ultrasonography

for

measurement of calf muscle blood flow at rest and after post-occlusive Reactive
Hyperemia. A subset (N=15) of the forty patients also underwent muscle biopsies of their
medial gastrocnemius belly and the muscle sample was processed for measurement of
parameters of the gastrocnemius architecture (Figure 14). The fifteen patients in this
analysis are the same as those participating in the microvascular architectural analysis
studies presented in Chapter II.
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Figure 14: Overview of Endpoints Measured

Figure 14: Overview of Endpoints Measured.
Forty Stage II PAD patients were recruited for this study and the ABI and CEU were
collected at rest and during post-occlusive reactive hyperemia. A subset of these patients
were evaluated for microvascular parameters. Microvessels from 14 controls, 15 Stage II
PAD, and 16 Stage IV PAD patients were evaluated for microvascular BM thickness, inner
BM diameter, and density.
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Ankle Brachial Index and Reactive Hyperemia Assessment

ABI measurements were performed by a dedicated vascular laboratory
technologist for all Stage II PAD patients. Systolic pressures were taken from the bilateral
brachial, dorsalis pedis (DP), and posterior tibial (PT) arteries after a period of rest in the
supine position. The maximum systolic pressure from the DP or PT was divided by the
highest of the bilateral brachial systolic pressure. Following resting pressure
measurements, a cuff occlusion of the superficial femoral artery was performed for five
minutes at the level of the distal thigh. Occlusion was confirmed by absence of ipsilateral
Doppler signal in the pedal arteries. After the cuff was released systolic pressure
measurements, from the higher-pressure pedal artery at rest, were repeated every fifteen
seconds until pressures returned to baseline. The ABI collected at 15 seconds after cuff
release was collected and recorded as the post-occlusive reactive hyperemia ABI.

Contrast Enhanced Ultrasonography Acquisition

Continuous real time CEU perfusion imaging was performed using a phased-array
transducer (S5-1, IE33; Philips Ultrasound, Andover, MA, USA) with a low mechanical
index (0.19) triggered ultrasound contrast imaging with intermittent high mechanical index
impulses. Definity ultrasound contrast (3%; 4ml/min) was continuously infused during the
procedure. Patients were resting in a lateral recumbent position before and during the
procedure. The ultrasound probe was placed on the lateral head of the gastrocnemius.
Once a steady state of contrast infusion had been achieved, two minutes of baseline
imaging of the lateral gastrocnemius and soleus was acquired. On completions of the
resting image acquisition, a cuff was inflated around the distal thigh to 90 mmHg above
the patient’s systolic pressure to occlude superficial femoral artery flow and held for a 90
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second period of ischemia. Reperfusion imaging began on the release of the cuff and
ended after two minutes of post-occlusion imaging.

Contrast Enhanced Ultrasonography Quantification

Video intensity (VI) was measured for the whole acquired region of muscle.
Sequential end-diastolic frames were obtained and imported into Image Pro Plus 8
software (Media Cybernetics, Warrendale, PA). The second frame post high mechanical
index pulse was used as the background image, and was digitally subtracted from the
subsequent pulse-interval images to remove large vessel signal and tissue artifacts. Time
versus VI data were fit to the function:
𝑦 = 𝐴(1 − 𝑒 −𝛽𝑡 )
where 𝑦 is the VI at pulsing interval 𝑡, 𝐴 is the plateau value of VI that reflects
microvascular blood volume, and 𝛽 is the rate constant of microbubble replenishment
reflecting red blood cell velocity, also known as the microvascular blood flux rate (Figure
15). Microvascular blood flow (MBF) was derived by the product of 𝐴 × 𝛽. Flow reserve
was calculated as the ratio of reperfusion (hyperemic) MBF to resting MBF.
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Figure 15: CEU Measurement Acquisition

Figure 15: CEU Measurement Acquisition.
CEU images are collected during the diastolic phase of each heartbeat and represent the
pulse interval. Microbubble contrast is continuously injected both at rest and during
reactive hyperemia. A high mechanical index pulse destroys the microbubbles (inertial
cavitation) in the imaging plane and during the subsequent pulses, new microbubbles
arrive. During the initial pulses after inertial cavitation, microbubbles arrive in small
vessels but very few microbubbles arrive into the microvasculature. The subsequent
pulses visualize microbubbles in both small vessels and microvessels. By subtracting the
initial pulse interval signal from the remaining pulse intervals, microvessel signal can be
extracted and quantified. (Top panels) Time intensity curves are generated, and each
measurement represents a pulse interval in the video sequence. The time intensity curve
describes the kinetics of microbubble replenishment in the microvasculature after inertial
cavitation. Time versus video intensity data are fit to the function 𝑦 = 𝐴(1 − 𝑒 −𝛽𝑡 ) where
the plateau value A estimates blood volume when contrast ingress and egress reaches a
steady state and β approximates the red blood cell velocity, also known as blood flux.
(Bottom panel) MBF can be calculated by the product of blood flux and volume (A • β).
Time intensity curves are generated for rest and reactive hyperemia, and can be used to
determine the flow reserve (reperfusion MBF/resting MBF).
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Biopsy

A subset (n = 15) of the 40 Stage II PAD patients underwent a biopsy of their medial
gastrocnemius belly.

Gastrocnemius samples weighing approximately 250 mg were

obtained from the anteromedial aspect of the muscle belly, 10 cm distal to the tibial
tuberosity. All biopsies were obtained with a 6 mm Bergstrom needle. Samples were
immediately placed into cold methacarn and fixed for 48 hours.

Specimens were

transferred to cold 50% ethanol, and subsequently embedded in paraffin.

Microvascular

Architecture

Analysis,

Microvascular

Density,

and Pericyte

Abundance

Microvascular architecture, microvascular density, and pericyte abundance were
assessed in a subset of Stage II PAD patients who underwent CEU evaluation (n=15)
using the methodology described in detail in chapter II. Briefly, specimens were labeled
with Collagen IV antibody and photomicrographs were collected using a 40x objective.
Images were processed in Image Pro Plus software and transferred to a custom MatLab
program for quantification of microvessel BM thickeness, inner BM diameter, and total
microvessel diameter. Microvessels reaching a circularity criterion threshold and total
diameter of <12m were included in analysis. Approximately 50-250 microvessels were
analyzed per biopsy specimen. Collagen IV labelled images were used, and partitions
were created that yielded accurate vessel identification. The number of microvessels and
total tissue area were determined. A ratio of microvessels per total tissue area was
calculated to determine microvascular density per ROI, which were subsequently

126
averaged to generate a patient mean microvascular density. Specimens were labeled
with Collagen IV, αSMA, and CD31 to identify and quantify αSMA+ pericytes.
Grey scale images were transferred into Image Pro® Plus software, and the abundance
of αSMA+ pericytes within microvessels <15 μm in diameter was calculated as the product
of event area by mean pixel intensity (gsu•μm2).

Statistical Analysis

All biological parameters were assessed for normality. Linear regression analysis was
conducted. For normally distributed parameters we conducted parametric analysis using
Pearson regression and reported R2 values. Remaining parameters were assessed
using non-parametric Spearman Rank correlations and reported Spearman R values.
Covariate analysis was completed using multilinear regression. All statistical analyses
were performed with NCSS 12 data analysis software using a 95% confidence level.

Results

Patient Demographics
The demographics of the control, Stage II and Stage IV patients assessed for
microvascular architecture are presented in Table 4, and a summary of the age, ABI, and
microvascular features are presented in Table 6. The demographics of the 40 patients
evaluated in this chapter are presented in Table 7.
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Table 6: ABI, Age, and Microvascular Characteristics Across Stages of PAD

Table 6: ABI, Age, and Microvascular Characteristics Across Stages of PAD
Gastrocnemius biopsy specimens were labeled with Collagen IV and microvascular
architectural features were measured. Measurements were obtained for approximately
50 – 200 microvessels per each biopsy specimen. Measurements are presented as mean
 S.E.M.

*

P values were calculated by Kruskall Wallis test
† number of microvessels per 103 m2
# gsu • m2
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Table 7: The Demographics of Stage II PAD Patients Included in the CEU and
Biopsy Analysis

Table 7: The Demographics of Stage II PAD Patients Included in the CEU and
Biopsy Analysis
Microvascular and macrovascular hemodynamics were characterized in a group of Stage
II PAD patients. CEU was used to assess the microvascular hemodynamics in 40 patients,
and a subset of 15 patients underwent biopsy analysis of microvascular features.
Note: Continuous variables are presented as mean  S.E.M. All other variables are
presented as percentages.
# Body Mass Index > 30
† Creatinine clearance < 60 ml/min / 1.73 m2
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Microvascular Pathology is Associated with Macrovascular Disease

We

investigated

the

relationship

between

macrovascular

hemodynamic

compromise and microvascular pathology. To assess hemodynamic compromise, we
utilized ankle brachial index at rest (ABI) and after post-occlusive reactive hyperemia (RH).
To quantitate microvascular pathology, we utilized histology-based microvascular
architecture measurements, microvessel density, pericyte abundance, and CEU-based
microperfusion parameters
ABI was assessed in control (n = 14), Stage II (n = 15) and Stage IV PAD(n = 16).
ABI was progressively lower between control (1.089  0.027) and Stage II PAD (0.604 
0.033; p<0.0001) and between Stage II PAD and Stage IV PAD (0.184  0.058; p =
0.001)(Figure 16A). Microvascular density increased as ABI decreased (R = -0.36, p =
0.02)(Figure 16B). A strong linear relationship was observed between decreasing ABI
and increasing SMA+ pericyte abundance (R = -0.85, p = 0.0001)(Figure 16C). An
inverse linear relationship was present between ABI and microvascular architectural
parameters, including BM thickness (R = -0.66, p < 0.0001), inner BM diameter (R = -0.51,
p = 0.0004), and total microvessel diameter (R = -0.63, p < 0.0001) when data were pooled
across control and stages of PAD (Figure 16D-F).

This suggests that worsening

macrovascular hemodynamic restriction increases the number of microvessels, although
the quality of those microvessels worsens, and that advancing hemodynamic restriction is
tightly linked to increasing SMA+ pericyte abundance.
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Figure 16: Microvascular Basement Membrane Thickness Increases are Associated
with Decreases in Ankle Brachial Index Across Stages of PAD.

Figure 16: Microvascular Basement Membrane Thickness Increases are Associated
with Decreases in Ankle Brachial Index Across Stages of PAD.
ABI was assessed in control (n = 14, blue), Stage II (n = 15, green) and Stage IV PAD(n
= 16, purple). ABI was progressively lower between control (1.089), Stage II PAD (0.604),
and Stage IV PAD (0.184)( p <0.001 between all groups)(A). There are inverse
relationships between ABI and microvessel density(R = -0.36, p = 0.02)(B), SMA+
pericyte abundance (R = -0.85, p = 0.0001)(C),microvascular BM thickness (R = -0.66, p
< 0.0001)(D), inner BM diameter (R = -0.51, p = 0.0004)(E), and total microvessel diameter
(R = -0.63, p < 0.0001)(F).
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Microvascular BM Thickness is Strongly Linked to Microvascular Density in Stage
II PAD Whereas Inner BM Diameter is Linked to Microvascular Density in Stage IV
PAD
In Chapter II we demonstrated that microvascular density increases with PAD
severity, which supports the presence of an angiogenic response in PAD muscle.
Microvascular density may influence several parameters of microperfusion and may be
related to microvascular architecture. Therefore, we assessed the relationship between
the microvascular architecture and density across stages of PAD. When the patients from
control and PAD groups were pooled, there was no association between microvessel
density and microvascular BM thickness (R = 0.02, p = 0.88), inner BM diameter (R = 0.08, p = 0.62), and total diameter (R = -0.05, p = 0.74). However, when separated into
control and PAD stages, associations between microvessel density and microvascular
architecture were observed.
As microvessels became thicker, the microvascular density decreased in control
(R = -0.53; p = 0.05) and Stage II PAD (R = -0.63; p = 0.01). Additionally, a trend between
thicker microvascular BM and decreased microvessel density was observed in Stage IV
PAD (R = -0.43; p = 0.10). Interestingly, BM thickness had a stronger association with
microvascular density in Stage II PAD patients relative to control and Stage IV PAD
(Figure 17A). Next, we assessed the relationship between microvessel density and inner
BM diameter. We observed that as inner BM diameter expands, microvessel density
decreases in Stage IV PAD patients (R = -0.54; p = 0.03). The relationship between
increasing inner BM diameter and decreasing microvessel density was marginal in
controls ((R = -0.46; p = 0.097), and absent in Stage II PAD patients (R = -0.20, p = 0.43)
(Figure 17B). Taken together, these data suggest that microvessel density is altered by
PAD. In Stage II PAD, microvessel density changes in relation to BM thickness, whereas
in Stage IV PAD, microvessel density changes in relation to inner BM diameter.
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Figure 17: Microvascular Density is Differentially Associated with Microvascular
BM Thickness and Inner BM Diameter Across Stages of PAD

Figure 17: Microvascular Density is Differentially Associated with Microvascular
BM Thickness and Inner BM Diameter Across Stages of PAD.
Microvascular density is progressively increased between control (n = 14, blue), Stage II
PAD (n = 15, green), and Stage IV PAD (n = 16, purple). A stronger inverse relationship
is present between microvascular density and BM thickness in Stage II PAD (R = -0. 63,
p = 0.01) relative to control (R = -0.53, p = 0.05) and Stage IV PAD patients (R = -0.43, p
= 0.097) (A). Conversely, the relationship between microvascular density and inner BM
diameter is stronger in Stage IV PAD (R = -0.54, p = 0.032) relative to Stage II PAD (R =
-0.20, p = 0.43) and control patients (R = - 0.46; p = 0.099)(B).
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The Relationship Between Microperfusion and Macrovascular Hemodynamic
Limitations in Stage II PAD Patients
Functional alterations within the microvascular beds may arise as a result of
diminished arterial perfusion.

Thus we next assessed the relationship between

microperfusion (measured by CEU) and macrovascular hemodynamic limitations
(measured by ABI and RH) in Stage II PAD patients (n = 40). The resting microvascular
blood volume (2.14  0.22 VIU) increased during reperfusion after ischemic stress (4.84 
0.50 VIU), whereas blood flux remained relatively constant between rest (0.43  0.04 s-1)
and reperfusion (0.47  0.05 s-1). MBF was enhanced during reperfusion (1.85  0.23
ml/min/g) relative to resting MBF (0.82  0.09 ml/min/g), and FR was calculated (2.84 
0.39)(Table 8). An inverse relationship was observed between resting MBF and ABI (R =
-0.34; R2 = 0.12; p = 0.038)(Figure 18A). No linear association was observed between
resting MBF and RH (p = 0.42)(Figure 18C). Additionally, no relationships were observed
between reperfusion MBF and either ABI (p = 0.53) or RH (p = 0.57)(Figure 18B,D).

134

Table 8: Microvascular Perfusion in Stage II PAD Patients

Table 8: Microvascular Perfusion in Stage II PAD Patients
CEU parameters of microperfusion are summarized for rest and reperfusion after ischemic
stress. Microvascular blood flow was calculated as the product of blood volume by flux.
Flow reserve was calculated as the ratio of reperfusion MBF to resting MBF. n = 40 Stage
II PAD patients.
Measurements are presented as mean  S.E.M.
* Video Intensity Units (VIU)
† 1/seconds
# ml/min/g
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Figure 18: The Relationships Between MBF, ABI, and RH.

Figure 18: The Relationships Between MBF, ABI, and RH.
ABI and microperfusion were assessed at rest and during post-occlusive reactive
hyperemia. As ABI decreases, resting MBF increases (n = 37; R = -0.34, p = 0.038)(A).
A linear relationship is absent between ABI and reperfusion MBF (n = 38; R = 0.10, p =
0.53)(B). Both resting MBF (n = 36; R = -0.14, p = 0.42) and reperfusion MBF (n = 37, R
= 0.10, p = 0.57) do not share a linear relationship with RH.
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Microvascular Architecture Affects Microperfusion

ABI, but not RH, correlates with resting MBF (out of seven parameters of CEU),
which suggests that macrovascular hemodynamic limitation does not fully account for the
microperfusion in claudicating skeletal muscle. Thus, we assessed whether microvascular
architecture (BM thickness, inner BM diameter) shared a relationship with microperfusion
(as assessed by CEU).

We determined that microvascular BM thickness may be

associated with resting microvascular blood volume (n = 11, R = -0.45, p = 0.16) and
resting MBF (n = 11, R = -0.40, p = 0.23), however these relationships did not reach
statistical significance.
Review

of

ultrasound

images

revealed

that

qualitative

differences

in

microperfusion were present with increasing inner BM diameter. We compared the resting
microperfusion of patients with large versus small inner BM diameters and observed both
lower microvascular perfusion and more areas devoid of flow in patients with greater inner
BM diameters (bottom panels, Figure 19) relative to those with smaller inner BM
diameters (top panels, Figure 19). Comparison of the time intensity curves demonstrated
that both blood volume and flux may be diminished as inner BM diameter increases. Thus,
we next assessed the relationship between inner BM diameter and resting MBF.

Inner

BM diameter had a strong linear correlation with microperfusion, both at rest and after
ischemic stress, which was more robust than the relationships observed between BM
thickness and microperfusion. As inner BM diameter increased, resting MBF decreased
(R = - 0.76, p = 0.006) (Figure 20).

Quantitative analysis revealed that the decrease in

MBF may be moderated by a slowing of blood velocity through the microvascular beds,
however the relationship between microvascular blood velocity and inner BM diameter
was only a trend (R = -0.44, p = 0.18).
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Figure 19: Microvascular Inner BM Diameter Influences Resting Microperfusion

Figure 19: Microvascular Inner BM Diameter Influences Resting Microperfusion
Representative images of a patient with smaller (top panels) and larger (bottom panels)
microvascular inner BM diameters. Patients are given a continuous infusion of Definity
ultrasound contrast. Baseline images are acquired immediately after a high mechanical
index pulse (continuous infusion) and are subsequently subtracted from the remaining
frames to remove both tissue artifact and large vessel signals. Microvascular images are
presented from the beginning (pulse 1), middle (pulse 9), and end (pulse 18) of the imaging
interval. Greater microvascular perfusion is present in the patient with smaller inner BM
diameters than the patient with larger inner BM diameters. Additionally, the patient with
the larger inner BM diameters has more areas that do not receive microvascular perfusion.
The corresponding time intensity curves are presented for the patient with smaller
(triangles) and greater (diamonds) inner BM diameters.

138

Figure 20: Resting Microvascular Blood Flow is Strongly Associated with
Microvascular Inner BM Diameter in PAD Gastrocnemius

Figure 20: Microvascular Blood Flow at Rest is Strongly Associated with
Microvascular Inner BM Diameter in PAD Gastrocnemius.
In stage II PAD patients (n = 11), microvascular inner BM diameter has an inverse linear
relationship with resting MBF (Spearman R = -0.76, p = 0.006).
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A strong positive linear association was found between inner BM diameter and RBC
velocity (blood flux) during reperfusion (R = 0.7818; p =0.005) (Figure 21A). A trend
emerged between increasing inner BM diameter and decreasing microvascular blood
volume (R = -0.5091, p = 0.11) (Figure 21B). Although blood flux and volume appeared
to be related to inner BM diameter, the reperfusion MBF was not (Figure 21C). Taken
together, these data suggest that with increasing inner BM diameter, blood travels more
rapidly through the microvascular beds at the expense of decreased microvascular blood
volume in response to ischemic stress.

Additionally, we observed that increases in

microvascular inner BM diameter were associated with increases in FR (R = 0.65; p =
0.03) (Figure 21D).
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Figure 21:
The Relationship of Microvascular Inner BM Diameter and
Microperfusion After an Ischemic Stress.

Figure 21: The Relationship of Microvascular Inner BM Diameter and
Microperfusion After an Ischemic Stress.
In stage II patients (n = 11), microvascular inner BM diameter is positively correlated with
RBC velocity during reperfusion (R = 0.78; p = 0.005) (A). An emerging negative trend
between inner BM diameter and reperfusion blood volume was present (R = -0.51; p =
0.11) (B). Reperfusion microvascular blood flow (MBF), the product of volume by velocity,
was not linearly related to microvascular inner BM diameter (R = 0.1364; p = 0.68) (C).
Microvascular inner BM diameter was positively associated with flow reserve (R = 0.65; p
= 0.03) (D).
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Discussion

PAD begins with the atherosclerotic narrowing of peripheral large caliber arteries,
including arteries supplying the legs (macrovascular disease). Increasing macrovascular
atherosclerosis produces supply to demand limitations, particularly during exercise. Distal
to the stenosis, our group and others have shown that vascular remodeling occurs
throughout the vascular tree. Our laboratory has published the findings that microvascular
remodeling occurs in PAD microvessels between 50 – 150 m in diameter,67 and include
hypertrophy and hyperplasia of the VSMC of arterioles and perivascular collagen
deposition. In Chapter II we have shown that the microvascular architecture of the terminal
microvessels is also altered, and progressively worsens with PAD severity.
Arterial flow limitations are fairly well characterized in PAD, however, the structural
and functional changes of the microcirculation to increasing hemodynamic restrictions
remain poorly characterized. In this study we have shown that microvascular pathology
worsens with decreasing ABI. We demonstrated that as ABI declines, microvessel BM
thickness, inner BM diameter, and total diameter increase. Additionally, we have shown
that microvessel density and SMA+ pericyte abundance are increased with decreasing
ABI. We have demonstrated that the presence of PAD affects capillary density in relation
to microvascular structure and that Stage II PAD microvessel density changes in relation
to BM thickness, whereas microvessel density changes in relation to inner BM diameter
in Stage IV PAD. We have shown that resting ABI, but not reactive hyperemia ABI, is
associated with resting MBF, and that reactive hyperemia MBF is not associated with ABI
during rest or reactive hyperemia.

Importantly, we have shown that microvascular

architecture, particularly inner BM diameter, is associated with microperfusion in PAD
patients. We have demonstrated that as inner BM diameter increases, resting MBF

142
decreases and that during reactive hyperemia, larger inner BM diameters are associated
with increased blood flux and greater flow reserve.
In this study we shown that increasing arterial hemodynamic restrictions are
associated with microvascular pathology. As the ABI declined, BM thickness, inner BM
diameter, total diameter, microvessel density, and SMA+ pericyte abundance increased.
Alterations of microvascular structure, number, and function may contribute to a
compensatory mechanism to maintain microvascular perfusion pressure through PAD
legs. We observed a strong relationship between increasing SMA+ pericyte abundance
and declining ABI. SMA+ pericytes are likely proliferative and vasoconstrictive in PAD
muscle. Enhanced vasoconstriction of pre-capillary sphincters by SMA+ pericytes may
reflect a compensatory mechanism for pre-capillary pressure correction that leads to a
reduction in distal resistance, increase in blood flux, and maximization of blood distribution
across hypo-perfused tissues.117 In support of this, we observed that as the inner BM
diameter increased (likely reflecting the accommodation of SMA+ pericytes), the blood
flux during reactive hyperemia increased.
Interestingly, there appeared to be a trade-off between increasing blood flux and
decreasing blood volume during reperfusion, which suggests that less surface area is
being perfused, thus it is possible that select terminal microvascular beds may be
bypassed during whole leg ischemia. As a result, microdomains of severe ischemia may
develop, especially in regions with thickened microvessels, and may account for the
spatial heterogeneity of MBF distribution in PAD muscle that has been observed in this
study and others.114 Importantly, we also observed that as inner BM diameters increased
in Stage II PAD patients, the resting MBF declined to very low levels, which suggests that
as microvascular disease advances, microperfusion of PAD muscle worsens not only
during ischemia, but also at rest.

143
A novel finding of our study was that macrovascular disease both at rest and during
reactive hyperemia may have a rather small contribution to microperfusion in Stage II PAD
muscles and that microvascular disease has a dominant effect on CEU-based parameters.
Rest ABI, but not reactive hyperemia ABI, only correlated with resting MBF (out of the
seven CEU parameters assessed), which suggests that macrovascular hemodynamic
limitation does not account for the microperfusion defects in claudicating skeletal muscle.
Paradoxically, we observed that as ABI declines, resting MBF increases. It is possible
that increased MBF reflects increased microvessel density, or potentially increased
vasodilation of the microcirculation at rest.
Our findings provide further evidence that microvascular disease imposes
limitations on microperfusion, both at rest and during reactive hyperemia in claudicating
muscle. We have demonstrated that a strong relationship exists between expanding inner
BM diameter and diminishing resting MBF. We have also shown that increases in inner
BM diameter are strongly associated with increased blood flux, possibly at the expense of
blood volume, during reactive hyperemia.

Taken together, these data support that

microvascular disease (relative to macrovascular disease) is the dominant component of
microperfusion limitations in claudicating muscle.
A novel finding of our study was that microvascular density is altered by PAD, and
is associated with microvascular architecture.

Interestingly, we observed differing

relationships between microvessel density and architectural parameters between Stage II
and Stage IV PAD patients. In Stage II PAD muscles, thickening BM appears to be the
dominant factor in microvessel density. This suggests that as microvessels become
thicker in claudicating muscle, either fewer microvessels are produced or conversely,
more microvessel damage, cellular death, and consequently microvessel regression
occurs. In Stage IV PAD muscles, expansion of the inner BM diameter was the dominant
factor in microvessel density. The microvessels are substantially thickened in Stage IV
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muscle, and additional thickening may have a relatively smaller contribution to microvessel
density than observed in Stage II PAD muscle. In Chapter II we demonstrated that the
abundance of αSMA+ pericytes is substantially increased within the microvessels of Stage
IV PAD muscles, and that the expansion of the inner BM diameter likely represents
accommodation of more pericytes within the microvascular BM. It is possible that these
αSMA+ pericytes differentiate into myofibroblasts and subsequently migrate into the
interstitial space. As a result, pericyte loss may leave the endothelium vulnerable to
regression and fewer pericytes may remain to promote microvessel repair, which may
account for the relationship observed between increasing inner BM diameter and
decreasing microvessel density in Stage IV PAD patients.
Our findings support and expand prior studies that assessed CEU-based
microperfusion in PAD patients. Several studies have observed a delayed time to peak
intensity (TTP) in PAD patients relative to controls after exercise and post-occlusive
reactive hyperemia.99,102,108,109,133-136 Collagenous investment of microvessels may result
in loss of flexibility, which may enhance red blood cell shear stress and vascular resistance
within the capillaries, ultimately slowing the rate of blood flow through the microcirculation.
We have shown that microvascular BM thickening increases between Stage II and Stage
IV PAD muscle. Others have shown that as the severity of PAD increases, the TTP
becomes further prolonged.109 Moreover, Duerschmied and colleagues demonstrated that
blood traversed the muscle more rapidly in the controls compared to PAD, with the
greatest delays in CEU contrast transit time arising within the microvascular compartment
of PAD patients,136

which supports that worsening microvascular disease, including

thickened microvascular BM, may contribute to the delayed transit across the
microvascular bed.
In the current study we observed slightly larger post-occlusive flow reserves in
PAD patients than previously reported.103 Substantial variation in flow reserve has been
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observed in relatively similar cohorts from both control and PAD patients,114

which

suggests that skeletal muscle flow reserve may have limited clinical utility, particularly in
PAD muscle. When resting MBF values are low, small absolute differences in reperfusion
flow can create deceptively large flow reserves.114 Our findings that the patients with
highest inner BM diameter had the lowest resting MBF and highest flow reserves are in
agreement with prior studies that higher flow reserves may not indicate better
microcirculatory health and therefore may have limited utility in determining PAD
severity.114
There are limitations to our study. We did not have an age-matched control group
for comparison. Future studies are necessary to assess the contribution of microvascular
structure and pericyte coverage to normal microcirculatory physiology. Our study did not
assess the extent of collateralization present, which may have an impact on microvascular
disease and microperfusion. Prior studies in PAD muscle have shown that “poorly”
collateralized limbs had prolonged TTP, however collateralization did not correspond to
ABI,109 which suggests that poor collateralization may accelerate microvascular disease
progression.

Thus, the contribution of collateral flow to microvascular disease is of

particular interest for future study. Additionally, the modest number of patients included
in this study limited our ability to assess confounding variables in our analysis of
microperfusion. Microperfusion deficits in PAD may be exaggerated in DM.136 Likewise,
smokers experience a complex alteration in regulation of microperfusion.137

Thus,

additional studies are merited to determine the contribution of smoking status (never,
former, current) on PAD microcirculatory performance in patients with and without
diabetes.

Alterations of PAD microcirculatory performance have also been observed

during exercise and may be central to the walking limitations observed in PAD. Studies
assessing the relationship between walking performance, microvascular architecture, and
microperfusion are of high interest, and may yield novel treatment targets and strategies.
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Conclusions
Increased arterial hemodynamic limitations (macrovascular disease) are
associated with worsening microvascular disease, which is characterized by increasing
microvascular BM thickness, inner BM diameter, total microvessel diameter, SMA+
pericyte abundance, and microvessel density.

Microvascular disease may have a

dominant role relative to macrovascular disease in imposing microperfusion limitations in
the muscles of PAD patients with claudication.
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Chapter IV: Microvascular Architectural Features Are Associated
With PAD Patient Walking Performance
Introduction

In chapter II we demonstrated that microvascular architectural changes are
progressive across advancing stages of PAD. Microvascular BM thickness increases with
increasing PAD stage and inner BM diameter is significantly increased in advanced
disease.

Expansion of the microvascular collagen ring likely reflects the increased

presence of SMA+ pericytes, a subset of which express TGF-1. The phenotypic change
and proliferation of these pericytes suggests that pericytes are instrumental in
orchestrating fibrosis, and additionally they may contribute to the microperfusion deficits
present in PAD limbs.
In chapter III we described the relationship between macrovascular occlusion and
microperfusion. We also determined that microvascular architecture, especially inner BM
diameter, is linked to microperfusion both at rest and after occlusive hyperemia (ischemic
stress) in patients with IC. Perfusion limitations caused by atheroscelerotic stenosis and
narrowing of arteries supplying skeletal muscle have long been considered to be the major
contributor to patient ambulation limitations. Our work and the work of others supports
that microperfusion deficits may have a substantial contribution to the declining walking
performance in PAD patients. Inefficient delivery of oxygen and nutrients to hypoxic
tissues and removal of toxic metabolites could exacerbate oxidative damage to myocytes,
subsequently compromising myocyte performance and consequently the patient’s walking
performance.

However, morphological alterations of the microvasculature and their

relationship to myocyte morphology, muscle force generation, and patient walking
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limitations remain unknown.

We hypothesize that alterations in the microvascular

architecture of PAD patients with IC are associated with oxygen delivery deficits and are
related to both qualitative and quantitative metrics of walking performance. We will
demonstrate that worsening microvascular architecture accelerates the decline of
oxygenation within PAD gastrocnemius. The relationship of microvascular architecture
and the patient’s perception of walking ability, as assessed by the WIQ, will be determined.
We will also demonstrate that microvascular architectural features are associated with
onset of claudication pain as well as the maximal duration of walking.

Methods

Human Subjects

The experimental protocol was approved by the University of Nebraska Medical Center
and the Veterans Affairs Nebraska-Western Iowa Institutional Review Boards. All subjects
gave informed consent.

PAD Patient Recruitment and Biopsy Preparation

We recruited 15 patients with intermittent claudication (Fontaine Stage II). Medical history,
physical examination, decreased ankle brachial index (ABI< 0.9), and computerized or
standard arteriography that revealed stenotic and/or occluded arteries supplying the lower
extremity were evaluated to establish the diagnosis for each PAD patient. Patients with
rest pain or tissue loss were excluded from CEU analysis. Biopsies of the gastrocnemius
were acquired and prepared as described in chapters II and III.
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Microvascular Architecture Analysis

Microvascular architecture was assessed in patients with IC who underwent
evaluation for walking performance, which included claudication onset time (COT), peak
walking time (PWT), and the scores collected from the Walking Impairment Questionnaire
(WIQ).

Microvascular architecture analysis was completed using the methodology

described in detail in Chapter II. Briefly, specimens were labeled with Collagen IV antibody
and photomicrographs were collected using a 40x objective. Images were processed in
Image Pro Plus software and transferred to a custom MatLab program for quantification
of microvessel BM thickness, inner BM diameter, and total microvessel diameter.
Microvessels reaching a circularity criterion threshold and total diameter of <12m were
included in analysis.

Approximately 50-250 microvessels were analyzed per biopsy

specimen.

Near Infrared Spectroscopy

Near Infrared Spectroscopy (NIRS) measurements were taken with a wireless,
continuous-wave, MOXY near-infrared spectrophotometer (Fortiori Design LLC,
Hutchinson, MN) in 13 Stage II PAD patients. This device noninvasively measures
oxygenated and deoxygenated heme-containing molecules (hemoglobin + myoglobin) in
a target tissue. Tissue oxygen saturation (StO2) represents the percentage of hemecontaining molecules that are oxygen-bound. Muscle StO2 measurements were relayed
wirelessly in real time using the software PeriPedal (PeriPedal, Napoleon, IN). A MOXY
NIRS probe was placed over the gastrocnemius bilaterally. Seated baseline
measurements were taken for a minimum of three minutes or until StO 2 signal stabilized,
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whichever was longer. Measurements were continuously captured during an exercise
interval. Minimum StO2 values achieved were also documented, as well as the time
required to reach the minimum StO2. In addition, specific StO2 measurements were
collected during exercise and were recorded for COT and PWT.

Claudication Onset Time and Peak Walking Time

Thirteen Stage II PAD subjects completed a Gardner treadmill walking test.367 Subjects
walked on a dynamic gait and pressure analysis treadmill (FDMT SciFit AC5000M,
Noraxon USA, Inc., Scottsdale, AZ) which collects synchronized pressure measurements
allowing for gait analysis and calculation of steps taken during exercise. Subjects initiated
exercise at 2.0 miles per hour at 0.0% incline. With each subsequent two-minute stage,
the treadmill incline was increased 2.0% to a maximum of 12.0%. Time of initial symptoms
(COT) and time at which claudication symptoms were prohibitive to further walking (PWT)
were recorded.

Walking Impairment Questionnaire

The WIQ has been validated in patients with IC and is qualitative physical function
quality of life survey. Fourteen Stage II PAD patients completed the questionnaire. We
utilized three of four subscales in this study (distance, walking speed, and stair climbing).
The subscale for pain was not analyzed in this study. The WIQ is scored on a scale from
0 to 100, with lower scores representing greater functional limitations within that
category.330,332
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Statistical Analysis

All biological parameters were assessed for normality. Linear regression analysis was
conducted. For normally distributed parameters we conducted parametric analysis using
Pearson regression and reported R2 values. Remaining parameters were assessed using
non-parametric Spearman Rank correlations and reported Spearman R values.

All

statistical analyses were performed with NCSS 12 data analysis software using a 95%
confidence level.

Results

Patient Demographics

Patient demographics are included in Table 9 and include mean ABI, age,
microvascular architecture measurements, COT, and PWT. For additional demographic
details, please review the Stage II PAD group described Table 4.
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Table 9: Stage II PAD Vascular Characteristics and Walking Performance

Stage II PAD
Number of subjects
Ankle Brachial Index
Microvascular BM thickness (μm)
Microvascular inner BM diameter (μm)
Microvessel total diameter (μm)
Claudication onset time (s)
Peak Walking Time (s)

15
0.61  0.03
1.577  0.030
3.295  0.064
6.448  0.112
210.5  35.4
471.0  61.1

Table 9: Stage II PAD Vascular Characteristics and Walking Performance
Macrovascular (ABI) and microvascular (microvascular architecture) features and
quantitative measures of walking performance (COT and PWT) are summarized.
Variables are presented as mean ± S.E.M.
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The Rate Decline in Oxygen Saturation During Exercise in PAD Gastrocnemius is
Related to the Muscle’s Microvascular Architecture

Previous work from our group has demonstrated that Stage II PAD patients exhibit
distinct calf muscle NIRS profiles during exercise characterized by rapid StO2 decline,
substantial hypoxia throughout exercise, and slowed recovery to baseline StO2 after
exercise.

NIRS measurements were collected during a session of graded treadmill

walking (Gardner test). StO2 was measured at rest and after 60 seconds of exercise.
Additionally we measured the time period between walking onset and the point at which
muscle SpO2 reached a minimum. No linear relationships were found between resting or
post occlusive ABI and StO2 at rest, after 60 seconds of exercise, and the time interval to
minimum StO2. This suggests that arterial hemodynamic restriction is not the dominant
factor determining muscle oxygen saturation in PAD legs.

To determine whether

limitations in muscle oxygenation were related to microvascular architecture we examined
muscle oxygen saturation by NIRS in Stage II PAD patients. As BM thickness increased,
the time to minimum muscle SpO2 decreased, however this relationship was marginally
significant (n = 13, R = -0.49, p = 0.09). A negative linear relationship was present
between microvascular inner BM diameter and the time to minimum muscle SpO2 (n = 13;
R = -0.58, R2 = 0.34; p = 0.04) (Figure 22). These data suggest that muscle oxygen
tension reaches its minimum more rapidly with increasing microvascular pathology, and
supports our previous findings that microvascular pathology worsens microperfusion
deficits.
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Figure 22: Microvascular Architecture Is Associated with Muscle Oxygenation

Figure 22: Microvascular Architecture is Associated with Muscle Oxygenation.
A negative linear relationship exists between microvascular inner BM diameter and the
time to minimum muscle SpO2 (n = 13; R = -0.58, R2 = 0.34; p = 0.04).
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Microvascular Pathology is Associated with Patient Perception of Walking
Limitations

The relationship of microvascular architectural features to both muscle
oxygenation and microperfusion suggests that microvascular pathology may influence
PAD patient walking performance. We explored the relationship of microvascular BM
thickness and inner BM diameter with a subset of WIQ fields (walking distance, walking
speed, and stair climbing) to assess whether microvascular pathology is associated with
patient reported walking performance. WIQ-1 (pain) is a categorical variable and could
not be assessed by linear regression methods, thus WIQ-1 was excluded from the current
analysis.

As BM thickness increases, patient self-reported walking performance

decreases (Figure 23).

Patients tended to report walking shorter distances as BM

became thicker (n = 14; R = -0.41; p = 0.14)(Figure 23A). There was inverse relationship
between BM thickness and patient’s perception of walking speed (n = 14; R = -0.54; p =
0.05)(Figure 23B) and stair climbing ability (n = 14; R = -0.57; p = 0.03)(Figure 23C).
Interestingly, the relationships between patient’s perception of walking ability and inner
BM diameter were stronger than those found for BM thickness (Figure 24). As inner BM
diameter increased, patients reported walking shorter distances (n=14; R2 = 0.31; p =
0.04)(Figure 24A), at slower speeds (n = 14; R2 = 0.34; p = 0.03) (Figure 24B), and
greater difficulty in climbing stairs (n = 14; R2 = 0.34; p = 0.03) (Figure 24C).
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Figure 23: Qualitative Measures of Walking Performance in PAD are Associated
with Microvascular Thickness in Stage II PAD Patients

Figure 23: Qualitative Measures of Walking Performance in PAD are Associated
with Microvascular Thickness.
Patient self-reported walking performance decreases as microvessels become thickened.
Patients tended to report walking shorter distances as BM became thicker (n = 14; R = 0.41; p = 0.14)(A). As BM thickness increased, patients reported slower walking speeds
(n = 14; R = -0.54; p = 0.05)( B) and greater difficulty climbing stairs (n = 14; R = -0.57; p
= 0.03)(C).
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Figure 24: Qualitative Measures of Walking Performance are Associated with
Microvascular Inner BM Diameter in Stage II PAD Patients

Figure 24: Qualitative measures of walking performance are associated with
microvascular inner BM diameter
As inner BM diameter increased, patients reported walking shorter distances (n=14; R2 =
0.31; p = 0.04)(A), at slower speeds (n = 14; R2 = 0.34; p = 0.03) (B), with greater difficulty
in climbing stairs (n = 14; R2 = 0.34; p = 0.03) (C).
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Next we explored if macrovascular disease (ABI and RH) was a stronger determinant of
patient self-reported walking performance than microvascular disease. We assessed the
relationship between resting and post-occlusive ABIs and WIQ subcategory scores. No
linear relationship was observed between ABI at rest and walking speed (R = -0.04, p =
0.82), walking duration (R = -0.15, p = 0.39), and ability to climb stairs (R = -0.03, p =
0.86). Also absent were relations between post-occlusive ABI and walking speed (R = 0.04, p = 0.82), walking duration (R = -0.17, p = 0.33), and ability to climb stairs (R = 0.04, p = 0.84). Taken together, these data point to microvascular disease being dominant
to macrovascular disease in patient self-reported walking performance.

Onset of Claudication Pain Occurs More Rapidly as Microvascular Pathology
Worsens

To determine if microvascular pathology was associated with standard
assessments of PAD patient walking performance, we assessed COT and microvascular
architecture. We observed a trend between BM thickness and COT (n = 13; R = -0.45; p
= 0.13). Inner BM diameter and COT had a moderate correlation (n = 13; R = -0.62; p =
0.03), which suggests that as inner BM diameter increases, patients experience pain
more rapidly (Figure 25).
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Figure 25: COT is Decreased with Increasing Microvascular Inner BM
Diameter

Figure 25: Claudication onset time is decreased with increasing microvascular
inner BM diameter.
Patients experience pain during walking more rapidly as inner BM diameter increases (n
= 13; R = -0.62; p = 0.03).
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Maximal Duration of Walking is Limited by Microvascular Pathology
We next assessed the relationship between microvascular architecture and
maximal walking duration. The association between PWT and BM thickness was not
significant (n = 13; R = -0.41; p = 0.16). However, a negative linear relationship was
present between PWT and inner BM diameter (n = 13; R = -0.67; p = 0.01)(Figure 26).
Inner BM diameter is a stronger predictor of both COT and PWT in Stage II PAD patients
than BM thickness.
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Figure 26: Peak Walking Time is Influenced by Microvascular Inner BM Diameter

Figure 26: Peak walking time is influenced by microvascular inner BM diameter.
PWT is shortened as inner BM diameter increases (n = 13; R = -0.67; p = 0.01).
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Discussion
Arterial atherosclerotic occlusion impairs blood flow to the lower extremities of PAD
patients, and during exercise the limitations in arterial perfusion become exaggerated and
initiate pain and encumber ambulation.

However, the pathophysiology of PAD limb

dysfunction is complex and is not fully explained by the hemodynamic limitation produced
by large artery occlusive disease (macrovascular disease).

In this study we have

established that microvascular disease is dominant to macrovascular disease in the
correlation and likely contribution to more rapid declines in oxygen saturation and
diminishing walking performance. We have demonstrated that there is a relationship
between microvascular architecture (inner BM diameter and BM thickness) and both
subjective and objective measures of walking performance.

Interestingly, inner BM

diameter appears to be a stronger predictor of walking performance than BM thickness.
Taken together with the findings in the previous chapters, microvascular architectural
pathology appears to be linked with myofibrosis and worsening myopathy, as well as
muscle oxygenation, muscle performance, and pain responses.
Our findings support work from our groups and others that ischemic myopathy
plays a central role in pathogenesis and pathophysiology in PAD legs. The microvascular
disease described in this thesis may be a key component of PAD myopathy. The data
presented in these studies demonstrate that microvascular disease contributes to and
possibly determines the development of perivascular and muscle fibrosis, PAD muscle
microperfusion limitations, and both symptoms and walking limitations in PAD patients
with claudication. We have previously shown that a state of repetitive cycles of exerciseinduced ischemia followed by reperfusion at rest operates in PAD patients and mediates
a large number of structural and metabolic changes in the muscle (PAD myopathy). The
most important myopathic changes in PAD are myofiber degeneration, fibrosis, and
cytokine upregulation.

In this thesis, we have shown that microvascular disease is
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associated with every aspect of myopathy. We have shown that microvascular disease
may contribute to muscle hypoperfusion. Microvascular disease appears to be involved
in the fibrotic process, and fibrosis appears to originate around pathologic microvessels
and subsequently spread to involve myofibers and myofascicles of the affected muscles.
Therefore, it is highly likely that microvascular pathology is an important contributer to PAD
myopathy. In this study, we have shown that as microvascular pathology worsens, muscle
oxygenation during exercise diminishes more rapidly. Thus, alterations of microvascular
architecture may predispose muscle to ischemia, particularly during ambulation. Rapid
decline of muscle oxygen tension in PAD limbs may hasten pain initiation and escalation
with consequent decreases in walking performance.

The inability to efficiently deliver

blood and the limitation in diffusion of oxygen predispose working myocytes to oxidative
stress, damage, and degeneration. Therefore, microvascular architectural alterations may
also contribute to myopathy propagation with subsequent deterioration of muscle function
and walking performance.
In Chapter II we demonstrated that the inner BM diameter expands to
accommodate SMA+ pericytes. SMA+ pericyte abundance increased in association
with increasing BM thickness, inner BM diameter, peri-microvascular Collagen IV
abundance and peri-microvascular Collagen I density. In Chapter III we observed that as
the BM becomes thickened in Stage II PAD patients, the microvascular density decreases.
Thickening of the BM and deposition of collagens around the microvessels may alter their
hemodynamic properties, as well as the ability to deliver oxygen (diffusion capacity) to
myocytes. Oxygen delivery may be further challenged by the reduction in microvessel
density as Stage II PAD microvessels becomes thicker. Initiation of walking increases
metabolic demands in PAD skeletal muscle and the combination of macro- and
microvascular disease leads to a drop in tissue oxygenation and an increase in the
byproducts of alternative fuel consumption, such as lactic acid. In addition to hypoxia
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signals, these metabolites may contribute to the induction of C-fiber-mediated pain
signals, which grow in intensity as the patient continues to walk. Additionally, SMA+
pericytes are likely proliferative and vasoconstrictive in PAD muscle.

Enhanced

vasoconstriction of pre-capillary sphincters by SMA+ pericytes may reflect a
compensatory mechanism for pre-capillary pressure correction that leads to a reduction
in distal resistance, increase in blood flux, and maximization of blood distribution across
hypo-perfused tissues117 but may also create microdomains of severe ischemia in PAD
muscle. We have observed a non-uniform pattern of perfusion by CEU imaging of
claudicating muscle, which supports that blood flow may be shunted around select
capillary beds. Taken together, these data suggest that microvascular disease may
contribute to local ischemia and may directly contribute to myocyte ischemia/reperfusion
injury.
Our observation that microvascular architectural alterations correlate with the
walking impairment and severity of the symptoms experienced by patients with
claudication is significant. Patients report walking shorter distances at slower speeds, and
climbing stairs with greater difficulty as inner BM diameter increases, suggesting that
microvascular pathology contributes to limitations of executing routine daily activities.
The decline in ambulation speed and duration suggest a behavioral modification to limit
microvascular-mediated ischemia in PAD muscle. Moderate correlations between inner
BM diameter and both COT and PWT suggest that microvascular pathology directly
contributes to patient walking limitations, including the initiation and worsening of pain
during walking.

This further points to the possibility that microvascular architectural

alterations are not limited to skeletal muscle, but rather may be a ubiquitous finding across
tissues of PAD limbs, such as nerves and skin, which may contribute to the well
documented neuropathy of PAD and the loss of hair follicles, oil- and sweat- glands and
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overall thinning and dryness of PAD skin.

Declines in microvascular density are

concordant with microvascular architectural alterations, suggesting that angiogenesis
becomes exhausted, which, when coupled to perfusion and oxygenation deficits, may
account for the poorer wound healing observed in PAD patients, particularly in advanced
stages.
This study has several limitations. We used the WIQ to assess the patient’s ability
to perform normal activities of daily living. Additional studies that quantitatively assess
ambulation and duration of activity throughout the day using objective methodology (e.g.
with the use of an accelerometer) may provide insight on the impact of microvascular
pathology during routine activities. In our assessment of tissue oxygenation, we used
NIRS probes which are portable and allow measurements during ambulation but have a
limited spatial resolution. Higher resolution modalities, such as BOLD MRI, may provide
additional characterization of the oxygenation deficits in PAD and clarify the functional
contribution of microvascular pathology to oxygenation limitations across PAD muscles.
Future studies are needed to better understand the role of microvascular pathology
in both PAD myopathy progression and walking limitations. In this study we characterized
the correlation of microvascular structural alterations to oxygenation and ambulation
deficits.

However, functional alterations in blood flow regulation remain poorly

characterized, particularly within the microvasculature.

Our findings suggest that

microvascular pathology may contribute to ischemic damage within PAD muscle, and
studies that assess the relationship between microvascular architecture, oxidative
damage, and mitochondrial dysfunction are warranted. Furthermore, the potential of
standard and currently developing therapies to reverse microvascular architectural
pathology and thereby improve symptoms and ambulatory ability of PAD patients remains
to be tested.
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Conclusions

Microvascular remodeling in PAD, particularly the expansion of the inner BM diameter,
are linked to worsening muscle oxygenation, walking performance, and pain responses in
PAD limbs. Microvascular pathology may contribute to ischemia/reperfusion injury and
myopathy propagation.
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Chapter V: Discussion
In this dissertation, we have demonstrated that there is a progressive alteration of
the microvascular architecture across stages of PAD that corresponds to increases in
microvascular density, SMA+ pericyte abundance, and decreasing ABI across stages of
PAD. These studies also reveal an association between microvascular pathology and not
only perivascular collagen deposition, but also total fibrotic burden. We have also shown
that microvascular architecture, particularly inner BM diameter, is linked to oxygen tension
and microperfusion in PAD muscle, as well as PAD patient walking performance. Taken
together, the results of these studies indicate that microvascular pathology may have a
substantial role in the pathogenesis of PAD myopathy, particularly fibrogenesis, and may
have a direct contribution to the walking limitations experienced by patients with PAD.
Although these studies are observational in nature, they provide a solid foundation
for future studies to explore in greater depth the mechanisms by which microvascular
pathology arises in PAD muscle. Of particular interest are studies that explore the impact
of treatment interventions in PAD, such as revascularization surgery, supervised exercise,
or pharmacological interventions.

Such studies would assist in understanding the

mechanisms by which microvascular architecture and perfusion are altered, potentially
enabling the development of more effective treatment strategies for PAD. Additionally,
they offer the unique opportunity to characterize with greater accuracy and validity the
utility of non-invasive imaging modalities that assess microperfusion, particularly CEU.
Defining the relationships between microvascular pathology, myopathy, and CEU
parameters could aid clinical decision making, and may one day be of use in tailoring
individualized therapeutic strategies. We hypothesis that the extent of microvascular
pathology is linked to the risk of failure of revascularization surgery. To clarify, there may
be a threshold of microvascular pathology, that once exceeded, will not regress upon
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reinstitution of arterial flow, which would thus result in poorer outcomes and limited benefit
of performing a risky and invasive operation.
An ongoing study in our laboratory is assessing the impact of six months Ramipril
(ACE-inhibitor) intervention on the microvascular of Stage II PAD muscles. Comparing
pre and post Ramipril parameters allows the opportunity to begin understanding causality
between microvascular architectural features and outcomes. Preliminary data from our
lab suggests that after six months of Ramipril treatment, patients have a significant
increase in inner BM diameter and total microvascular diameter, but BM thickness remains
unchanged (Table 10). However, CEU parameters were not significantly altered (Table
11).
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Table 10: Microvascular Architecture Before and After Ramipril Treatment

Table 10: Microvascular Architecture Before and After Six Months of Ramipril
Treatment.
Patients (n = 15) were assessed before and after six months of treatment with Ramipril.
Gastrocnemius biopsy specimens were labeled with Collagen IV and microvascular
architectural features were measured. Measurements were obtained for approximately
50 – 200 microvessels per each biopsy specimen. Measurements are presented as
mean  S.E.M.
* p values were calculated by parametric paired t-test
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Table 11: Microperfusion Characteristics Before and After Ramipril Treatment

Table 11: Microperfusion Characteristics Before and After Ramipril Treatment
CEU imaging was performed on Stage II PAD patients (n = 13) both before and after six
months of treatment with Ramipril. CEU parameter measurements are presented as
mean  S.E.M.
* p values were calculated by parametric paired t-test
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Comparison of the percent change of across parameters revealed several
interesting relationships that support that microvascular pathology is indeed central to
PAD myopathy. Our early results show that there may be robust relationships between
microvascular architecture and blood flux (Figure 27). The patients who had an increase
in BM thickness also experienced an increase in blood flux at rest (R = 0.77), though
currently this association is marginally significant (n = 6, p = 0.07)(Figure 27A). The
patients that experienced an inner BM diameter expansion had an increase in reperfusion
blood flux (n = 6, R = 0.89, p = 0.02)(Figure 27B).

We also observed emerging

relationships between microvascular architecture, microperfusion, and oxygen saturation.
A trend was observed between increasing inner BM diameter and decreasing time to
minimum SpO2 (n = 12, R = -0.55, p = 0.07)(Figure 28A). Additionally, we observed a
strong inverse relationship between resting MBF and time to minimum SpO 2 (n = 10, R =
-0.85, p = 0.002)(Figure 28B). These data support that oxygen saturation becomes
increasing limited as BM thickness and resting MBF increase.
Furthermore, emerging correlations are also present between changes in
microvascular architecture, microperfusion, and PWT. Although marginally significant,
there is evidence that increasing inner BM diameter (n = 12, R = -0.52, p = 0.08)(Figure
29A) and increasing resting MBF (n = 10, R = -0.60, p = 0.07)(Figure 29B) are moderately
associated with declines in walking duration. Given our observations that blood flux is
increased with increasing microvascular architectural alterations, it is possible that
microvascular pathology has advanced in the Ramipril treated patients. Thus it is possible
that the blood may remain in larger vessels with lower resistance and may be diverted
around capillary beds.

Alternatively, six months of Ramipril treatment may improve

collateralization and the quality and function of the arterioles, which may increase resting
MBF without improving terminal microvascular pathology, and consequently without
improving walking performance.
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Figure 27: Alterations in Microvascular Association are Associated with Changes
in Blood Flux

Figure 27: Alterations in Microvascular Architecture are Associated with Changes
in Blood Flux.
Quantification of microvascular architecture and microperfusion by CEU were obtained in
PAD patients with IC (n = 6) before and six months after Ramipril treatment. The percent
change (%) was calculated. A trend was observed between increasing BM thickness
and increases in resting blood flux (R = 0.77, p = 0.07) (A). A strong linear relationship
was observed between enlarging inner BM diameter and reperfusion blood flux (R = 0.89,
p = 0.02). Relationships were assessed by non-parametric correlation analysis, and
Spearman R values are reported.
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Figure 28: The Relationship Between Oxygen Tension, Inner BM Diameter, and
Resting MBF

Figure 28: The Relationship Between Oxygen Tension, Inner BM Diameter, and
Resting MBF.
Quantification of microvascular architecture, microperfusion by CEU, and oxygen
saturation by NIRS were obtained in PAD patients with IC before and six months after
Ramipril treatment. The percent change (%) was calculated. A trend was observed
between increasing inner BM diameter and shortening of the interval to minimum SpO2 (R
= -0.55, n = 12, p = 0.07) (A). A strong linear relationship was observed between enlarging
inner BM diameter and reperfusion blood flux (R = 0.85, n = 10, p = 0.002). Relationships
were assessed by non-parametric correlation analysis, and Spearman R values are
reported.
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Figure 29: Alterations of Microvascular Architecture and Resting MBF are Related
to Declines in PWT

Figure 29: Alterations of Microvascular Architecture and Resting MBF are Related
to Declines in PWT.
Quantification of microvascular architecture and microperfusion by CEU were performed
in PAD patients with IC before and six months after Ramipril treatment. The percent
change (%) was calculated. A trend was observed between increasing microvascular
total diameter and declining PWT (R = -0.52, n = 12, p = 0.08) (A). A marginally significant
linear relationship was observed between increasing resting MBF and declining PWT (R
= -0.60, n = 10, p = 0.07). Relationships were assessed by non-parametric correlation
analysis, and Spearman R values are reported.
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It is possible that improvements of the arterioles may precede improvements of the
microvascular beds. Therefore, six months of Ramipril treatment may be too short of an
interval to capture beneficial alterations of microvascular architecture or function in the
legs of PAD patients. Future studies are merited in exploring the changes in terminal
microvasculature against alterations of larger microvasculature and the relationship of
these features to microperfusion, muscle strength, and walking performance.
Collectively, the data presented in this thesis point to a mechanism of progressive
deterioration of the microvasculature and subsequently microperfusion and walking
performance. Microvascular BM thickening appears to be an early event in PAD myopathy
and is likely initiated by inflammatory and ischemic cues from early atherosclerotic
narrowing of the arteries. As inflammation and hypoxia become more frequent, the
endothelium swells, endothelial dysfunction arises, and the likely consequence is
endothelial cell and pericyte damage and cell death.

Thus, the first step in PAD

microvascular pathology includes microvascular regression, which contributes to local
ischemia and subsequent initiation of an angiogenic response.
Our data support that an angiogenic response is mounted in PAD muscle and
becomes more robust with PAD severity.

Studies of more proximal muscle groups

consistently demonstrate non-significant alterations of microvascular density.

Two

possible explanations for the divergent results between our studies and theirs include: 1)
blood traveling through more proximal muscle may have better oxygen tension than blood
arriving in distal microvascular beds; 2) the atherosclerotic burden across a larger arterial
area leads to more dramatic reductions in arterial flow to distal muscle and drives more
significant pathological changes to the microvasculature.
Increasing microvascular density leads to the second step in PAD microvascular
pathology, where the loss of microvascular constituents stimulates repair, and
consequently

BM

thickening.

Prolonged

exposure

to

inflammation

and
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ischemia/reperfusion injury predispose the muscles of PAD patients to repetitive cycles of
microvascular to damage, death, and regeneration. With each iteration, fragments of lost
cells, such as the pericyte ghosts that have been reported, become incorporated into the
BM. As incoming endothelial cells interact with pericytes, they form a new layer of BM, in
effect adding a layer with each attempt at microvascular repair. Thus, perpetual damage
and repair cycles may account for the progressive nature of the BM thickening we have
observed in our studies. As the BM continues to expand, the deleterious sequelae of
deteriorating oxygen diffusion and microperfusion arise and worsen.
In our studies we observed that the fibrotic burden parallels the microvascular
architectural alterations, which supports that the origin of fibrosis may be the
microvasculature. Thus, the third step in PAD microvascular pathology includes the
abnormal accumulation of TGF-1-producing SMA+ pericytes to the microvasculature.
These pericytes are likely capable of vasoconstriction and may be involved in the initiation
and propagation of fibrosis. Pericytes can synthesize collagens, but they can also recruit
and direct fibroblasts to deposit collagen via TGF-1signaling.

Additionally, SMA+

pericytes may be able to differentiate into myofibroblasts.
Pericyte-mediated constriction may be a response to chronically low arterial flow,
where shunting of blood around terminal microvascular beds maintains adequate
perfusion pressure and better distribution of blood throughout the microvascular network.
However, with chronic intermittent hypoxia, oxidative damage cumulatively injures
pericytes, and may ultimately induce SMA+ pericyte death, resulting in pericyte rigor and
loss of perfusion of selected capillary beds. This mechanism may in part account for the
spatial heterogeneity observed in Stage II PAD muscle, both for myopathic changes and
microdomains devoid of microvascular blood flow in CEU studies.
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In advanced stage PAD muscle, microvascular remodeling is pronounced, and
includes substantial increases in SMA+ pericyte abundance (and consequently
expansion of the inner BM diameter) around the microvasculature, which gives the
appearance of “arteriolization” of the smallest microvessels. The significance of this
observation is two-fold. Muscularization of capillaries may reflect additional shunting of
blood around microvascular beds. It may also represent pericytes that are differentiating
into myofibroblasts.

Acellular capillaries appear to be limited to vessels that had

substantial BM thickening.

This supports the notion that pericyte egress as

myofibroblasts, leaving in their wake an unstable endothelium prone to regression. An
alternative explanation for the increased frequency of acellular capillaries is that
angiogenesis becomes “exhausted”, leading to a late stage regression of microvessels,
and further ischemia and myocyte damage.
Undoubtedly, microvascular pathology contributes to PAD myopathy.

Our

findings that associations are present between microvascular architecture, particularly
inner BM diameter, and both subjective and objective measures of walking performance
are significant. Targeting microvascular pathology, potentially by coaxing pericytes from
a pro-fibrotic to a pro-regenerative phenotype may improve outcomes in PAD patients. A
better understanding of PAD microvascular pathology may prove to be a meaningful
predictor of disease progression and response to interventions. For example, assessment
of microvascular pathology, possibly by CEU, may have clinical utility in the selection of
revascularization surgery candidates.
Threats to the internal validity in this study, and the ongoing study of pre/post
Ramipril intervention, include history, maturation, testing, measurement, and selection.
The relatively short duration of Ramipril intervention (24 weeks) limits the influence of
maturation. However, we anticipate some effects from history and testing, as continuous
interactions with our clinical staff allow multiple points of education about their disease
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process, and thus may affect the motivation of the patients to engage in new behaviours,
such as decreased smoking, increased exercise, and better diet. Our collection of data is
not completed in one clinic visit. Instead, separate sessions are scheduled for clinical
assessment, biopsy, CEU acquisition, and biomechanics data acquisition. Thus, history
and testing are still relevant concerns to consider in the assessment of our native PAD
and control cohorts. Although the impact of maturation should be very low across studies
of native Stage II PAD, there may be a non-negligible contribution to the interventional
study of Ramipril. Selection bias may occur, as patients who volunteer to take part in the
study may have better access to clinical care, and thus better management of
comorbidities than the general population. Quantitative measurements of microvascular
architecture and microvascular density have been tested for reliability in this study, with
test-retest values agreeing within 10% of each other. However, our measurements may
not be as accurate as those acquired by evaluation of higher resolution electron
micrographs.
A threat to external validity exists in our limited sampling of patients within eastern
Nebraska and western Iowa. Since our recruitment is limited to UNMC and the VA
Hospitals within Omaha, Nebraska, it is possible that our effects may have a loss in
generalizability due to our convenience sampling.
homogeneous and is predominantly male.

Our patient population is fairly

Follow up studies may be necessary in

additional centers with access to more women and minority patients with PAD. We do not
anticipate a large effect from the interaction of treatment and setting, as the UNMC hospital
and VA Hospital do not differ greatly. As was discussed for internal validity, history may
affect the generalizability of this study, as future studies may not involve as much
opportunity for patient education and lifestyle modification.
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Future Studies

Microvascular pathology remains poorly characterized in PAD limbs. However,
the potential for discovery of pharmacological targets is high, as well as the clinical
relevance for diagnostic and therapeutic approaches. Elucidation of the mechanisms
involved in microvascular pathology can also have a broad impact on other pathologies,
such as the microvascular pathology observed in transplant organs, MI, congestive heart
failure, and PAH.

Pericytes, in particular, have a very unclear role in PAD

pathophysiology. Future studies should be targeted towards the characterization of the
role of pericytes in fibrogenesis. Animal models may provide clarification of the lineage of
myofibroblasts in hindlimb ischemia and determine if the contribution of pericytes to the
myofibroblast pool is significant. Additionally, these studies may identify markers that may
be of use in conformational studies in human PAD muscle. Tissue culture may also
provide mechanistic insights to the contribution of pro-inflammatory cytokines, alterations
in shear stress, and hypoxia to pericyte function and adaptation.
Studies that assess the impact of current interventions to microvascular pathology
are needed. Revascularization surgery and supervised exercise interventions are of great
interest, as these studies may assist in understanding the physiologic responses of the
microvasculature in human muscle, which can provide mechanistic insights in
microvascular pathogenesis. It is highly recommended that these studies be conducted
in a way such that tissue oxygenation, microperfusion, and microvascular architecture can
be concurrently analyzed.
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